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Abstract 
Ovarian carcinoma is considered to be the most deadly of the gynaecological malignancies 
which in its earliest stages is usually asymptomatic. The unsatisfactory survival rates of 
patients on conventional chemotherapy regimens, necessitates vehicles capable of carrying 
cytotoxic agents directly to the malignant cells. This mode of targeted delivery allows for 
efficient tumour cell kill whilst sparing surrounding normal tissue and substantially reducing 
side-effects. 
This project examined the possible therapeutic role of a targetable sustained drug delivery 
system, albumin immunomicrospheres containing the chemotherapeutic agents, cisplatin 
and 5-fluorouracil , for the treatment of ovarian adenocarcinoma. A rodent cell line, as a 
model, has proved to be similar to its human counterpart and also has shown to be 
transplantable from one animal to another. Such a model could therefore be useful for 
performing experiments relating to drug delivery targetability and therapeutic trials, as well 
as survival studies, in cases of ovarian adenocarcinoma. 
In particular, this project examines the efficacy of the immunospecific microspheres 
containing the drugs in a highly concentrated form, administered intraperitoneally and 
targeted to an ovarian adenocarcinoma, in an attempt to enhance tumour cell kill whilst 
largely sparing surrounding normal tissue. It is widely recognized that the effectiveness of 
most chemotherapeutic drugs would be enhanced if they were to act selectively where they 
are needed. In order to achieve a therapeutically relevant dose in tumour cells, the amount 
of drug required usually proves also to be highly toxic to normal tissues. It was postulated 
that, to overcome the above, it may be feasible to develop a sustained immunospecific drug 
delivery system to optimize the action of cisplatin and 5-fluorouracil at the target site. With 
the attainment of the above, it was further postulated that higher doses of drugs could be 
delivered to the target area effecting higher tumour cell kill, that less normal tissue damage 
should occur and that toxic side effects of the drugs should be reduced. The rationale for 
selecting combination therapy of cisplatin and 5-fluorouracil is that, although it has been 
inferred that DNA intrastrand and interstrand cross-links produced by the cisplatin often 
repair, this repair can be blocked by 5-fluorouracil by inhibition of thymidylate synthetase, 
thus preventing DNA strand repair. 
Albumin immunomicrospheres are relatively innocuous in terms of toxicity, non-antigenic 
and are capable of accommodating chemotherapeutic agents in a non-specific fashion. We 
showed that they were capable of a 0. 94% entrapment of 5-fluorouracil and 1.23% cisplatin. 
Delivery of these drugs at a target site, and at these concentrations, should effect extensive 
cell kill. As the microspheres are chemically stable and can be manipulated to offload the 
entrapped drugs satisfactorily, in vitro drug release profiles were performed employing 
immunospecific microspheres directed towards its target cells. Slow degradation of the 
drug- containing albumin immunomicrospheres showed that 0.283 µg cisplatin/ml plasma 
and 0. 799 µg 5-fluorouracil/ml plasma could be made available at the target site over a 14 
day period. These concentrations could be maintained over at least another 14 days and 
effect tumour cell kill satisfactorily. In order to assess the tumour cell kill , we performed 
clonogenic assays, cell survival growth curves, MTT cytotoxicity assays and assessed the 
induction of micronuclei in the tumour cells. The synergism between 5-fluorouracil and 
cisplatin showed a modulation of cisplatin cytotoxicity and total tumour cell kill was achieved 
at concentrations of 0.5 µg/ml 5-fluorouracil and 0.1 µg/ml cisplatin at the target site. 
The above-mentioned evidence of effective targeting of the drugs was then investigated in 
female Wistar rats with ovarian adenocarcinoma to assess comparative survival times when 
treated with free drugs or immunospecific albumin microspheres containing the drugs. 
Animals given a free drug dose of 5 mg/kg cisplatin and 20mg/kg 5-fluorouracil, followed 
by a repeat dose at the same concentrations 7 days later showed that only 14% of the 
animals survived a 90 day trial period. Animals given an intraperitoneal bolus dose of 
immunomicrospheres at a dose of 1 O mg/kg cisplatin and 40 mg/kg 5-fluorouracil showed 
that 60% of the animals survived the 90 day trial period. This data indicated to us that the 
survival probability of animals treated with drug-containing immunomicrospheres was 
substantially superior to other protocols employed in this study. 
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Chapter 1 
Introduction 
1.1 General Introduction 
Ovarian cancer, although less common than endometrial or cervical cancer, has been 
shown to have a low survival rate. 
While the majority of women with advanced disease live 2 years with a reasonable 
quality of life, recurrent cancer eventually becomes symptomatic in most, and by 5 years 
only 35% still survive. Young and colleagues (1990) demonstrated that women with 
Stage I ovarian cancer may have survival rates as high as 90%, therefore, early 
diagnosis of ovarian cancer may offer a significant opportunity to improve survival rates 
in this deadly disease. 
The treatment of ovarian cancer often involves one or more treatment modalities such 
as surgery, chemotherapy, radiotherapy and frequently treatment of recurrent and 
metastatic disease. 
Most patients with ovarian cancer require post-operative chemotherapy. Cisplatin, the 
cornerstone of most regimens, is usually either given alone, or more commonly, in 
combination with other agents.Response rates of 60% to 80% are reported, but only 
approximately 20% to 30% of this treatment group experiences a complete 
resolution with normalization of clinical, radiological and immunological testing 
(Jones, 1993). 
After extensive surgical cytoreduction, chemotherapy is the treatment of choice for 
patients with advanced ovarian cancer. A number of new treatments are currently being 
tested in clinical trials and among them are methods to overcome tumour resistance, the 
use of dose-intensive regimens and new drugs (Neijt, 1995). The dose of the drugs 
delivered seems to be important in clinical outcome, but new drugs and/or strategies are 
needed to improve the outcome in advanced disease. 
In the design of chemotherapeutic regimens, all available data must be evaluated to 
ensure maximization of the therapeutic index of the regimen. While testing of anticancer 
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drugs in preclinical systems frequently fails to predict activity of a drug for a specific 
tumour (Schabel et al., 1979), pharmacokinetic parameters from such studies are often 
much more helpful in defining the optimal dose and rate of infusion of the agent (Jones 
et al., 1995). In reporting the results of standard-dose treatment trials, many observers 
have noted the importance of describing the actual delivered dose rather than the 
protocol-specified dose (Coppin, 1987). Because of the potential morbidity of high-dose 
therapy, strict adherence to protocol-described doses seems more common than in 
standard dose trials (Jones et al., 1995). 
Basic pharmacological and biological principles imply that the dose of chemotherapy 
delivered per unit of time is likely to be an important consideration in determining 
treatment outcome (Levin, 1993). This is implied because maximum cell kill is a function 
of adequate drug dose (Frei & Canellos, 1980) and the interval between treatments to 
prevent cell regrowth (Levin, 1993). The importance of dose density (defined as mg/m2 
/time period) in relation to clinical outcome in ovarian cancer has been reviewed by Levin 
and Hryniuk (1987). This concept has been applied to most chemotherapy regimens in 
which sequential courses are often administered as close together as drug-induced 
toxicity allows (Levin, 1993). Although drug dose is unquestionably important in 
determining the response to chemotherapy, the impact of dose intensity has only 
recently been analyzed for ovarian tumours (Levin & Hryniuk 1987). 
Epithelial ovarian cancer is a highly drug-sensitive tumour. Approximately 60% to 80% 
of patients with advanced ovarian cancer will have objective responses to treatment with 
cisplatin-based regimens, and 50% of patients will achieve a complete clinical remission. 
(Ozols et al. , 1993). Unfortunately, a complete remission is not tantamount to a cure, 
and approximately 30% to 50% of patients will ultimately relapse. Patients who never 
achieve a complete remission, as well as those patients who relapse, are essentially 
incurable. Thus, even though ovarian cancer is highly responsive to chemotherapy, most 
patients are not cured. A multiplicity of pharmacological, biological and biochemical 
factors are likely to interact to limit the effectiveness of chemotherapy in the disease. 
Unfortunately, all chemotherapeutic agents have side-effects. These can range from the 
production of minimal short-term interference with the patient's quality of life to severe 
effects which , in some cases, become life-threatening. 
Ultimate success in the treatment of ovarian cancer should come when physicians are 
able to match given parameters concerning the tumour and its host with the most 
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appropriate options. 
It is generally accepted that the principle of combination chemotherapy is normally 
extended to combined modality treatment for ovarian cancer, in which chemotherapy is 
used in conjunction with surgery or radiotherapy, or both, in an attempt to eradicate 
malignant neoplasms. Platinum-based therapy, either alone or in combination with other 
drugs, is the standard approach in the treatment of ovarian cancer. This is usually 
administered by intravenous infusion. Employing cisplatin by intraperitoneal infusion has, 
however, been demonstrated to be superior to the intravenous route, especially when 
administered together with another drug(s) (Ozols & Vermorken, 1997). Due to the fact 
that the systemic administration of most chemotherapeutic agents are limited by their 
resulting toxic side-effects, escalation of dose is confined within a relatively narrow 
range (Blackledge et al. , 1993). However, within the peritoneal cavity, very high 
concentrations of drugs may be achieved for long periods of time. This could possibly 
have an advantageous effect in the treatment of disease limited to that area. Drugs that 
appear to have theoretical advantages when given via the intraperitoneal route, include 
cisplatin and 5-fluorouracil (Markman, 1987). 
For many years there has been a need to regulate and target drugs in the body where 
they are required, in order to reduce undesirable side-effects whilst still maintaining 
therapeutic levels of the drug at the target site. During the past 20 years, considerable 
progress has been made in this regard due to the development of a myriad of drug 
delivery systems. Many of these systems were tailored to carry all types of drugs 
including chemotherapeutic agents. One of the popular systems was microspheres 
containing therapeutic agents. 
As mentioned earlier, to increase the efficacy of drugs, a drug delivery system should 
be designed to increase the amount of drug at the target site, while reducing the effect 
with non-target cells. Poste and Kirsch ( 1983) recognised that targeting of a drug should 
be established at three levels. Not only should the drug localise within the target organ, 
it should specifically interact with target cells and deliver its payload at therapeutic 
concentrations to subcellular compartments within these cells. It was also shown by 
Stella and Himmelstein (1980, 1985) that an improvement in therapeutic index depends, 
not only on successful site-specific delivery, but also on retention of the drug at the site 
of action. 
The above-mentioned concepts formed the basis of our studies as it was postulated that 
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the use of particulate drug-containing microspheres, coupled to monoclonal antibodies, 
is a potential drug delivery system which can be targeted to specific sites or organs in 
the body. It was argued that an improvement in therapeutic efficacy of antineoplastic 
drugs such as cisplatin and 5-fluorouracil, by selective targeting to an ovarian 
adenocarcinoma, would be of clinical importance. It was also thought that the covalent 
linking of these drugs to albumin may impair functional activity, but can be circumvented 
by employing drug-loaded albumin microspheres coupled to monoclonal antibodies 
raised against the tumour. For this purpose, Santos (1996), recently raised two lgM 
monoclonal antibodies, anti-DMBA43 and anti-DMBA93, against a rodent ovarian 
adenocarcinoma cell line, DMBA-OC-1 R, to couple to cisplatin- and 5-fluorouracil-
containing albumin microspheres for the purpose of this study. 
1.2 Principal aims of the study 
The main aim of this study was to investigate the possible role of monoclonal antibody-
conjugated albumin microspheres containing either cisplatin or 5-fluorouracil as a 
targeted drug delivery system against ovarian adenocarcinoma. In order to do this, we 
performed the following studies: 
(i) we established whether albumin microspheres would entrap cisplatin and 5-
fluorouracil in high enough concentrations to have a therapeutic effect on the tumour; 
(ii) we determined whether the surface characteristics of the microspheres would allow 
the coupling of monoclonal antibodies; 
(iii) we investigated the cytotoxic effects of cisplatin and 5-fluorouracil in combination in 
immunomicrospheres on a rodent ovarian adenocarcinoma cell line, DMBA-OC-1 R. For 
this purpose, use was made of clonogenic assays, cell survival growth curves, MTT 
cytotoxicity assays, as well as assessment of nuclear damage by induction of 
micronuclei. It was assumed that these in vitro assays would give guidance as to our 
approach for in vivo therapeutic trials in an animal model; 
(Iv) we thus acquired an animal model in which we could perform therapeutic trials. 
In the rodent model we used, we first studied the drug distribution of cisplatin and 5-
fluorouracil to the major organs to establish whether sufficient drugs would reach the 
ovary. The results showed that the disposition of the drugs in the ovary were of sufficient 
concentration to demonstrate a therapeutic effect at the target site ( 9,3% for cisplatin 
and 6,0% for 5-fluorouracil , respectively). 
It was also important to establish the toxic side effects of the drugs, therefore 
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comparative studies employing free drugs and drug-loaded immunomicrospheres, on the 
blood chemistry and haematology, were performed. Only mild renal failure and 
hepatocellular toxicity was demonstrated which corrected itself without any observable 
clinical adverse reactions. 
DMBA-OC-1 R cells transplanted intraperitoneally into Wistar rats, rendered a 
transplantable ovarian adenocarcinoma as primary tumour, which was used as the 
model for evaluation of the drug delivery system. Four groups of tumour-bearing animals 
were used of which one group was not treated by any drugs. Another group was treated 
by free drugs and the remaining two groups by drug-containing immunomicrospheres 
of which the drug concentrations varied. The animal survival endpoints of all four groups 
were determined to establish the efficacy of the targetable drug delivery system. 
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CHAPTER2 
Literature Review 
Ovarian carcinoma is considered to be the most deadly of the gynaecological 
malignancies due to the occult nature of this disease. While it is less common than 
cancer of the endometrium or cervical cancer, ovarian cancer has been shown to have 
an overall survival rate of only about 35%. It is further estimated that approximately 1 
in 70 women, will develop at some stage of their lives, ovarian cancer. 
2.1 Aetiology of epithelial ovarian cancer 
The aetiology of ovarian cancer is unknown. Except for some relatively uncommon 
familial tendencies and some rare genetic clustering of breast, colon and ovary cancer, 
it has not been possible to identify any clinical useful high-risk groups for increased 
surveillance. Multiple pregnancies and the use of oral contraceptives may, to some 
extent, be protective because of decreased ovulation and hormonal influences. 
Whittemore (1994) found that a history of involuntary infertility, low parity, and a long 
time from menarche to menopause are associated with increased life time risk of ovarian 
cancer. 
A review by Heintz et al. (1985) implies several factors which may play a role in the 
aetiology of ovarian cancer. Amongst these, an environmental factor might be of 
importance as suggested by the fact that the highest incidence of ovarian cancer occurs 
in industrialized countries where women with higher education, have higher incomes and 
different dietary habits. However, it is clear that not everyone is equally susceptible to 
these environmental factors. This variation in susceptibility may be dependant on 
genetically controlled factors. 
2.2 Invasion and metastasis 
It is known that more than 80% of epithelial ovarian cancers have metastasised by the 
time the disease is diagnosed. Most case studies have shown that tumour cell spread 
usually occurs over the surface of the peritoneal cavity, although haematogenous and 
lymphangitic metastases can occur. Many studies in cancer models have shown that 
tumour cell dissemination is a multistep process that requires loss of adherence to 
adjacent cells, increased motility, proteolytic degradation of basement membranes, 
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migration, adherence to vascular endothelium, proliferation, and tumour-induced 
angiogenesis (Elbendary et al., 1992). Once successfully completed, this process can 
be repeated in a cyclical manner, resulting in further dissemination of tumour cells. 
2.2.1 lntraperitoneal spread of ovarian cancer 
The tendency of malignant epithelial ovarian tumours to develop papillary formation , 
often on the surface, lead to malignant epithelial desquamation and rapid spread over 
the surface of the peritoneum (Pickel et al., 1992). It is not yet clear at which degree of 
proliferation and at what tumour size the exfoliated cells implant and grow to metastases 
on the peritoneum. 
As ovarian cancers advance, mestastases are more frequent in the upper abdomen than 
in the pelvis. Using the universally accepted staging system of the International 
Federation of Gynaecology and Obstetrics (FIGO}, Pickel et al. ( 1992) found metastases 
on the surface of the liver in only 15. 7% of patients with Stage Ill disease, but in 54.5% 
of those with Stage IV. Peritoneal tumour deposits were similarly frequent in Stages Ill 
and IV, 71 .6% and 68.2% respectively. 
2.2.2 Retroperitoneal spread of ovarian cancer 
Haematogenous dissemination of ovarian cancer is known to occur with very small 
primary tumours. This explains early extra-abdominal metastases in patients with Stage 
IV disease. However, lymphatic spread via the retroperitoneal lymphatics is much more 
common and always proceeds via the efferent lymphatic channels cranially into the 
regional lymph nodes (Pickel et al. , 1992). 
Reports of the frequency of lymph node involvement by stage are conflicting, since they 
are not based on comparable surgical techniques. However, Tulusan et al. (1992) have 
found that the incidence of lymph node metastases is closely related to the surgical 
stage and extent of the histological examination. Many nodal metastases probably 
escape detection because enlarged nodes do not always contain tumour, while positive 
nodes are often macroscopically normal. 
2.3 Diagnosis of epithelial ovarian cancer 
In its earliest stages, ovarian cancer is usually asymptomatic. In approximately 60% of 
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cases, widespread intra-abdominal metastases are present by the time the diagnosis is 
made. Despite improvements in diagnosis and therapy, the long-term survival rate in 
patients treated for epithelial ovarian cancer is still disappointing. Because of the 
advanced stage of disease at the time of diagnosis, survival is poor. While the majority 
of women with advanced disease live 2 years with a reasonable quality of life, recurrent 
cancer eventually becomes symptomatic in most, and by 5 years only 35% still survive. 
In view of the significantly better survival with early-stage disease, efforts to develop 
methods for early detection of ovarian cancer should be emphasised. Young and 
colleagues (1990) demonstrated that women with Stage I ovarian cancer, after 
treatment, may have survival rates as high as 90%, therefore, early diagnosis of ovarian 
cancer may offer a significant opportunity to improve survival rates in this deadly 
disease. Serum levels of the tumour-associated antigen CA-125 (Zurawski et al., 1990) 
and other tumour markers, as well as transvaginal sonography (Bourne et al., 1991), 
have shown promise. However, as Creasman and Di Saia (1991) remark, the relative 
rarity of ovarian cancer, combined with the non-specific nature of the currently available 
screening tests, makes ovarian cancer screening unsatisfactory and not cost effective 
at the present time. Panza et al. ( 1988) showed that CA-125 is ineffectual as a marker 
in mucinous ovarian tumours, whereas Lloyd (1993) found that the carcinoembryonic 
antigen (CEA), expressed in the majority of mucinous ovarian tumours, is useful to 
distinguish between serous and mucinous cancers. 
In 1974, Yamanaka and Deamer showed that superoxide dismutase activity in 
transformed cells is abnormal. The first in vivo observations of altered superoxide 
dismutase activities in malignant neoplasm were reported at nearly the same time by 2 
different groups (Dionisi et al. , 1975; Sahu et al., 1977). Oberley and Buettner (1979) 
reported that diminished amounts of manganese - containing superoxide dismutase 
have been found in all tumours which they have studied. However, Ishikawa and 
associates (1990) assessed a monoclonal antibody against manganese superoxide 
dismutase for use as a marker for epithelial ovarian cancer. An ELISA indicated that 
less than 1% of normal individuals had serum levels over 150 ng per ml of serum, 
whereas over 50% of patients with epithelial ovarian cancer showed amounts above 150 
ng/ml. Because a high level of manganese superoxide dismutase is found in epithelial 
ovarian carcinoma cases, as compared with normal individuals and patients with non-
epithelial ovarian carcinoma and other gynaecological malignancies, these authors 
suggested that the determination of this enzyme could provide a useful method for the 
detection and monitoring of responses to treatment in epithelial ovarian carcinomas. 
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For screening to thus be effective, the screening test must be able to detect cancers at 
a stage in their development when treatment can improve outcome more than treatment 
of symptoms. The ideal screening test for ovarian cancer should be able to detect the 
disease in a premalignant phase and hence provide a method for prevention of invasive 
disease. Unfortunately, there is as yet no well defined precancerous lesion of the ovary 
analogous to cervical intra-epithelial neoplasia or atypical endometrial hyperplasia 
(Jacobs & Oram, 1992). 
Current efforts to improve survival rates for ovarian cancer by screening are, therefore, 
directed towards the detection of early stage disease. The rationale of screening for 
early stage ovarian cancer is the well documented observation that 5 year survival for 
this disease is closely correlated with stage at presentation (Kottmeier, 1982). 
2.4 The histopathology of malignant ovarian tumours 
The great variety of ovarian tumours makes a discussion of each type overwhelming. 
As mentioned previously, the most common type of malignant tumours is epithelial, 
accounting for 80% to 90% of the malignant tumours of the ovary. Discussion of other 
than epithelial tumours of the ovary is not in the interest of this study. For a wider 
review which includes amongst others, the sex-cord stromal tumours, germ cell tumours 
and tumours of uncertain histogenesis, see Saigo (1993). 
According to the MD Anderson Cancer Centre (1996) there are basically 8 different 
major histological groups of epithelial ovarian carcinoma: 
Histological Types % of Ovarian Tumours % Bilateral 
Serous 46 73 
Mucinous 36 47 
Endometrioid 8 33 
Clear cell 3 13 
Transitional 2 -
Mixed 3 -
Undifferentiated <2 
Unclassified <1 -
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Ovarian carcinomas are histologically similar to those which originate in the uterine 
cervix, proximal vagina and endometrium (Saigo, 1993). The four most common 
histological subtypes are serous, mucinous, endometrioid and clear cell carcinomas. 
The most common of these is serous carcinoma, as compared to the approximately 8%-
10% of endometrial carcinomas with a similar histological pattern (Hendrickson et al. , 
1982). All ovarian tumours can show more than one histological pattern, however, they 
are generally classified according to the predominant type and are graded according to 
the degree of differentiation in the primary tumour in the ovary. The most differentiated 
tumours, deviating little from their benign counterparts, are the carcinomas of low 
malignant potential or borderline tumours. All other carcinomas are graded on the 
degree of differentiation: well-differentiated or Grade I, moderately differentiated or 
Grade 2; and poorly differentiated or Grade 3 carcinomas (Saigo, 1993). 
2.5 Overview of the management of ovarian cancer 
In general, the treatment of ovarian carcinoma usually involves one or more of the 
following treatment modalities: surgery, chemotherapy, radiation therapy, "second-look" 
surgery and the treatment of recurrent and metastatic disease. 
2.5.1 Prognostic factors in ovarian cancer 
The literature addressing prognostic factors in epithelial ovarian cancer has a number 
of recurring problems, including poor definition of measurement, missing data, restricted 
groups, differing endpoints, mixed pretreatment and post-treatment, and univariate 
analyses. These factors often create problems for the clinician, as prognostic factors 
essentially predict survival in epithelial ovarian cancer, and successful indices of 
prognosis usually reflect the growth potential of the tumour. Therefore, once factors are 
identified in univariate analysis, they must be placed in perspective with other known 
factors by multivariate analysis (Hakes, 1993). 
Prediction of survival in epithelial ovarian cancer seems to remain a controversial 
subject and some reasons for this controversy have been mentioned. However, a 
review of a large number of multivariate analyses suggests that the most important 
traditional factors predicting survival are stage, residual disease, grade, and 
performance status. These factors overshadow other variables such as histology, 
mitosis, morphometrics, initial volume of disease, age, ascites, abdominal cytology, type 
of surgery, and others (Hakes, 1993). Ploidy and DNA index stand out as important 
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predictors among other variables which include S-phase fraction, oestrogen receptor, 
progesterone receptor, androgen receptor, CA-125, HER-2/neu proto-oncogene, P-
glycoprotein, and others which are appearing in the literature at an accelerating pace. 
With such a variety of factors, along with the rapid appearance of new factors, it is not 
surprising that the relative importance of these factors is controversial. 
2.5.2 The role of surgery in the management of ovarian epithelial cancer 
Surgery plays a unique role in the treatment of ovarian cancer. It is generally considered 
to be the most important facet of therapy for this disease, but only rarely does it produce 
a cure without the aid of another modality. Because surgery must be combined with 
other types of therapy, the physician must be aware of the interactions between the 
various types of treatment. 
Surgery for ovarian carcinoma is both diagnostic and therapeutic. If the pelvic mass in 
question turns out to be ovarian carcinoma, tumour debulking, including total abdominal 
hysterectomy and bilateral salpingo-oophorectomy, if possible, is usually performed. 
The therapeutic goal is thus to remove all tumour, if possible, to provide the greatest 
possibility of cure. Ovarian cancer is surgically staged and samples of tissues from 
various sites examined histologically for confirmation of the diagnosis, as well as grading 
of the tumour. Ascites or pelvic and abdominal washings are cytologically evaluated. 
Accurate surgical staging is imperative as it provides the basis for the most appropriate 
post-operative treatment. It is still controversial as to whether extensive surgical 
resection actually improves 5 to 10-year survival rates. It is agreed however, that 
optimal tumour debulking (<1 .0 cm residual) results in prolonged, good-quality survival 
(Williams & Hoskins, 1990). According to Hoskins (1994), surgical management of 
ovarian cancer involves: (a) establishment of diagnosis, (b) staging, (c) primary tumour 
cytoreduction, (d) interval tumour cytoreduction, (e) secondary tumour cytoreduction, (f) 
assessment of the status of the disease, and (g) palliation. 
Whether diagnosing early cancer in a patient with an adnexal mass or confirming cell 
type and site of origin in a patient with ascites and carcinomatosis, the definitive 
diagnosis of ovarian cancer can only be made by surgical exploration (Hoskins, 1994). 
For patients with disease apparently confined to the ovary or pelvis, full surgical staging 
is required to confirm proper stage. This operation involves sampling of multiple 
peritoneal sites in the pelvis and abdomen. 
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Second-look surgery allows an opportunity to evaluate the effect of primary therapy and 
to remove any obvious residual tumour. However, until more effective therapy is 
available, second-look surgery in the asymptomatic patient with a normal physical 
examination is probably indicated only as a research procedure in patients on specified 
investigative protocols. 
2.5.3 The role of radiotherapy in the management of ovarian epithelial cancer 
Numerous reports published over the last two decades indicate that radiation is capable 
of permanently controlling ovarian cancer, however, its role in the management of 
ovarian carcinoma remains a controversial subject (Mychalzak & Fuks, 1993). These 
authors report that the long-term results of radiation therapy have, in general, been 
disappointing. For patients in early stage disease, 5-year and 10-year survival ranges 
from 60% to 80%, and for advanced stage patients, 5-year and 10-year survival ranges 
from only 7% to 20% (Dembo, 1985; Martinez et al., 1985; Weiser et al. , 1988). Also, 
patients with macroscopic residual disease, after platinum chemotherapy, do not benefit 
from whole-abdomen radiotherapy (Sch ray et al., 1988) which is thought to be equally 
as effective as chemotherapy (Sell et al., 1990). The toxicity of radiation therapy, 
especially gastrointestinal effects, has usually been more severe than that associated 
with chemotherapy, and, for that reason, most oncologists prefer chemotherapy (Jones, 
1993). 
lntraperitoneal radioactive colloids have also been used, however, only patients with 
very early disease are considered to be good candidates for this therapy, which requires 
complete and uniform intraperitoneal distribution of the radioactive suspension (Jones, 
1993). 
2.5.4 The role of chemotherapy in the management of ovarian epithelial cancer 
Most patients with ovarian cancer require surgery as well as post-operative 
chemotherapy. In the design of chemotherapeutic regimens, all available data must be 
evaluated to ensure maximization of the therapeutic index of the regimen. Of particular 
importance are the pharmacokinetic parameters obtained by the testing of anticancer 
drugs in preclinical systems. The information obtained is often helpful in defining the 
optimal dose and rate of infusion of a particular agent to be used (Jones et al. , 1995). 
12 
2.5.4.1 Chemotherapeutic regimens and epithelial ovarian cancer 
It is generally accepted that combination chemotherapy is used in conjunction with 
surgery or radiotherapy, or both, in an attempt to eradicate malignant ovarian 
neoplasms. 
When selecting agents for combination chemotherapy, it is important to realise that, 
where a combination requires a reduced dose because of additive toxicity, the 
advantage of the combination may be neutralized by the disadvantage of dose reduction 
(Frei, 1995). The effective combinations are those wherein qualitatively different toxicity 
allows for little or no dose reduction . Under these circumstances, a major additive and 
sometimes synergistic effect with a cure rate can be achieved (Einhorn & Donohue, 
1977; Frei, 1985; Li et al. , 1980). 
Another crucial issue for the use of agents in combination relates to cross-resistance. 
If cross-resistance exists among the agents, the effect of the agents might be no greater 
than that of a single agent (Frei, 1995). It must, however, be expected that at least 
some degree of cross-resistance, even among unrelated agents, will be frequently 
found. 
The results of several studies have established that platinum-based combination 
chemotherapy is more effective than single agents or combination of drugs without a 
platinum analogue in ovarian cancer (Neijt, 1995). Of the platinum analogues, cisplatin 
is the most extensively studied compound that has clear-cut activity in patients with no 
prior chemotherapy, as well as in those who have received prior alkylating agents 
(Thigpen et al., 1983; Wiltshaw & Kroner, 1976). It is usual in combination therapy that 
one or more of the following groups of drugs is used with cisplatin: alkylating agents, 
anthracylines, paclitaxel, hexamethylamine, ifosfamide and etoposide, all being effective 
in the treatment of ovarian cancer (Brandl et al. , 1997; Dimopoulos et al. , 1997; Dorval 
et al., 1996; Miglietta et al. , 1997; Neijt, 1995; Thigpen, 1993; Veldhuis et al., 1997). In 
the present study, this concept was employed, using cisplatin in combination with the 
antimetabolite, 5-fluorouracil. 
In a recent study by Hoskins et al. (1996), twenty nine women with advanced ovarian 
carcinoma were treated with a developmental combination chemotherapy regimen 
consisting of mitomycin C, etoposide, cisplatin and carboplatin (MECCA). Prior to 
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chemotherapy, abdominal hysterectomy, salpingo-oophorectomy, omentectomy, 
washings for cytology and nodal and diaphragmatic palpation was the standard primary 
surgery. The protocol utilized the concepts of dose intensity, front-end loading, non-
cross resistance and synergy. The rationale behind the development of the MECCA 
protocol was: ( 1) patients with epithelial ovarian cancer survived longer as the dose of 
the cisplatin increased. The intent was therefore to give as much chemotherapy as 
possible in as short a time as possible; (2) the Goldie-Goldman hypothesis (Goldie & 
Goldman, 1979) postulates that chemotherapy resistance is the cause of eventual 
treatment failure and emphasizes the importance of using non-cross resistance drugs. 
Previous experience of Hoskins and colleagues was that mitomycin C is occasionally 
active in platinum-resistant epithelial ovarian cancer and there has also been preliminary 
evidence of such activity for etoposide and, therefore, these drugs were included; (3) the 
efficacy of etoposide is known to be schedule-dependent with more protracted courses 
being more effective and so this was adopted; (4) the work of Skipper (1990) had 
suggested that the total dose of the drugs used was of paramount importance in 
improving the survival of patients with incurable cancers. Therefore, carboplatin was 
added to full-dose cisplatin to increase the total platinum dose without additional 
neurotoxicity or ototoxicity; (5) the cisplatin and etoposide were given together to make 
use of the potential synergy between them; (6) front-end loading (i.e. increasing the 
chemotherapy dose at the first cycle) would theoretically lead to a greater total cell kill 
because the number of cancer cells is then at its maximum. By decreasing the number 
of stem cells as quickly as possible, the chance of further development of resistant 
clones would be diminished. 
Although the median overall survival using the MECCA protocol was 37 months with a 
27% 5-year survival, the median failure-free survival was 15 months with a 14% 5-year 
failure-free rate. The predominant toxicity was haematologic and there was one toxic 
death. Hoskins and colleagues (1996) concluded that although the overall survival 
results are superior to their previous experience, the failure-free survivals were the same 
for their controls. They further concluded that the MECCA regimen has not 
demonstrated its apparent superiority in their randomized study and, at best, may only 
reflect selection differences and differences in relapse therapy. 
The above study, as well as several other clinical trials, have conclusively shown that 
new strategies need to be generated in the treatment of ovarian cancer. The 
development of novel therapies has become increasingly multidisciplinary and 
translational in nature. The natural agents, camptothecins and taxoids, hormonal 
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therapy, photodynamic therapy, gene therapy, and targeted drug delivery systems are 
increasingly being investigated for the treatment of ovarian cancer. 
The advent of paclitaxel for salvage therapy and, more recently, as a component of first-
line treatment in advanced disease, has further improved response rates and prolonged 
survival (Dunton, 1997). Based on prospective trials by the Gynecologic Oncology 
Group, paclitaxel/cisplatin has become the new standard regimen in the United States 
(Ozols & Vermorken, 1997). In addition, it has now been demonstrated that peripheral 
blood stem cell support permits the administration of multiple cycles of high-dose 
chemotherapy. However, prospective randomized trials are needed to determine 
whether such dose intensive treatment is superior to standard-dose chemotherapy 
(Ozols & Vermorken, 1997). 
A large number of combination chemotherapy regimens for various cancer types have 
been reported, most with higher response rates and toxicity than single agents (Bloss 
et al., 1991 ; Forastiere et al. , 1992; Jacobs et al., 1992; Kohno et al., 1992). Several 
of the reported regimens includes combination therapy with cisplatin and 5-fluorouracil, 
most of them for the treatment of colorectal cancer and squamous cell carcinoma of the 
head and neck. 5-Fluorouracil (5-FU) and cis-diamminedichloroplatinum II (cisplatin} , 
in combination, have been shown to have synergistic cytotoxicity against both murine 
and human neoplasms (Harstrick et al., 1997; Rooney et al. , 1985; Schabel et al., 
1979). In all studies performed, higher response rate with combination therapy was 
found as compared to single agent treatment alone. Despite higher response rates 
achieved by combination therapy, overall survival did not improve in most cases. 
From the above, it is realised that chemotherapeutic drugs such as cisplatin and 5-
fluorouracil, have to be given to the limits imposed by toxicity, on a definite schedule, 
which may have to be tailored around other methods of treatment such as surgery or 
radiotherapy or the use of sustained drug delivery systems. 
The introduction of cisplatin-based chemotherapy has greatly improved the prognosis 
of patients with ovarian cancer (Van der Hoop et al., 1990). Although complete recovery 
was very unlikely approximately 15 years ago, as many as 30% of the patients survive 
for 5 years or longer, despite the presence of tumour in International FIGO Stage Ill or 
IV disease at diagnosis (Van der Hoop et al., 1990). 
Cisplatin is a platinum co-ordination complex which demonstrates activity against a 
15 
variety of tumours, and is used as a chemotherapeutic agent alone or in combination 
with other antineoplastic drugs for the treatment of several types of genitourinary 
tumours. Platinum disposition in the body is biphasic, with a relatively rapid distribution 
phase in minutes and elimination half-lives which vary on average from 16, 1 to 53,3 
hours, with total doses ranging from 90 to 120 mg when infused intravenously at a rate 
of 360 to 480 mg/hr (Litterst et al., 1976). Initial concentrations of platinum have been 
found to be highest in organs of excretion, gonads, spleen and adrenals, but remain 
significantly elevated only in the kidneys, liver, ovaries and uterus. 
Cisplatin is an inorganic complex that contains a platinum atom surrounded in a plane 
by 2 chlorine atoms and 2 ammonia atoms in the cis-position (Lippard, 1982; Drug 
Information, 1986). 
Neutrality of charge and the cis-configuration are necessary for the cisplatin complex to 
exert antineoplastic activity. In the relatively high chloride concentration in plasma, the 
complex is believed to be unionized, allowing passage of the drug through cell 
membranes. lntracellularly, in the presence of low chloride concentrations, the chloride 
ligands of the complex are displaced by water, resulting in the formation of positively 
charged platinum complexes that are toxic and probably act as the active form of the 
drug. Cisplatin binds to DNA and inhibits DNA synthesis by binding to guanine residues 
(Butour & Macquet, 1977); protein and RNA synthesis are also inhibited, but less 
extensively. The drug produces intrastrand and interstrand cross-links in DNA by 
binding at areas of specific base sequences; DNA-protein cross-links are also formed 
(Lippard, 1982; Drug Information, 1986). 
Also, cisplatin can inhibit methionine uptake into tumour cells and cause perturbation of 
the methionine pools (Gross & Scanlon, 1986; Scanlon et al. , 1983). Cells may respond 
by increasing methionine biosynthesis and increasing the pools of folate cofactors 
(Krebs et al., 1976). 
It was also reported by Ormerod et al. (1994) and Gibb et al. (1997) that cisplatin kills 
ovarian tumour cells by inducing apoptosis and that apoptotic cell death does not require 
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degradation of DNA into nucleosomal-sized fragments. 
5-Fluorouracil is an antimetabolite used alone, mostly for the palliative treatment of 
carcinoma of the colon, rectum, breast and pancreas that is not amenable to irradiation 
and/or surgery (Drug Information, 1986). Objective remissions, varying between 6 
months to 5 years, have been reported in 10% to 35% of metastatic breast cancer 
patients who respond to 5-fluorouracil therapy (Drug Information, 1986). 
5-Flourouracil in vivo is converted to 5-fluoro-2'-deoxyuridine-5' phosphate and 5-
fluorouridine triphosphate which are incorporated into the RNA (Scanlon et al. , 1986). 
One or both of these 5-FU metabolites account for the antineoplastic activity of 5-FU in 
experimental models (Heidelberger et al., 1982). In Drug Information, American Hospital 
Formulary Service (1986) these antimetabolites act by three different ways: 
• it inhibits thymidylate synthetase thus interfering with thymidine production, 
• it is incorporated in RNA to produce fraudulent RNA, and 
• it inhibits the utilization of preformed uracil, required for RNA production, by 
blocking uracil phosphatase. 
Any one of the above will block and prevent any action of the cell to repair the steady 
state of thymidylate synthetase and thus DNA synthesis. 
Shirasaka et al. ( 1993) is of the opinion that the high response rate of cancer patients 
to 5-FU plus cisplatin may be due to a reciprocal relationship of the cytotoxic actions of 
both agents. In this connection, it is noteworthy that Scanlon et al. (1983 & 1986) 
reported that cisplatin inhibits the transport of neutral amino acids, including L-
methionine, into L 121 O murine leukaemia cells and also induces an elevation of the 
intracellular levels of reduced folates such as 5, 10-methylenetetrahydrofolate and 
tetrahydrofolate, whereby the increased level of 5, 10-methylenetetrahydrofolate results 
in a 2.5-fold increase in the binding of 5-fluoro-2'deoxyuridine-5'-monophosphate to 
thymidylate synthase. 
Although various combination schedules have been reported as regards the potentiation 
of antitumour efficacy by the use of 5-fluorouracil plus cisplatin, it is suggested by 
Shirasaka et al. (1993) that the elevation of response rates in cancer patients is based 
on the mechanism as described in the above paragraph. 
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The present study is based on the synergistic anti-tumour activity of cisplatin and 5-
fluorouracil as described by Shirasaka et al. ( 1993) and Scanlon et al. ( 1983 and 1986). 
Another route being exploited in the treatment of ovarian cancer, is by intraperitoneal 
infusion. lntraperitoneal cisplatin has been shown to be superior to intravenous cisplatin 
when administered together with another drug(s) (Ozols & Vermorken, 1979). 
2.5.4.2 lntraperitoneal chemotherapy 
Since the late 1970's, investigators at a number of centres have actively investigated the 
intraperitoneal administration of cytotoxic agents as therapy for ovarian cancer (Braly 
et al., 1995; Bruzzone et al. , 1997; Dedrick et a/. , 1978; Markman et al., 1989). 
The metastatic spread of ovarian cancer is well defined and in the early stages is 
primarily intraperitoneal (Blackledge et al., 1993). lntraperitoneal spread is invariably a 
major factor in the clinical presentation of a woman with ovarian cancer and also usually 
implicated in problems associated with progressing or relapsing disease. The 
importance of controlling intraperitoneal disease, therefore, is a major factor in the 
management of ovarian cancer. 
All parts of the peritoneum interconnect with one another and therefore, fluid introduced 
in one area of the peritoneum should, in the absence of obstructions, reach all parts of 
the peritoneal surface ( Ozols et al., 1997). 
Systemic administration of chemotherapeutic agents is limited by the resulting toxicity, 
and therefore, dose escalation is confined within a relatively narrow range (Blackledge 
et al., 1993). Within the peritoneal cavity, however, high concentrations of cytotoxic 
agents may be achieved for long periods of time, which could have an effect on disease 
limited primarily to that area. 
It has been demonstrated that drug uptake from the peritoneal cavity is principally 
through the portal circulation (Kraft et al., 1968; Lukas et al., 1971). Thus, cytotoxic 
agents to be rapidly metabolized in the liver during their first passage through the organ, 
would be expected to demonstrate the greatest pharmacokinetic advantage following 
regional delivery (Markman, 1993). Drugs such as 5-fluorouracil would fall into this 
category (Speyer et al. , 1980). When choosing agents for intraperitoneal administration, 
it is important to choose agents with slow clearance from the peritoneal cavity and rapid 
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clearance from the systemic circulation (Markman, 1993). An additional advantage of 
intraperitoneal administration, particularly as regards cisplatin , is that concentrations 
exceeding those required to overcome resistance, may be achievable within the 
peritoneal cavity following regional drug delivery. 
After intraperitoneal therapy, drug uptake from the peritoneal cavity into tumour occurs 
by the mechanism of free surface diffusion, and it is critical that the drug-containing 
treatment volume come in direct contact with tumour tissue (Markman, 1993). A major 
factor defining the clinical situations in which intraperitoneal therapy is a rational 
therapeutic option, is the known limited penetration of anti neoplastic agents directly into 
tumour or normal tissues (Markman, 1993). Unfortunately, the penetration of drug 
directly into tissue is quite limited and ranges from several cell layers to 1-3 mm (Los et 
al., 1989; Nederman & Carlsson, 1984; West et al., 1980; Ozols et al., 1979). Certain 
agents, including cisplatin, however, enter the systemic compartment in significant 
concentration following intraperitoneal delivery. Thus, it is not surprising that cisplatin 
will be found deep within tissue of the peritoneal lining following intraperitoneal delivery 
because the agent reaches this area through capillary flow. However, near the surface 
of the peritoneal lining, cytotoxic drug concentrations are increased significantly following 
regional delivery (Los et al. , 1989). 
Markman ( 1993) reported that the side effects associated with regional anti neoplastic 
drug delivery may be systemic or local and occasionally both. For cisplatin, dose-limiting 
side effects are emesis, neurotoxicity and nephrotoxicity, particularly in the salvage 
setting, in which the patient may have pre-existing side effects from prior systemic 
cisplatin delivery. For 5-fluorouracil, the dose limiting side-effects are essentialy 
haemopoietic toxicity, gastrointestinal toxicity and cardiac toxicity, as reported by Keefe 
(1993). Drugs can also cause local irritation leading to abdominal pain. Perhaps an 
additional concern is the establishment of a convenient and safe method of drug 
delivery, especially when a peritoneal catheter is used as bowel perforation and/or 
infection may be a risk. 
Cisplatin appears to be the drug with the greatest experience with intraperitoneal therapy 
of ovarian cancer. This drug is associated with limited adhesion formation and minimal 
or no abdominal pain following regional delivery (Markman, 1993). Markman (1986) 
further showed that approximately 25%-30% of patients with small-volume disease 
(largest tumour mass <0.5-1 mm in diameter) can achieve a significant response 
following intraperitoneal delivery of cisplatin. This finding was confirmed by Berek 
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(1990),Hacker et al. (1987), Howell et al. (1982), Markman et al. (1991), Pretorius et al. 
(1983) and ten Bokkel Huinink et al. (1990). Studies by Alberts et al. (1996) showed 
that cisplatin combined with cyclophosphamide, intraperitoneally administered, is 
associated with superior patient survival and less hearing loss and myelosuppression 
in patients with Stage Ill ovarian cancer. 
Based on pharmacokinetic parameters, cisplatin and 5-fluorouracil are examples of 
drugs that have theoretical advantages when given by intraperitoneal routes (Markman, 
1993). 
Due to the advantages of intraperitoneal cisplatin delivery described by Ozols and 
Vermorken (1997), the present study exploited this route in order to, amongst others, 
reduce systemic toxicity. It was further decided to utilize microparticulate drug carriers 
as a vehicle to deliver the chemotherapeutic agents to the ovarian tumour cells. 
2.6 The role of microparticulate drug carriers in ovarian epithelial cancer 
Several other modalities for the treatment of ovarian carcinoma have recently been 
explored. These include immunotherapy, hormone therapy, cytokine therapy, 
photodynamic therapy and the use of microparticulate drug delivery systems. 
Since the feasibility of artificial cells was first demonstrated by Chang in 1957, an 
increasing number of approaches in their preparation and application have become 
available. Artificial cell membranes can now be formed using a variety of synthetic or 
biological materials to produce desired variations in their permeability, surface properties 
and blood tissue compatibility. Almost any material can be included within artificial cells, 
which can then act as drug delivery systems. Since cells are the fundamental units of 
living organisms, it is not surprising that artificial cells can have a number of possible 
applications. This is especially so since these cells can be tailor-made to have 
specialized functions. 
Medical science has long recognized the need to control, regulate and target the release 
of drugs in the body. In general, the aim has been to provide less frequent drug 
administration, constant and continuous therapeutic levels of drug in the systematic 
circulation or at a specific target site, and a reduction in undesirable drug side effects. 
During the past decade, considerable progress has been made in this regard . 
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Particulate drug delivery systems have received much attention as a means of targeting 
drugs to specific sites in, for example, cancer chemotherapy. Various particulate 
systems have been described, including emulsions, liposomes, microcapsules and 
microspheres, prepared from a variety of materials such as polysaccharides, lipids, 
alkylcyanoacrylates, polylactic acid and related polymers and proteins. Many of them 
are tailored to specifically carry chemotherapeutic agents, one of the more popular 
configurations being that of microspheres. 
The basic rationale for controlled drug delivery is to alter the pharmacokinetics and 
pharmacodynamics of pharmacologically active moieties by using novel delivery 
systems, or by modifying the molecular structure and/or physiological parameters 
inherent in a selected route of administration (Li et al., 1985). It is desirable that the 
duration of drug action become more a design property of a rate-controlled dosage form, 
and less, or not at all, a property of the drug molecule's inherent kinetic properties. 
Thus, optimal design of controlled release systems necessitates a thorough 
understanding of the pharmacokinetics and pharmacodynamics of the drug. 
The way in which a drug is distributed within the body, will normally be determined by 
the intrinsic properties of the drug molecule itself (lllum, 1987). The final amount of drug 
reaching the target site in the body may normally only be a fraction of the administered 
dose. Some drugs are able to interact specifically with a few selected cell types due to 
the presence of relevant receptors present only on those cells. Most other drugs are 
less specific and will interact with receptors shared by a large number of cell types or will 
interact with cells by non-receptor mediated mechanisms. Thus, often the therapeutic 
effect of a drug will not be limited to an action on the target cell, but involve an action on 
non-target cells as well (Ilium, 1987). This may lead to undesirable adverse reactions 
and in some cases, severe side effects. 
In order to increase the efficacy and therapeutic index of drugs, it would be highly 
desirable to have delivery systems or techniques that can increase the amount of drug 
reaching the target site, while reducing the interaction with non-target cells. To obtain 
optimal site specificity, targeting at three levels should be established (Poste & Kirsh, 
1983). The drug should not only localise within the target organ, but also interact 
specifically with target cells and deliver therapeutic concentrations of drug to specified 
subcellular compartments within the target cells. However, as shown by Stella and 
Himmelstein ( 1980, 1985), the retention of the drug at the site of action is also important 
if successful site specific delivery is to be followed by an improvement in therapeutic 
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index and clinical effect of the drug. 
Various approaches, such as chemical modification of the drug carrier systems, have 
been considered in an attempt to achieve the goal of site specific delivery (Juliano, 
1980). In the present context, the active targeting of colloidal particles refers to a 
change in the natural distribution pattern of a carrier particle by a deliberate modification 
of its size or surface characteristics, thereby directing it to specific cells, tissues or 
organs (lllum, 1987). These modifications include the use of hydrophilic agents to 
suppress opsonisation and particle adhesion to macrophages, together with cell-specific 
ligands and particle-monoclonal antibody conjugates. 
A way to avoid uptake by the reticuloendothelial system is to change the surface 
properties of the colloidal carriers. The uptake of particles by the phagocytic cells is 
known to be determined mainly by the physicochemical characteristics of the particles, 
especially their size, surface charge and surface affinity (hydrophobicity/hydrophilicity) 
(lllum & Davis, 1982; Van Oss et al. , 1975). Van Oss et al. (1975) suggested that 
hydrophobic particles will be removed from the circulation rapidly, while more hydrophilic 
particles would be expected to remain in circulation for longer periods of time. It has 
also been suggested that coating of particles with negative or positive macromolecules 
can alter organ uptake considerably (Wilkens & Myers, 1966). Roerdink et al. (1983) 
examined whether surface charge can play a role in the phagocytosis of opsonised 
liposomes and found that the presence of negatively charged lipids within the liposome, 
profoundly suppressed the uptake by mouse peritoneal macrophages. Many advances 
in liposome formulation have resulted in a new generation of phospholipid vesicles with 
improved pharmacokinetic properties (Allen et al. , 1989; Allen et al., 1992; Blume & 
Cevc, 1990; Gabizon & Papahadjopoulos, 1988; Klibanov et al., 1990; Senior et al., 
1991; Papahadjopoulos et al., 1991 ). Several studies by the groups of lllum & Davis 
(1983, 1984, 1986 and 1987) and Moghimi et al. (1991) have demonstrated that non-
ionic hydrophilic coating agents, such as poloxamer and poloxamine block co-polymers, 
are able to dramatically diminish phagocytosis of intravenously injected microspheres 
in rats and rabbits, mainly due to the steric repulsive effect of the hydrophilic 
polyoxyethylene segments of the polymers to protein adsorption. The authors suggest 
that by coating the particles with the named block co-polymers, it has now been made 
possible to achieve a state of non-recognition by the reticuloendothelial system and a 
significantly prolonged circulation time. The lasting effect found for these block co-
polymers has been attributed to the fact that they consist of a large hydrophobic group, 
which anchors the polymer to the surface of the microsphere, and large hydrophilic 
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groups that minimize both the uptake of plasma components (opsonization} and the 
adhesion between microspheres and macrophages by the so-called repulsion effect. 
Therefore, one of the major obstacles in drug targeting has now been overcome. 
Although the major obstacle of particle phagocytes can now be overcome, an 
improvement in therapeutic efficacy of drugs by selective targeting to specific sites, 
would be of clinical importance. One method by which this may be achieved, is by 
antibody-mediated targeting of the drug (Rowland, 1983}. Although drugs may be 
coupled directly to antibodies, only a small number of functional groups are available per 
antibody molecule, which can be successfully used without significant loss of antibody 
activity (Rowland, 1983}. This effectively limits the molar drug-to-antibody ratio to 1 O: 1. 
To increase this ratio, drugs have been conjugated to carrier molecules such as dextran 
and human serum albumin (Tsukada et al., 1982}. However, the covalent linking of 
drugs to such complexes may also impair the functional activity of the drug. The use of 
drug-loaded microspheres coated with monoclonal antibody (immunomicrospheres} may 
circumvent these problems (lllum & Jones, 1985). 
From the above discussion, it can be argued that the use of particulate sterically-
stabilized microspheres coupled to monoclonal antibodies can be considered to be a 
potential system of drug delivery to specific organs in the body. A major aim in 
chemotherapeutic treatment of ovarian epithelial cancer, is to improve the efficiency of 
the cytostatic treatment, and the killing of tumour cells will be facilitated by exposing the 
tumour and its metastases to high concentrations of anti neoplastic drugs. However, by 
conventional administration, it is not possible to use very high doses of drugs due to 
their toxic side-effects. Most current research employing drug delivery systems, employ 
the above-mentioned regimen for cancer therapy. The concept of using 
immunomicrospheres containing chemotherapeutic agents is therefore a feasible 
alternative approach in the treatment of ovarian epithelial cancer. 
When developing an immunomicrosphere system containing substantial concentrations 
of drugs for targeting the following should be kept in mind. An effective system should: 
• be relatively innocuous in terms of toxicity; 
• be non-antigenic and also metabolizable within the body; 
• possess high drug-entrapment properties; 
• be capable of accommodating the selected chemotherapeutic agents; 
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• possess surface properties which do not lead to recognition as a foreign particle 
by the reticuloendothelial system; 
• be chemically stable in solution; 
• be amenable to preparation in large batches, and 
• allow the attachment of monoclonal antibodies to its surface. 
Human serum albumin immunomicrospheres are considered by many to be a potentially 
useful vehicle for carrying chemotherapeutic agents and, theoretically, complies 
satisfactorily with the above-mentioned criteria (Cheng et al. , 1993; Hagiwara et al. , 
1997). 
2.6.1 lmmunospecific albumin microspheres 
There has been considerable interest of late in using protein or polymer based 
microspheres as drug carriers. In 1972, Evans described methods for preparing heat 
cross-linked albumin microspheres which are free-flowing and non-agglomerated. Their 
size could be varied in the range from 0.5 µ m to 1 mm and the rate of biodegradation 
in vivo could be adjusted by varying the time and temperature of cross-linking. 
Many techniques of albumin microsphere preparation, as well as a myriad of potential 
uses are available today (Brown et al. , 1997; Burgess et al. , 1987; Burger et al., 1985; 
Chen et al. , 1994; Gallo et al., 1984; Latha & Jayakrishnan, 1995; Liu & Leong, 1997; 
Luftensteiner et al., 1997; Longo et al., 1982; Pavenetto et al., 1994; Schafer et al. , 
1994; Scheffel at al., 1972; Yapel, 1985). Two basic methods of microsphere 
preparation have been described. One approach involves coacervation of an albumin 
solution and subsequent desolvation and hardening of the colloidal particles formed 
(Oppenheim 1984). A more widely used approach involves a phase separation emulsion 
technique. Here the albumin in water is emulsified by homogenization or/and sonication 
into an organic phase (usually cottonseed oil). The polymeric particles are either 
chemically crosslinked or hardened by heat treatment and the residual organic phase 
is removed ( Gallo et al., 1984). Also, heat-stabilized albumin microspheres are 
hydrophobic by nature, however, non-ionic surfactants from the poloxamine group are 
known to adsorb strongly to hydrophobic surfaces, rendering the microspheres 
hydrophilic. Water soluble drug molecules can be incorporated into the microspheres 
by including them in the albumin solution. Up to 10% w/w drug can sometimes be 
trapped in the microspheres in this way (Kramer, 197 4; Widder & Senyei, 1983; Widder 
et al. , 1982). In contrast to the case of liposomes, there has been little concern about 
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the in vitro stability properties of albumin microspheres as they can be lyophilized and 
thus, should be reasonably stable during prolonged storage. Several techniques for the 
preparation of albumin microspheres containing various water-soluble chemotherapeutic 
agents have subsequently been developed (Goldberg et al., 1984; Gupta et al., 1986; 
Gupta eta/., 1988; Gupta & Hung, 1990; Kim eta/., 1993; Mehta et al., 1988; Poznansky 
eta/., 1982; Tomlinson eta/., 1982; Tomlinson eta/., 1984). Ofparticularinterestisthe 
study by Nishioka et al. (1989) on the preparation of albumin microspheres with 9.2% 
cisplatin entrapment and lower drug concentrations over time in the peripheral blood 
when compared to a control group who received free-drug intravenous injections. 
Significant cisplatin levels were still present in the blood four weeks after administration 
of the cisplatin microspheres. This was thought to be of benefit as lower cisplatin 
concentrations in the circulation will reduce the side effects of the drug, while the 
sustained release of cisplatin over four weeks will maintain the therapeutic index. 
Another study by Truter (1995) on the preparation of albumin microspheres containing 
the antimetabolite, 5-fluourouracil , showed a drug entrapment of 1,5% and a sustained 
release over 30 days. These microspheres were incorporated intraperitoneally in Wistar 
rats and resulted in only mild toxic effects as shown by haematological and blood 
chemistry profiles, when compared to intravenous administration of the drug at the same 
concentrations. 
As mentioned earlier, an improvement in therapeutic efficacy of anti-neoplastic drugs by 
selective targeting to specific sites would be of clinical importance. One method by 
which this may be achieved, is to conjugate drugs such as cisplatin and 5-fluorouracil , 
to human serum albumin. However, the covalent linking of these drugs to albumin may 
impair its functional activity. To circumvent these problems, the use of drug loaded, heat 
stabilized albumin microspheres coated with monoclonal antibodies, is proposed. 
Monoclonal antibodies can be attached to microspheres by means of direct coupling if 
functional groups capable of covalently bonding with proteins, e.g. aldehyde groups are 
available on the surface of the microspheres (lllum & Jones, 1985). However, 
microspheres often carry a variety of groups on the surface such as carboxyl, hydroxyl, 
and/or amino groups, which either can be linked to monoclonal antibodies employing a 
coupling reagent, or can be modified to give reactive aldehyde groups. Albumin 
microspheres contain, due to their nature, functional groups on the surface, e.g. amino 
groups and carboxyl groups (lllum & Jones, 1985). These authors describe a technique 
for linking monoclonal antibodies to albumin microspheres by using a water-soluble 
carbodiimide derivative, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, to activate 
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carboxyl groups present on the surface of the microspheres, and thereby coupling the 
amino groups on the antibody molecule to the carboxyl group through an amide linkage 
(Goodfriend et al., 1964). 
2.7 Monoclonal antibodies against ovarian cancer 
More than 50 monoclonal antibodies have been developed against ovarian cancer. 
However, only OC-125 has proved useful in the monitoring of disease as its antigen, 
CA-125, is expressed in the majority of endometrial adenocarcinomas, a small 
proportion of mucinous tumours and 80% of serous, clear cell and undifferentiated 
ovarian tumours (Bast et al., 1990; Finkler et al., 1988; Lloyd, 1993). Recently, Santos 
( 1996) raised two lgM monoclonal antibodies, anti-DMBA-43 and anti-DMBA-93, against 
a rat ovarian cell line, DMBA-OC-1 R, to link to cisplatin- and 5-fluorouracil albumin 
microspheres for the purpose of the present study. 
2.8 Rodent tumour models in experimental chemotherapy 
Animal cancer models have been used for many decades in the development of new 
cancer therapies and there is no doubt that they have contributed to some major 
breakthroughs. They have, for instance, been important in understanding dose 
response relationships and developing the concept of combination chemotherapy. 
However, many drugs that show activity in animal models, are inactive in humans 
(Martin et al., 1986). This may be because of interspecies differences in anatomy, 
physiology and metabolism. In addition, transplantable tumours often come from highly 
selected tissue culture lines which can kill an animal within 2 to 3 weeks, bear little 
relationship to the original tissue of origin and may be immunogenic for the host. 
Moreover, tumours often grow at inappropriate sites. The activity of chemotherapeutic 
drugs may also be overestimated because criteria for anti-tumour activity in some animal 
experiments, for instance, reduction in the growth rate of tumours or an increase in 
lifespan, would not be recorded as a response in Phase 1/11 clinical trials (Balkwill et al., 
1990). Screening in animals may also fail to pick up important toxicities for human 
patients. Thus, while the use of murine tumour models has contributed to the general 
development of chemotherapy, it has not generally resulted in the development of 
therapies specific for ovarian cancers. 
Rodent tumour models have been the basis for the majority of advances in human 
cancer biology over the last few decades, from the discovery of new anti-cancer drugs 
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to understanding the mechanism of action of other modalities to defining the biology of 
cancer - from oncogenes to studies of resistance, to cellular heterogeneity and to cell-
kinetic principles (Valeriote, 1985). Thus, rodent tumours are useful in the study of 
human cancer to answer fundamental as well as clinically applicable questions on 
cancer. 
2.8.1 Types of tumour models 
Rockwell (1987) states that two processes are essential to the performance of 
successful and interpretable studies with transplantable rodent tumours. Firstly, the 
tumour/host system must be maintained as a stable biological model that will yield 
reproducible and meaningful data. Secondly, the techniques used to handle the animals 
and to treat the tumours must be chosen so as to minimise artefacts and allow 
meaningful extrapolation to clinical situations. 
At present there are only a limited number of tumour models available which resemble 
human ovarian cancer (Schmal! & Zeller, 1992). A useful and reproducible model is, 
however, an essential prerequisite for preclinical studies, hence several models have 
been developed, for example, induction of ovarian tumours in Wistar rats by the 
administration of 7, 12-dimethylbenz (a) anthracene (Kato et al. , 1974). This model was 
characterized in vitro and in vivo by lmaishi (1992), Kataoka et al. (1987) and Sugiyama 
et al. (1986). An autochthonous adenocarcinoma, which histologically indicated a 
similarity to high grade human serous tumour was raised. This tumour was found to be 
surgically transplantable serially in Wistar rats with relative stability over a number of 
transplant generations (Sugiyama et al., 1986) and a transplantability rate of 87% 
(lmaishi, 1992). 
The present study makes use of the above-mentioned cell line, which was supplied to 
our laboratory with the compliments of Dr Kataoka, Kurume University, Japan. 
2.8.2 Maintenance of tumour models 
Several techniques are used to maintain experimental rodent tumour lines (Hewitt, 1978; 
Hewitt & Blake, 1978; Mccredie et al., 1971; Rockwell , 1977; Twentyman et al., 1980). 
Some are maintained by serial transplantation of small pieces of tumour or aliquots of 
tumour cell suspensions. Some malignant cell lines are maintained by continuous 
passage in cultures and tumours produced by injecting the cells into animals. 
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Sometimes tumours are stored frozen in liquid nitrogen, and aliquots of frozen stock can 
be thawed and inoculated into animals when tumours are required for experiments 
(Rockwell , 1987). 
Each maintenance regimen has advantages and disadvantages. Frozen storage of 
aliquots of primary tumour is thought to have theoretical advantages over other 
maintenance regimens when it is desirable to maintain the phenotype of the primary 
tumour (Hewitt & Blake, 1978), as any form of serial passage will exert selection 
pressures on the tumour line. However, some selection will occur during freezing, 
storage, thawing and transplantation. Because of this, even maintenance in liquid 
nitrogen need not yield experimental tumours identical to the primary (Rockwell, 1987). 
A major problem encountered with frozen maintenance is the small amount of tumour 
available. Moreover, if the primary tumour is heterogeneous, different samples may 
contain subpopulations having different characteristics and therefore may yield tumours 
with different behaviours (Rockwell, 1987). 
Maintenance of tumour cells in vitro will select for rapid growth under the culture 
conditions used for passage. As most cultures are maintained in an atmosphere of 95% 
air/1-5% CO2, cells will generally be selected for an ability to withstand high oxygen 
concentrations, which are unphysiologic and may be toxic to unadapted, unselected cells 
(Richter et al. , 1972). Most cultures are initiated with small numbers of cells; this will 
select cells with an ability to proliferate rapidly without close contact with host cells or 
other tumour cells. Routine passaging of cultures to confluency will select those cells 
that experience the least growth inhibition under high density, acidic and nutrient-
deprived conditions (Rockwell, 1987). In vitro maintenance will also select cells with 
adhesion characteristics suited to the culture system used for passaging. The selection 
pressures will be different for cells grown attached to a surface, cells grown in liquid 
media, cells grown suspended in agar and cells grown as spheroids (Rockwell, 1987). 
The nature and strength of the selection pressure will depend on the culture protocols. 
Maintaining cells in vitro will also favour the selection of cells that are able to grow in that 
particular hormonal milieu. Frequently, conditioned media, feeder layers of radiation-
sterilized cells, or red blood cells may be used to supply nutrients and stimulating 
factors, favouring proliferation of the tumour cells (Rockwell, 1987). 
Thus, the media used to culture tumour cells are complex entities, which contain a 
variety of identified and unidentified factors that affect cell proliferation. Maintenance 
in vitro will select those cells that are best suited to the specific medium chosen to 
28 
culture them. 
The characteristics of the tumour/host system will reflect changes in the hosts, as well 
as in the malignant cells. Genetic drift (Bailey & Scott, 1987) in the breeding stock may 
lead to animals, that are genetically different from the animal in which the tumour arose. 
Even changes in the microbiological status of the animals as well as changes in the 
husbandry practices used in the colony, may change the system. Bailey and Scott 
(1987) are of the opinion that movement of a colony from one institution to another 
creates special problems. One may inadvertently select nucleus stock not genetically 
representative of the original breeding colony and the genetic variant may become fixed 
in the new colony. 
Unless the investigator has an unusual degree of control over the operation of the 
colony, he/she may find that the move results in changes in the breeding management 
protocols, husbandry practices and microbiological status of the colony, thereby 
changing the health and physiology of the animals and the behaviour of the tumour/host 
system (Rockwell , 1987). 
2.8.3 Quality control of tumour models 
The choice of tumour is critical. Of obvious importance is the appropriateness of the 
tumour line as a model for the subject being studied (Hewitt, 1978; Kallman, 1968; 
Kallman & Rockwell , 1977; Rockwell , 1977). One must also consider the genetic and 
immunological relationships between tumours and hosts. 
One of the most serious problems that can occur in the use of transplantable tumour 
models is the presence, or the development, of genetic incompatibility between the 
tumour and the host (Corbett & Valeriote, 1987). In experimental chemotherapy, this 
can be a particularly treacherous occurrence if it goes unrecognized, because the 
immune system can markedly magnify a small tumour cell kill by a given agent, thereby 
resulting in a misleading set of experimental data. 
Recognition of a developing incompatibility problem between host and tumour is 
sometimes difficult, unless one has extensive experience with that model and there are 
suitable quality controls (Corbett & Valeriote, 1987). These authors report the 
occurrence of genetic drift in their breeding stock which resulted in incompatibility of the 
host animals with several tumour models. They further report that it can also happen that 
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a particular subline of a tumour model can become less compatible with its usual host. 
They recommend the routine return to frozen storage of samples as a guard against 
change, but only if the material stored, is of proven quality. Changes in chemotherapy 
responsiveness can also be used as a simple test to evaluate the presence of minor 
tumour-host incompatibility. 
It is well-known that the host immune response to tumours is an important parameter 
that can affect experiments intended to assess the effectiveness of anti-tumour 
therapies (Lord, 1987). Although it has often been recommended that non-immunogenic 
tumour models be chosen in order to avoid potential problems, this is not always 
possible. Also, although it may be ideal to use tumours of recent origin arising within a 
strictly inbred colony and to perform all experiments with animals from that same colony, 
that may also not always be possible. 
Tumour models in which only one response endpoint can be assessed, usually tumour 
growth delay, are clearly of limited value (Siemann, 1987). It is nearly impossible in such 
models to evaluate mechanisms of action at either the cellular or molecular level. 
Models in which tumour growth delay, cure, or tumour growth delay and clonogenic cell 
survival can be evaluated, are more appropriate for evaluating biologically relevant 
questions, especially if supplemented by in vitro tumour cells grown in culture (Siemann, 
1987). Such models can investigate mechanisms of action of different treatment 
modalities and assess the role in the overall tumour response of factors, such as cell-
cycle redistribution, repopulation, reoxygenation, repair and drug uptake (McNally & De 
Ronde, 1980; Rockwell, 1977 and 1980). The ability to address and evaluate such 
factors using a variety of response assays is the advantage of transplanted tumour 
models. These tumours are well-characterized and highly reproducible (Siemann, 
1987). 
Because of the rapid growth of experimental neoplasms, tumours are generally 
implanted only 2-4 weeks before they are used for experiments (Rockwell , 1980). The 
tumour-host interactions may, therefore, be different from those of primary animal 
tumours, which require months or years to reach sizes at which they are detected. The 
relationships between the malignant cells and the various components of the 
haematopoietic system involved in specific and non-specific immune responses, may be 
quite different for tumours 2 weeks after implantation and for tumours which have grown 
and evolved in a host for months or years (Rockwell , 1980). Interactions between the 
malignant cells and the vascular and connective tissues may also differ greatly in rapidly 
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and slowly growing tumours. This might result, for example, in atypical vascular beds 
and larger hypoxic fractions in rapidly growing tumours. Rockwell (1980) is of the 
opinion that these limitations are not unique to in vivo - in vitro tumours, but are shared 
by all the rapidly growing tumours used in experimental therapeutics. 
Animal survival endpoints can be quantified for solid tumours, but only for those tumours 
for which the median survival time is 25 days or less (Corbett & Valeriote, 1987). The 
size of the tumour inoculum must also be selected. According to these authors, the size 
must be at least one log10 higher than the number of cells required for 100% takes. This 
usually limits survival studies to solid tumours that grow rapidly and are also highly 
invasive. Furthermore, suitable implant sites must be selected for a specific tumour to 
be used. A mistake that is frequently made is the use of a number of cells that is only 
a small increment above the level that will produce takes in all the animals where 
quantification of survival time is essentially impossible. 
Survival experiments require large numbers of animals. Many implants of tumour tissue 
are performed subcutaneously, making tumour measurement by calipers easy (Corbett 
et al., 1984 and 1982; Skipper et al., 1978). With a few simple precautions, tumour 
measurement endpoints can reliably be converted to cell kill by employing this method 
(Corbett & Valeriote, 1987). The tumour growth delay is based on the median tumour 
size of the group of animals inoculated. 
Another consideration which should be kept in mind with an experimental 
chemotherapeutic model, is drug distribution factors. Essentially, there are three major 
drug distribution factors which must be taken into consideration (Corbett & Valeriote, 
1987). The first, pharmacokinetics, deals with the change in activity of the agent as a 
function of time in the blood, and is related to drug activation and metabolism as well as 
drug excretion. Also of importance is the partitioning of the drug between the aqueous 
phase and serum components. The free drug is of major importance and is taken to 
reflect the concentration that bathes the tumour cells. Generally, this parameter is the 
one that investigators attempt to correlate with drug effect at a given tissue or cell level. 
The second factor is the distribution of drug at the level of the tumour cell . This depends 
upon the vasculature of the tumour and the subpopulations that make up the tumour. 
The former determines the concentration of the drug at the tumour cell level. The third 
factor relates to the concentration of drug or its active species within a cell. This can be 
modified by the environment of the cell , which affects the uptake and metabolism of the 
drug. Manipulation of the internal biochemistry of the cell itself can greatly influence the 
degree of sensitivity. 
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In experimental tumour models, the problem of drug resistance may be encountered. 
Therefore, care should be taken with both the dose and the schedule of drug exposure 
in developing resistant cell lines. One may consider to either study human tumour cells 
directly or at least employ treatment schedules in the model that parallel those used in 
the clinical setting (Corbett & Valeriote, 1987). 
Factors seldom considered to have a direct effect on rodents in a chemotherapeutic 
model, are the effects of anaesthesia or restraint. Immobilization methods can have a 
variety of profound effects. Anaesthetics generally depress the respiration rate, 
decrease the heart rate and lower blood pressure (Pakes et al., 1984). In tumours, 
anaesthetics may affect cell proliferation patterns (Kuramoto & Takahashi, 1977). 
Anaesthetics may also alter the response of tumours to chemotherapy (Brown, 1979; 
Pakes et al., 1984; Peacock & Stevens, 1978). Anaesthetics may alter tumour and host 
drug sensitivity by a number of mechanisms. Changes in body temperature and blood 
flow through normal tissues may lead to changes in the pharmacokinetics and 
biodistribution of drugs (Brown, 1979; Homsey et al., 1977). Repeated anaesthetization 
can induce liver microsomes, leading to altered drug metabolism (Pakes et al., 1984). 
Also, anaesthesia-induced changes in tumour blood flow, tumour oxygenation and 
tumour temperature may affect tumour cell proliferation, intratumour drug distributions 
and activation of drugs by tumour cells, thereby changing the antineoplastic effects of 
the drugs (Rockwell , 1987). 
Care must be taken to minimize stress during experiments with laboratory animals. 
Even routine handling can be stressful, especially for rodents born and reared in a 
"clean" colony, and never manipulated by hand (Sedlacek & Mason, 1977). 
2.8.4 Establishment of a transplantable rat ovarian adenocarcinoma model 
In general, experimental ovarian carcinoma is difficult to study, probably due to its 
anatomical position which may create some difficulties. However, in 197 4 Kato and 
associates successfully induced ovarian carcinoma in Wistar rats by embedding 7, 12-
dimethylbenz (a) anthracene (DMBA) intra-ovarially by the so-called "clipping" method. 
Morphologically, this tumour was found to be similar to human ovarian carcinoma, 
classified as a poorly differentiated adenocarcinoma. This finding was confirmed by 
Sekiya et al. (1979) who reported that adenocarcinoma is found in 39% of induced 
ovarian tumours when employing the clipping method. Nishida et al. (1982) is of the 
opinion that direct carcinogenesis to the ovarian superficial epithelium is caused by the 
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DMBA-saturated silk thread passed through it by piercing, rather than that the silk 
passed through the hilus ovarii , in an ovarian carcinoma model prepared by the same 
method. 
A pure new cell line, DMBA-OC-1, was established from the above-mentioned primary 
ovarian carcinoma by Kataoka et al. (1987) by serial passaging. The authors observed 
that, although fibroblasts grew vigorously after starting the primary culture, the tumour 
cells formed colonies by using the fibroblasts as a feeder layer and became predominant 
at the 1 ot11 passage and pure culture after 20 passages. Microscopically, the tumour 
cells showed a cobble-stone like arrangement and proliferated rapidly. Large nuclei with 
1 to 2 prominent nucleoli, were also observed. Electron microsocopy showed well-
developed cytoplasmic organellae with intercellular, desmosome-like gap junctions and 
microvilli on the cell surface. The doubling time of the cells was found to be 
approximately 32 hours. 
Cells, inoculated subcutaneously in nude mice, showed marked tumorigenesis from a 
week later and died in approximately 6 weeks. lntraperitoneal inoculation led to 
carcinomatous peritonitis with marked haemo-ascites and metastases to the liver and 
spleen, and filling the entire abdomen with bloody ascitic fluid causing death in 
approximately 4 weeks. 
Kataoka et al. (1987) concluded that the histological features of the DMBA-OC1 cells 
were very similar to the tumour and the cultured cell line originated from malignant 
tissue. Although both oestrogen and progesterone receptors were not found in the 
original tumour, Katabuchi (1983) noted the oestrogen receptor in 80% of DMBA-
induced tumours and Kamura (1983) reported the presence of progesterone receptors 
in 30% of these tumours. These authors reported accelerative effects on proliferation 
in vivo and in vitro by means of oestrogen load and progesterone load, respectively. 
However, they further reported that since the same accelerative effect was noted in 
receptor-negative cases when loaded with progesterone, the method of measuring the 
progesterone receptor levels may possibly induce false negative results in comparison 
with the oestrogen receptor. They therefore recommend that these non-specific and 
accelerative effects requires further studies. 
Sugiyama et al. ( 1986) serially transplanted OM BA-induced tumour fragments (4.0 mm3) 
subcutaneously from rat to rat in order to characterize the tumour growth pattern. 
Following subcutaneous implantation, tumours exhibited two phases of growth: an initial 
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avascular phase characterized by slow growth, followed by a later phase of rapid growth 
in which the tumour became vascularised. During the first seven days, all the tumours 
maintained the same tumour volume as at the time of implantation. Thereafter, they 
began to grow gradually for about seven days and then grew rapidly. The tumours 
appeared spheroidal or ellipsoidal in shape and when they reached an approximate 
volume of 500 mm3, the central portion of the tumour became necrotic, leaving a 
peripheral shell of living cells. All the tumour appeared well circumscribed by a capsule 
of connective tissue with obvious vascular development. Microscopically, the 
histological features of the transplanted tumours were similar to those of the primary 
tumours. They appeared less differentiated than the primary tumours and histologically 
they were classified as undifferentiated adenocarcinomas. In addition, the 
characteristics of the tumours were relatively stable over a number of transplant 
generations and no alteration of the histological pattern was observed. 
Sugiyama et al. (1986) concluded that the morphological observations of the 
transplantable DMBA-tumour indicates potential value in the testing of anti-tumour 
agents due to its stability in growth pattern and overall characteristics. 
lmaishi (1992) reported on the intraperitoneal implantation of ascitic cancer cells from 
the DMBA-tumour. He reported that in 87% of implants, the ascitic cells were 
successfully transplanted intraperitoneally in infant rats. The omentum was the first site 
at which the metastatic tumour appeared following the inoculation. Then the tumour 
disseminated throughout the peritoneal cavity and produced bloody ascites containing 
tumour cells by the 3rd week and caused death of the animals 34 ± 1 O days. Histological 
examination of the omental tumour revealed an adenocarcinoma with solid and glandular 
structures among scant stroma, indicating a similarity to a high grade human serous 
tumour. 
lmaishi ( 1992) concluded that the OM BA-model has clear-cut parameters to evaluate the 
anti-cancer effects of drugs, including changes in the survival period of the host. Thus, 
using this model, detailed observations on the mechanisms and efficacy of 
chemotherapeutic agents, as well as new modalities of treatment, should be possible. 
It was further reported by Nakata et al. (1992) that manganese superoxide dismutase 
is highly expressed in primary and transplanted ovarian cancers in rats induced by 
DMBA, as judged by ELISA and Northern blot analysis. The serum levels of manganese 
superoxide dismutase in tumour-bearing rats were substantially higher than those in 
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normal control rats. Their data suggest that DMBA-induced ovarian cancer in rats is a 
good experimental model for human epithelial ovarian cancer, and that manganese 
superoxide dismutase is a reliable monitoring marker for disease in this type of animal 
model. 
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Chapter 3 
Aims 
This project originated as a continuation of our previous research on the application of 
human serum albumin microspheres as a sustained drug delivery system for 
chemotherapeutic agents. We have examined the entrapment capability of human 
serum albumin microspheres for the cytotoxic agent, cisplatin, as well as for the 
antimetabolite, 5-fluorouracil. The in vitro release behaviour of the microspheres of its 
payload and subsequent effects of the released drugs on ovarian epithelial cells, as well 
as the in vivo organ distribution of these drugs when administered via the intraperitoneal 
route in Wistar rats, were also studied. 
Earlier studies by others have shown that the intraperitoneal delivery of 
chemotherapeutic agents in patients with ovarian cancers, is generally associated with 
drug uptake from the peritoneal cavity into tumour cells by the mechanism of free 
surface diffusion. Also, systemic administration of chemotherapeutic agents is limited 
by the resulting toxicity which confines dose escalation within a narrow range. Within 
the peritoneal cavity, however, high concentrations of drugs may be achieved for long 
periods of time, particularly if a targeted sustained drug delivery system is employed, 
which could have an effect on disease limited primarily to that area. 
We decided to extend our studies to examine the capability of human serum albumin 
microspheres coupled to monoclonal antibodies against an ovarian epithelial carcinoma 
and containing cisplatin and 5-fluorouracil, as a potential drug delivery system for 
application in the treatment of ovarian epithelial cancer. 
We obtained a transplantable rodent ovarian epithelial carcinoma model which was 
reported to be similar to its human counterpart. We managed to successfully raise two 
lgM monoclonal antibodies against this particular cell line. These monoclonal antibodies 
were coupled to drug-containing human serum albumin microspheres by employing 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide as a coupling agent, rendering 
immunomicrospheres. 
The immunomicrospheres containing cisplatin and 5-fluorouracil respectively, were 
thought to be useful for in vitro release studies and it is postulated that the drugs should 
be effectively released from the immunomicrospheres after having attached itself to the 
receptor sites on the tumour cells, which are cultured in RPMI medium in a 5% CO2 
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atmosphere, and affect cell kill. From our preliminary results it seems that human serum 
albumin immunomicrospheres containing cisplatin and 5-fluorouracil may be an ideal 
vehicle to obtain targeted drug delivery, maintaining therapeutic drug levels to cause 
tumour death, whilst having a reduction in the severe side effects caused by the drugs. 
It is also hypothesized that sufficient doses of cisplatin and 5-fluorouracil can be 
delivered to tumour cells, effecting high tumour cell kill and less normal cell damage as 
the delivery system will be targeted by the attached monoclonal antibodies. The toxic 
side effects caused by the drugs should also be reduced. Thus, whilst possibly 
increasing the efficacy of the drugs, tolerance to the cisplatin and 5-fluorouracil should 
also be increased. 
We further decided to perform in vivo studies to evaluate the drug delivery system. 
Primary transplantable rodent ovarian epithelial tumours are to be raised by 
intraperitoneal injection of 4x106 DMBA-OC-1 R cells in female Wistar rats. Tumour 
specimens, 5 mm in diameter, are to be aseptically excised after allowing 14 days for 
tumour development, and transplanted into several groups of female Wistar rats. The 
secondary tumours will be allowed 14 days to establish growth before treatment 
commences. 
One group of tumour-bearing rats will be left untreated to establish average survival time 
whilst two other groups will be treated with cisplatin and 5-fluorouracil systemically and 
with intraperitoneally administered immunomicrospheres containing the drugs, 
respectively. Tumour growth or shrinkage will be monitored by x-rays using barium 
sulphate background contrasting to observe the efficacy of the drug delivery system 
regimen compared to the systemic administration of the drugs. Similar studies have 
been performed with other drug delivery systems such as liposomes, however, studies 
using human serum albumin immunomicrospheres as a combination drug therapy 
regimen with cisplatin and 5-fluorouracil appear to have not been performed to date. 
This project may indicate that immunomicrospheres may be an acceptable modality for 
targetable drug delivery for the treatment of ovarian epithelial carcinoma which may 
enhance the advantages and usage of cisplatin and 5-fluorouracil combination 
chemotherapy. This type of delivery system may also reduce or possibly overcome 
some, if not the majority, of the severe side effects caused by these drugs. 
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CHAPTER4 
MATERIALS AND METHODS 
Except where otherwise mentioned, all analytical reagents were of Analar grade. 
For making up of reagents, see Appendix. 
4.1 Albumin microsphere preparation 
The method used and modified was essentially that of Gallo et al. ( 1984) and Truter 
(1995), as this method complied with the variables which might effect the microsphere 
size and drug release characteristics. These variables were: albumin concentration, 
emulsion time, emulsification power, aqueous-to-oil phase volume ratio, stirring rate, 
emulsion drop rate, temperature of heat-stabilization and method of cooling the 
microsphere suspension. As a point of interest, Gallo's variables and microsphere sizes 
are shown in Table 1. 
Number of particles Mean particle 
Order of evaluation Variable Level counted diameter (µ ;I: SD} 
First Albumin concentra- 500 564 0,44 ± 0,30 
tion (mg/ml} 
Second Emulsification time 2 647 0,51 ± 0,28 
(min) 
Third Power of emulsi- 125 584 0,54 ± 0,32 
fication (W) 
Fourth Aqueous-to-non 1,0:30 231 0,61 ± 0,45 
aqueous phase 
volume ratio (VN} 
Fifth Stirring rate (rpm) 1500 755 0,48 ± 0,29 
Sixth Miscellaneous Standard* 346 0,58 ± 0,42 
Seventh Heat stabilization 145 507 0,49 ± 0,37 
temperature (°C} 
Eighth Non-aqueous phase Cottonseed oil 462 0,56 ± 0,33 
*Standard conditions were: emulsion added at 40 ± 10 drops/min, heat stabilized for 10 min and allowed to cool at room 
temperature 
Table 1: Mean diameters and standard deviations for albumin microspheres 
(Gallo et al., 19841 
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4.2 Entrapment of drugs in albumin microspheres 
4.2.1 5-Fluorouracil microsphere preparation 
Albumin microspheres in the size range 1-5 µ m in diameter, containing 5-fluorouracil (5-
FU) (Farmitalia Carlo Erba), proved relatively simple to prepare by thermal denaturation 
at 120 ° C and by slowing the homogenate drop rate to 30 ± 10 drops/min rather than the 
normal 40 drops/min at 145°C. 
• 170 ml of purified cottonseed oil (Needham Oil, RSA) was heated in a round 
bottom flask by a thermal mantle to 120°C, constantly being stirred by a propeller 
blade at 1700 rpm. 
• 5 ml of an aqueous 50% human serum albumin (HSA) (Western Province Blood 
Transfusion Service, RSA) solution and 5 ml of an aqueous 5-FU solution (cone. 
50 mg/ml) were added to 50 ml purified cottonseed oil at room temperature. The 
mixture was homogenized in a vortex mixer followed by sonication in a UMC 
ultrasonic bath (lnstrulab) for 30 minutes at 125 W . 
• The homogenate was injected into the heated cottonseed oil through a 16 gauge 
needle, cooled by an aqueous cooling mantle next to the propellor shaft, using 
a LKB 2132 microperpex peristaltic pump at a ratio of 30 drops/min. Steam, 
which developed in the reaction flask, was removed by vacuum. 
• After the emulsion was added, heating and stirring was maintained for a further 
1 O minutes. The heating mantle was then switched off but the stirring continued 
until the emulsion had cooled to room temperature. 
• Stirring was stopped and 200 ml diethyl ether added to the microsphere-
cottonseed oil suspension. This was mixed well . 
• The mixture was transferred to polypropylene centrifuge tubes and centrifuged 
at 4000 rpm in a Beckman L8-55 ultracentrifuge for 15 minutes at 10°C. After 
resuspending the microspheres in diethyl ether it was again centrifuged for 15 
minutes at 10°C. This procedure was repeated 4 times to ensure complete 
removal of the oil. The ether was washed from the microspheres by suspending 
them in absolute alcohol and centrifuging at 4000 rpm for 15 minutes at 10°C. 
This procedure was repeated 3 times to ensure complete removal of the ether. 
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• After collection the microspheres were lyophilized using an Edwards Model VIF-
03 freeze-drying apparatus. Upon freeze-drying, the glass sample collecting vials 
were sealed with Parafilm and stored at 4°C in the dark. 
4.2.2 Cisplatin microsphere preparation 
Albumin microspheres in the size range 1-5 µm in diameter, containing cisplatin (COOP) 
(Farmitalia Carlo Erba), were prepared essentially in the same way as 5-FU 
microspheres. The COOP concentration was 0,5 mg/ml H20 and the cottonseed oil 
temperature was 100° C in order to allow satisfactory release of the drug as described 
by Yapel (1985). 
4.3 Determination of drug encapsulation efficiency 
4.3.1 Determination of 5-fluorouracil entrapment 
The method to determine 5-FU concentrations were developed by the Department of 
Analytical Chemistry, Cape Technikon. 
• To determine the entrapment of 5-FU in the HSA matrix, 10 mg of 5-FU 
microspheres were fused with 10 mg of sodium hydroxide pellets for 2 hours at 
500°C. This mixture was dissolved in distilled water (made up to 25 ml), of which 
10 ml was mixed with 10 ml Total Ionic Strength Adjustment Buffer (Merck). A 
calibration curve (Fig. 1) was constructed using standard aqueous sodium 
fluoride solutions in the following concentrations: 0,5 ppm, 1,0 ppm, 2,0 ppm and 
5,0 ppm. 
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The fluoride concentration was read with a millivolt meter fitted with a fluoride ion 
selective electrode (Metrohm Mod. 632). Millivolts were plotted on a graph against the 
concentration (in ppm) to calculate the fluoride concentration in a sample. The 
measured fluoride concentration (ppm(Q)) was converted to ppm(s) by the following 
formula: 
ppm(s) = ppm(Q) x ml 
g 
The 5-FU concentration (ppm(s)) was calculated by the following formula: 
measured fluoride concentration X 
= concentration of 5-FU in ppm (s) 
mol. mass of 5-FU 
mol. mass of F-
= µg 5-FU/g microspheres or converted to mg 5-FU/g microspheres 
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4.3.2 Determination of cisplatin entrapment 
• The method of Morazzoni et al. (1995) was used to determine the entrapment of 
COOP in the HSA matrix. 1 O mg of COOP microspheres were wet ashed in 2 ml 
of a 3: 1 mixture of 65% nitric acid and 70% perchloric acid in a glass beaker and 
heated on a hotplate until no nitrous oxide fumes were visible. The mixture was 
allowed to boil until dry on the hotplate. 3 drops of 1 % hydrochloric acid was 
added to the flask and mixed, before the contents of the flask was transferred to 
a 100 ml volumetric flask and the volume made to 100 ml with distilled water. 
The digested sample was analyzed for its platinum content with a Varian Mod. 
AA 1275 atomic absorption spectrophotometer fitted with a graphite tube atomizer 
(GTA95). 20 µ I of sample was injected into the tube with a p20 Gilson 
Pipetteman automatic pipette. 
• The temperature programme was as follows (McGahan & Tyczkowska, 1987): 
• Boiling off all volatiles 
" Burning the albumin 
• Ashing of the carbon 
• AtomiZing the sample and 
reading Pt levels 
• Cleaning the system 
Temperature 
(OC) 
150 
150 
400 
400 
1500 
1500 
2700 
2700 
3000 
Time (s) Gas flow Read 
rate(l/min) command 
10 3 
10 3 
20 3 
10 3 
20 3 
20 3 
1.3 0 .; 
2 0 .; 
3 3 
A calibration curve (Fig. 2) was constructed using Titrisol platinum standard solutions 
(Merck) in the following concentrations: 0,0 ppm, 0,2 ppm, 0,5 ppm, 0,7 ppm and 1,0 
ppm. 
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Fig. 2: Calibration curve for platinum 
Absorbance was plotted on a graph against the concentration (in ppm). A linear 
regression was performed on the data to obtain the formula for the straight line (y = 
mx+c, where y = absorbance and x = concentration in ppm). The platinum 
concentrations were calculated from the measured absorbance values by using this 
regression line equation ( x = X.. - c ). The measured platinum concentration 
m 
(ppm(Q)) was converted to ppm(s) by the following formula: 
ppm(s) = ppm(Q) x ml 
g 
The COOP concentration [ppm(s)] was calculated by the following formula: 
measured platinum concentration X 
= concentration of COOP in ppm(s) 
mol. mass of COOP 
mol. mass of Pt 
= µg COOP/g microspheres or converted to mg COOP/g microspheres 
43 
Note: Steric stabilisation of HSA microspheres. 
It is often deemed necessary to change the hydrophobic surface properties of the 
microspheres to avoid uptake by cells of the reticuloendothelial system, such as 
peritoneal macrophages (lllum & Davis, 1982; Van Oss et al. , 1975). Heat-stabilised 
albumin microspheres are hydrophobic by nature. However, if treated with a non-ionic 
surfactant, such as Poloxamine 908 (BASF), to be adsorbed to the hydrophobic surfaces 
of the microspheres, they can be made hydrophilic, thereby reducing macrophage 
uptake. 
However, it is known that the adsorption of a monoclonal antibody molecule onto the 
surface of a microsphere may occur via either its antigen binding sites (Fab) or the Fe 
portion of the molecule. If the surface of the microsphere is hydrophilic, the specific 
antibodies tend to bind to the surface through the two Fab groups with the Fe portion 
protruding outwards, thus forming a more hydrophobic outer surface. In contrast, if the 
surface of a microsphere is hydrophobic, the Fe portions can bind to its surface thereby 
leaving the Fab binding sites free to bind with the antigenic cells (lllum et al., 1983). 
Hence, for the purpose of this project, the albumin microspheres were left untreated with 
surfactant as to allow for more Fab binding sites to bind with the antigenic tumour cells. 
4.4 Monoclonal antibody coupling to albumin microspheres 
4.4.1 Monoclonal Antibodies 
A monoclonal antibody, specific for the tumour tissue, DMBA-OC-1 R, was required for 
targeted drug delivery employing immunomicrospheres. 
Two lgM monoclonal antibodies were raised against the DMBA-OC-1 R cells as follows: 
Three BALB/c mice were each immunized intraperitoneally with 100µ1 of versened 
mycoplasma-free DMBA-OC-1 R cells at a concentration of 2 x 107 cells per ml. After 
14 days, they were each boosted with 100 µI of DMBA-OC-1 R cells at a concentration 
of 2 x 107 cells/ml. 14 days later, a small sample of blood was drawn from each mouse 
and tested for the production of antibody against DMBA-OC-1 R cells in an indirect 
ELISA. One mouse was boosted 3 days later, while the other two were boosted 3 
months later. Three to four days after the final booster, the mouse was sacrificed, its 
abdomen sterilised with 70% alcohol and the spleen carefully removed into sterile RPMI-
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1640 medium. The hybridomas were prepared by fusing the spleen cells of the mouse 
with the SP2 myeloma cells as follows (Brown & Ling , 1988): The SP2 cells were 
versened off two or three 90 mm Petri dishes, washed in RPMl-1640 medium, 
centrifuged, resuspended in RPMl-1640 medium and counted. The viability of these 
cells were checked by the Trypan Blue exclusion method. The spleen cells were 
collected by squeezing the spleen through a sterile stainless steel sieve with the plunger 
of a 2 ml syringe. After further washing with RPMl-1640 medium, the cells were 
resuspended in 2 ml of RPMl-1640 medium and the cell number was determined by 
making a 1: 100 dilution of the cells in white cell counting fluid. One tenth the number 
of SP2 cells was added to the 2 ml of spleen cells in a 50 ml centrifuge tube (Sterilin) 
and these cells were carefully pelleted by centrifugation at 1000 rpm for 5 min. The 
supernatant was discarded and the fusion of the plasma membranes of the cells was 
initiated by adding 1.5 ml of PEG 4000 (Merck) (warmed to 37°C), which permits closer 
contact of cells by reducing surface tension (Ritter, 1986), dropwise over a time period 
of 60 to 90 seconds with gentle mixing. A further 1 ml of warm RPMl-1640 medium was 
added over the next minute and then another 8 ml over 2 to 3 minutes. The tube was 
gently topped up to 45 ml with RPMl-1640 medium and the cells were centrifuged for 3 
minutes at 700-1000 rpm. The pellet was gently resuspended in 50 ml of HAT-HUCS-
RPMl-1640 medium. 500 µI of the cell suspension was added to each well of four 24-
well plates (Corning). Another 500µ1 of the HAT-HUCS-RPMl-1640 medium was added 
to each well. The positive control , indicative of a successful fusion, was provided by 
SP2 cells grown in HAT-HUCS-RPMl-1640 medium. The basis of this is the SP2 cell's 
lack of the enzyme, hypoxanthine phosphoribosyl transferase, which is required for the 
de novo synthesis of nucleotides. The SP2 cell is unable to utilise the salvage pathway 
of nucleotide synthesis when grown in the presence of aminopterin and will therefore die 
(Kuby, 1992). The clones were fed with another 500 µI of HAT-HUCS-RPMl-1640 
medium after 1 week and after another week, their supernatants were screened for 
antibody production using an ELISA The positive clones were subjected to further 
screening by testing the reactivity of the antibody with living, unfixed DMBA-OC-1 R, 
NRK and RESF cells in suspension, as well as with paraffin-embedded, formalin-fixed 
tissues by immunocytochemistry. The selected clones (anti-DMBA43 and anti-DMBA93) 
were subcloned twice by limiting dilution in HT-HUCS medium to ensure the 
monoclonality of the hybridomas. These two hybridomas were then expanded in RPMl-
1640 medium with 10% FCS (RP10) and stocks stored frozen in liquid nitrogen. 
Anti-DMBA43 and anti-DMBA93 were produced by the DMBA hybridomas grown in 
culture, either in RPMl-1640 medium with 10% FCS or in serum-free and protein-free 
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hybridoma medium (Sigma) and were harvested after 10-14 days, aliquoted and stored 
at-20°C. Anti-J138, an lgM antibody against Mycoplasma pyrum, anti-P-galactosidase, 
an lgG1 antibody, and anti-SM047, an lgM antibody against the SM047 ovarian 
carcinoma cell line, were produced by hybridomas established in the laboratory of the 
Department of Clinical Science and Immunology, University of Cape Town. The 
antibodies were stored at 4 ° C in the presence of O. 02% sodium azide (Merck) once they 
were thawed. The rabbit anti-mouse immunoglobulin class- and subclass-specific 
antisera (lgM, lgG 1, lgG2a, lgG2b, lgG3 and lgA), used in the isotyping of anti-DMBA43 
and anti-DMBA93, and rabbit anti-mouse immunoglobulins (lg) were obtained from 
Serotec (UK). Fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse 
immunoglobulins, peroxidase-conjugated goat anti-mouse immunoglobulins, biotinylated 
rabbit anti-mouse immunoglobulins and peroxidase-conjugated strepavidin were 
obtained from Dako (Denmark) . Normal rabbit, goat and rat sera were obtained from 
the Animal Unit (University of Cape Town, RSA). 
The hybridomas were screened (Brown & Ling, 1988) for immunoglobulin production by 
coating the wells of a Corning 96-well microtiter plate with 100 µ I per well of DMBA-OC-
1 R cells at a concentration of 1x105 cells per ml. The cells were incubated for 72 hours 
in a humidified 37°C incubator in the presence of 5% CO2. After the removal of the 
conditioning medium, the cells were air-dried overnight. The cells were fixed with 0.1 % 
glutaraldehyde (Merck) in 0.54 M PBS (pH 7.2) for 5 minutes. The plate was washed 
by gently submerging it in 0.54 M PBS 6 times after aspirating off the fixative. Any 
potential binding sites in the wells were then blocked with 200 µI per well of 0.54 M PBS 
containing 2% skim milk and 100 mM glycine (Merck) for 30 minutes at 37°C. The 
blocking buffer was discarded and 50 µI supernatant from each hybridoma clone was 
added to a well and allowed to bind for 90 minutes at room temperature. The mouse 
serum, diluted 1: 1600 in ELISA diluent, provided the positive control , while anti-P-
galactosidase served as the negative control. Unbound antibody was removed by 
washing the plate gently in Tris-saline-Tween (TST) (pH 8.0) 10 times. 100 µI of 
biotinylated sheep anti-mouse immunoglobulins, diluted to a concentration of 1 µg/ml in 
ELISA diluent, was added to each well for 60 minutes. The unbound antibody was 
washed away with two washes of TST. 100 µ I of a 1 :5000 dilution of peroxidase-
conjugated strepavidin was added to each well for 30 minutes. After the last 1 O washes 
with TST, 200 µI of the chromogenic substrate, ABTS, was added per well and the 
colour allowed to develop for 15-20 minutes. Absorbance was measured at an OD of 
405 nm on a Organon Teknika ELISA reader. 
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As both extracellular and intracellular antigens are recognised in the ELISA, the 
supernatants of the positive clones were subjected to further screening. This was done 
to isolate those antibodies which only recognise surface antigens on DMBA-OC-1 R 
cells, and not antigens on normal rat kidney or rat embryo skin fibroblasts. The reactivity 
of the antibodies was tested by means of immunofluorescence microscopy on living 
unfixed cells. 
Cells were versened or trypsinised off confluent 100 mm Petri dishes, washed in RPMl-
1640 medium, pelleted at 1500 rpm for 5 minutes and resuspended in RP10 medium. 
The cells were counted and diluted to 5 x 106 cells/ml. 50µ1 of the cell suspension was 
incubated together with 50 µI of antibody (undiluted harvest fluid) for 30 min on ice to 
prevent capping. 0.54 M PBS was added to dilute out the antibody and stop the 
reaction. The cells were then washed twice with 0.54 M PBS and pelleted at 1500 rpm 
for 5 minutes. The bound antibody was detected by incubating the cell pellet with 50 µI 
FITC-labelled goat anti-mouse immunoglobulins (diluted 1 :4000 in RP1 O medium) for 30 
minutes on ice. After the cells were washed twice in 0.54 M PBS, the cells were 
mounted in 10 µI of 30% glycerol in 0.54 M PBS. The coverslips were sealed with nail 
varnish to prevent the slides from drying out. The slides were examined by fluorescence 
microscopy (Olympus-BH2 microsocope with blue dichromic filter, blue excitation filter, 
EY auxilliary excitation filter and 6435 barrier filter) (Johnson, 1989). 
In order to select clones that reacted only with DMBA-OC-1 R tissue and not with normal 
rat tissue, the supernatants were tested on normal rat tissue sections. 
Normal rat tissues and DMBA-OC-1 R tumour tissue from a nude mouse were fixed in 
formalin, dehydrated, cleared and embedded in paraffin wax, cut into sections 3 µ m 
thick, mounted on albumin-coated glass slides and air-dried. Before the sections were 
stained, the slides were heated to 60°C to soften the wax and then the sections were 
deparaffinized in three changes of xylene (4 minutes each) and two changes of 100% 
ethanol (2 minutes each). The sections were brought to water through graded alcohols 
(1 0 dips each in 100% ethanol, 100% ethanol, 95% ethanol , 70% ethanol and distilled 
water). The sections were washed for 5 minutes in running tap water. Overfixed 
antigenic sites were revealed by incubating the sections in pre-warmed distilled water 
at 37°C for 1 o minutes, followed by a 5 minute incubation in 0.1 % trypsin (Difeo) in 0.05 
M Tris buffer (pH 7.6) (Isaacson & Wright, 1986). The digestion was stopped by placing 
the slides in cold running tap water for 5 minutes. After the slides were washed in 
distilled water for 5 minutes and in two changes of Tris-buffered saline (TBS), pH 7.6, 
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(5 minutes each), the sections were blocked with 10% normal goat serum in TBS for 30 
minutes. The test or control (anti-~-galactosidase) monoclonal antibody (undiluted 
harvest fluid) was added for one hour after aspirating off the blocking buffer. The 
sections were washed for 9 minutes in 3 changes of TBS. The sections were incubated 
with the detecting antibody, FITC-labelled goat anti-mouse immunoglobulins, diluted 
1:400 in RPMl-1640 medium with 10% normal rat serum. After washing the slides in 2 
changes of TBS for 1 O minutes, the cells were counterstained with 1 µg/ml of ethidium 
bromide (Sigma) and rinsed in water. The sections were mounted in 30% glycerol in 
PBS and examined by fluorescence microscopy at a wavelength of 495 nm (Van 
Noorden, 1986). 
The specificity of the selected clones was further checked by testing their reactivity with 
a number of cell lines from various species and organ origins. lmmunofluorescence 
microscopy was therefore performed on fixed cells. 
25 µ I of a versened cell suspension was added to each well of a Teflon-coated multi-well 
slide (Veenstra & Dowdle, 1992). The cells were air-dried overnight, fixed in acetone 
for 5 minutes and then washed in 2 changes of 0.54 M PBS. The slides were flooded 
with RP10 medium for 15 minutes before the primary antibody (undiluted harvest fluid 
of either the test antibodies, anti-DMBA43 or anti-OMBA93, or the control antibody, anti-
J 138) was reacted with the cells for one hour. Unbound antibody was removed by 
washing in 2 changes of PBS for a period of 10 minutes. The bound antibody was 
detected by incubation for 30 minutes with FITC-conjugated goat anti-mouse 
immunoglobulins (Oako) which were diluted 1:400 in RP10 medium. The cells were 
counterstained for 1 minute with ethidium bromide (1 µg/ml) (Sigma) after they had been 
washed in 2 changes of PBS. The slides were gently rinsed under running tap water, 
then mounted in 30% glycerol in PBS and examined with the fluorescence microscope 
at a wavelength of 495 nm. 
The selected clones (anti-DMBA43 and anti-OMBA93) were subcloned twice by limiting 
dilution to ensure monoclonality of the hybridomas; the hybridomas were expanded in 
RPM1-1640 medium with 10% Foetal Calf Serum and stocks were frozen in liquid 
nitrogen. The class of the antibodies was determined by means of an ELISA 
A Greiner ELISA plate was coated with 50 µ I per well of a 1: 1000 dilution in 0.54 M PBS 
(pH 7 .2) of rabbit anti-mouse immunoglobulin class-and subclass-specific antisera and 
incubated overnight at 4 °C. The plate was washed three times with 0.54 M PBS and 
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then the wells were blocked for 50 minutes with 200 µI per well of 0.1 % BSA (Boehringer 
Mannheim) in 0.54 M PBS. 50 µI of the harvest fluids containing the test antibodies (i.e. 
anti-DMBA93 and anti-DMBA43) or the control antibody (anti-SM047), was added per 
well for 50 minutes after the blocking solution had been poured off. After washing the 
plate 3 times with TST, 50 µI of a 1 :2000 dilution in blocking solution of peroxidase-
conjugated goat anti-mouse immunoglobulins (Dako) was added per well for 30 minutes. 
The plate was washed 5 times with TST. Colour development was produced by adding 
100 µI of ABTS substrate per well. The colour was allowed to develop for 25 minutes 
and the OD was read at 405 nm on the ELISA reader. 
4.4.2 Purification of the monoclonal antibodies 
Anti-DMBA43 and anti-DMBA93 antibodies were purified by means of hydroxyapatite 
chromatography (Harlow & Lane, 1988) from conditioned media of hybridomas grown 
for 10-14 days in serum-free and protein-free hybridoma medium (Sigma) or in RPM1-
1640 medium with 10% Foetal Calf Serum or ascites from Balb/c mice. 
The matrix of the column was prepared by hydrating 2 g of biogel HTP (Biorad) in 40 ml 
of 1 O mM sodium phosphate buffer (pH 6.8) and tumbling it for 15 minutes at room 
temperature. The matrix was allowed to settle for 15 minutes, the supernatant was 
removed and the matrix was washed by tumbling with another 40 ml of 1 O mM sodium 
phosphate buffer. After the matrix was washed for a third time, it was transferred to a 
5 ml syringe column with a glass-sintered filter disc at its base. The matrix settled 
overnight and it was then washed with 5 column volumes (50 ml) of 1 O mM sodium 
phosphate buffer. The harvest fluid or ascites was centrifuged at 1 O 000 rpm and 
loaded on the column. The ascites was diluted 1:10 with distilled water prior to 
centrifugation. The column was washed with 1 O column volumes ( 100 ml) of 1 O mM 
sodium phosphate buffer (pH 6.8). The antibodies were eluted by raising the 
concentration of the sodium phosphate buffer (pH 6.8). 5 ml of each of the following 
concentrations were used: 50 mM, 100 mM, 200 mM and 300 mM and 1 ml fractions 
were collected. The column was washed with 1 O column volumes of 1 O mM sodium 
phosphate buffer and stored. The absorbance of the fractions were determined at an 
OD of 280 nm on a Unicam SP1800 UV spectrophotometer to establish the peaks. 
These fractions containing the peaks were then electrophoresed on SOS-PAGE gels to 
determine the location and purity of the antibodies. 
The proteins were subjected to one-dimensional denaturing gel electrophoresis on 11 % 
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sodium dodecylsulphate (SDS)-polyacrylamide gels according to the method of Laemelli 
( Coligan et al., 1995). The analysis was performed under reduced conditions. The 
protein samples to be analysed were diluted with an equal volume of double strength 
SOS/sample buffer containing the reducing agent, dithiothreitol (OTT} (Sigma). The final 
concentration of OTT in the sample/sample buffer mixture was 1 O mg/ml. The samples 
were boiled for 2 minutes and 12 µ I of the sample was loaded per well on a 15 cm x 9 
cm gel. High and low molecular weight markers (BDH Electran) were also boiled for 2 
minutes prior to loading. Electrophoresis was performed at room temperature. Initially 
a constant current of 1 O mA was applied to the gel and then, once the bromophenol blue 
tracking dye had entered the separating gel, it was increased to 20 mA. After 
electrophoresing the samples, the gel was stained with 0.1 % PAGE Blue stain for 1 hour 
and then destained with a 30% methanol: 10% acetic acid:60% distilled water mixture. 
The protein concentration was determined by means of the SCA protein test (Pierce)as 
follows: 
The working reagent (Pierce) was prepared by mixing 50 parts of Reagent A to 1 part 
of Reagent 8. The standard curve was prepared by diluting the Bovine Serum Albumin 
(BSA) provided in the kit, in the same diluent as the sample to the following 
concentrations: 1.2 mg/ml, 1.0 mg/ml, 0.8 mg/ml, 0.6 mg/ml, 0.4 mg/ml and 0.2 mg/ml. 
1 O µ I of the standard and samples were added to 200 µI of the working reagent in the 
wells of a microtiter plate. The plate was incubated at 37°C for 30 minutes and the OD 
was read at 405 nm on the ELISA reader. The concentrations were calculated by a 
programme for protein determinations in the ELISA reader which utilises the parameters 
obtained by fitting the linear regression curve to the standard curve. 
Antibodies purified from ascites were found to be heavily contaminated with serum 
albumin and other proteins. An attempt was made to reduce excess protein 
contamination by precipitating the antibody with ammonium sulphate (Coligan et. al., 
1995; Harlow & Lane, 1988). 
A predetermined volume of antibody was transferred to a beaker on a magnetic stirrer 
and stirred gently with a magnetic stirring bar. Ammonium sulphate crystals were added 
slowly to give a final concentration of 50% saturated ammonium sulphate solution so 
that the mouse antibodies would precipitate. The mass of crystalline ammonium 
sulphate (CAS) was calculated as follows: 
CAS (g) = (0.5 x volume of antibody) x 76/100 
Saturated ammonium sulphate = 760 g/1 
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The beaker was placed at 4 °C overnight and the precipitate was microfuged at 1 O 000 
rpm for 30 minutes. The supernatant was discarded and the pellet resuspended in a 0.1 
to 0.3 of the original starting volume of the antibody in 0.54 M PBS (pH 7.2). The 
antibody solution was transferred to dialysis tubing or to an Eppendorf tube for dialysis. 
Dialysis tubing was placed over the mouth of the Eppendorf tube and secured with the 
lid of the tube in which a large hole had been made to allow dialysis. Dialysis took place 
overnight versus three changes of 0.54 M PBS. The antibody solution was microfuged 
to remove any remaining debris and subjected to SDS-polyacrylamide gel 
electrophoresis in order to check the purity. The concentration of the antibody solution 
was determined by the BCA protein test. 
4.4.3 Attachment of monoclonal antibodies to human serum albumin 
microspheres 
The carbodiimide method of lltum and Jones ( 1985) was employed to attach the 
monoclonal antibodies. By this method, a water-soluble carbodiimide derivative is used 
to activate carboxyl groups present on the surface of the microspheres and thereby 
couple the amino group on the antibody molecule to the carboxyl group through an 
amide linkage. Alternatively, an amino group on the microsphere can be coupled to a 
carboxylic acid group on the antibody via this method. 
When microspheres do not carry groups which can link directly to the monoclonal 
antibodies, or when it is uncertain which groups they carry, it is possible to obtain 
antibody attachment by means of the carbodiimide method. The antibodies were 
dialysed versus 3 changes of 0, 1 M sodium chloride solution at pH 7,0 at 4 °C, prior to 
use. 0,5 mg/ml monoclonal antibodies (anti-DMBA43 and anti-DMBA93 at a 1:1 ratio) 
was added to each 50 mg of HSA microspheres. 1 O mg of 1-ethyl-3- (3-
dimethylaminopropyl) carbodiimide (Sigma) was added and the coupling reaction of 
antibodies to microspheres allowed to occur for 2 hours at 4 °C. The coupling reaction 
was then terminated by the addition of 0,03 g glycine for 2 hours at 4°C. The 
immunomicrospheres were then washed 3 times in PBS (pH 7.2) for 5 minutes with 
centrifuging between washings at 3000 rpm for 1 O minutes to remove the glycine and 
uncoupled antibodies. The supernatant was discarded after the final spin and the 
immunomicrospheres lyophilized and stored dry at 4 °C. 
4.5 Drug release from the immunomicrospheres 
In order to assess the availability of drug released from the immunomicrospheres, two 
separate experiments were conducted in which 150 mg 5-FU-loaded 
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immunomicrospheres and 150 mg COOP-loaded immunomicrospheres were incubated 
at 37°C in 3 ml fresh, sterile plasma. Leakage of 5-FU and/or its metabolites and COOP 
out of the immunomicrospheres were monitored at the first and every second day 
thereafter for a 14 day period. 
For 5-FU assays, plasma was sampled and 150µ1 supernatant added to 450 µI distilled 
water and filtered through a Millipore filter (pore size= 0,22µm). 200 µI of the filtrate 
was fused with 20 mg sodium hydroxide pellets for 2 hours at 500°C before dissolving 
in 25 ml distilled water of which 10 ml was mixed with 10 ml Total Ionic Strength 
Adjustment Buffer (Merck). The fluoride concentration was read with a pH meter having 
an ion selective fluoride electrode (Metrohm Mod. 632). The total 5-FU concentration 
was calculated as in Section 4.3.1 . 
For COOP assays, plasma was sampled and 150 µI supernatant added to 450µ1 distilled 
water and filtered through a Millipore filter (pore size = O, 22 µ m). 20 µI of the filtrate was 
analyzed directly in a Varian Mod. AA1275 atomic absorption spectrophotometer fitted 
with a graphite tube atomizer (GTA95). The sample was injected into the tube with a 
p20 Gilson Pipetteman automatic pipette. The COOP concentration was calculated as 
in Section 4.3.2. 
4.6 Morphology of the immunomicrospheres 
Using a Nikon Ultiphot light microscope, several fields of unstained 
immunomicrospheres were viewed. Eyepiece and stage micrometers were used to 
determine the size of the microspheres, as it was decided that they should be 
significantly smaller than the target cells as to possibly attach several microspheres to 
the cells and thus delivering higher concentrations of drugs. 
Samples for scanning electron microscopy were placed on aluminium specimen stubs 
and dried in an oven at 37°C overnight. Coating with 30 nm of gold was performed, 
using a Balzers sputter coater. The samples were then examined and sized in a 
Cambridge Stereoscan S 180 M scanning electron microscope at an accelerating 
voltage of 25 KV at various magnifications using latex spheres (0,5 µm; Polaron) as 
controls for sizing (750 microspheres per batch were examined). 
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4.7 Maintenance of the cell lines 
The rat ovarian adenocarcinoma cell line, DMBA-OC-1R, was a gift from Dr Akio 
Kataoka (Department of Obstetrics and Gynaecology, Kurume University, Kurume, 
Japan) and was established from an ovarian adenocarcinoma induced in rats by the 
carcinogen, 7, 12-dimethylbenz(a)anthracene (lmaishi , 1992; Kataoka et al., 1987; 
Sugiyama et al., 1986). The cells were passaged by splitting them in a ratio of 1: 1 O. 
Normal rat kidney cells were obtained from Dr J de Laree of the National Institute of 
Health (USA). Rat embryo skin fibroblasts (RESF) and six other cells lines were 
established in the Department of Clinical Science and Immunology, University of Cape 
Town (RSA). Goliath, Kercheff and Seafield cell lines were established from human 
ovarian carcinomas and Small, from a human melanoma. The B-Ov2 cell line was 
established from an ovarian metastatic deposit that had been excised from a nude 
mouse which had been inoculated subcutaneously with the human Bowes melanoma 
cell line. Regina (UCT-Br 1) cell line was established from a human breast carcinoma. 
UW-OV-1 , a human ovarian serous cystadenocarcinoma, was obtained from the 
University of the Witwatersrand Medical School. The following cell lines were obtained 
from the American Tissue Type Culture Collection (ATCC): MTW9/PL (a rat mammary 
gland carcinoma), SP2 (a mouse myeloma), SK-OV-3 (a human ovarian carcinoma), 
GH3 (a rat pituitary tumour), MCF7 and MDA-231 (human breast adenocarcinomas), T-
47D (a human breast carcinoma) and K562 (a chronic myelogenous leukemic cell line). 
The cell lines were maintained under sterile conditions in RPMl-1640 medium (Sigma) 
supplemented with 10% foetal calf serum (FCS) (State Vaccine, RSA) , penicillin 
(lntramed, RSA) and streptomycin sulphate (Merck) at 37 °C in a humidified 5% C02'95% 
air incubator (Hotpack). They were fed with medium and passaged twice weekly with 
versene or trypsin. Stocks were stored frozen in liquid nitrogen in RPMl-1640 medium 
with 10% FCS and 10% dimethyl sulphoxide (DMSO) (Freshney, 1983). 
For use, a vial of cells was removed from the liquid nitrogen and the cells thawed 
immediately in a 37°C waterbath . Following thawing, the cells were quickly transferred 
to a centrifuge tube containing 10 ml RP10 medium to dilute out the DMSO. The cells 
were centrifuged at 1500 rpm for 5 minutes. The cell pellet was resuspended in 1 ml of 
RP10 medium and the cells transferred to a 60 mm Petri dish (Corning) and incubated 
at 37°C in a humidified 5% C02'95% air incubator (Hotpack) . 
53 
Cells were routinely checked for mycoplasma infection (Freshney, 1983). Mycoplasma 
was detected by means of immunocytochemistry on multi-well test slides coated with 
OMBA-OC-1 R cell monolayers (Veenstra & Dowdle, 1992). 25 µI of a cell suspension 
was added to each well of a Teflon-coated multi-well test slide (Highveld Biologicals, 
RSA) and the slide was left to air dry. The cells were fixed by flooding the slide with 
Carnoy's fixative (1 part acetic acid : 3 parts methanol) for 5 minutes. The fixative was 
removed using a Pasteur pipette and suction. After more fixative was added for a 
further 1 O minutes, it was poured off and the slide was air-dried for 30 minutes. The 
slide was flooded with Hoechst 33258 stain which was either diluted 1 :400 in 0.54 M 
phosphate-buffered saline (PBS) (pH 7.2) if fresh, or undiluted if old. It was left for 10-
30 minutes in the dark. The stain was removed by suction and the slide washed in a 
Coplin jar with distilled water three times (1 minute per wash). The slide was drained, 
air-dried and mounted in 30% glycerol (Merck) in PBS. The nucleus fluoresced as 
expected when observed under a fluorescent microscope (Olympus BH-2). The 
appearance of granules of fluorescence in the cytoplasm indicated that the cells were 
contaminated with mycoplasma. 
Mycoplasma-infected cells were treated as follows: 
Human serum containing active complement was prepared from fresh blood by allowing 
the blood to clot for 45 min at 4 °C and centrifuging the sample to remove the clot. The 
serum was sterile-filtered and stored at -80°C until required. The adherent monolayer 
of infected cells was rinsed three times with RPMl-1640 medium before the cells were 
versened off the dish. The cells were pelleted at 1500 rpm and washed once again with 
RPMl-1640 medium before they were resuspended in RPMl-1640 medium containing 
10% human serum complement and incubated in a tube at 37°C in a 5% CO2 humidified 
incubator. After 2 hours, the medium was changed and the cells were incubated for 
another 2 hours with RPMl-1640 medium containing 10% human serum complement. 
The cells were pelleted and incubated overnight with RPMl-1640 medium containing 
human serum complement in a Petri dish (Corning). An aliquot of treated cells was 
tested for mycoplasma after they had been washed three times with RPMl-1640 
medium, versened off the dish, pelleted and resuspended in RP10 medium (RPMl-
1640+10%FCS). 
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4.8 In Vitro Studies: 
4.8.1 Drug treatment of DMBA-OC-1 R cells for use in clonogenic assays 
and cell survival growth curves 
The cytotoxic effects of either CDDP and 5-FU, either administered on their own or in 
combination, in either the free form or encapsulated in albumin microspheres, on DMBA-
OC-1 R cells were studied. The long term effects of the drug were evaluated by either 
studying the ability of cells to form clones in soft agar after treatment or by establishing 
cell survival growth curves in vitro. 1 x 105 DMBA-OC-1 R cells were seeded in 2 ml of 
RP10 medium in 35 mm Petri dishes and allowed to adhere overnight in a 37°C 
humidified CO2 incubator before exposing the cells to drugs. The cells were incubated 
for varying periods of time, ranging from 1 hour to 96 hours, with either free drug or 
encapsulated drug. Control samples consisted of cells that had not been exposed to 
drugs. The concentrations of COOP drug administered varied from 0.01 µg/ml to 1 
µg/ml in the free form and from 5 µg/ml to 25 µg/ml in the encapsulated form while that 
of 5-FU varied from 0.1 µg/ml to 1 µg/ml for the free form and from 5 µg/ml to 25 µg/ml 
when cells were treated with microspheres. After drug exposure, the cells were rinsed 
with RPMl-1640 medium and then detached with versene, centrifuged and the cell pellet 
washed 3 times with RPMl-1640 medium. After the final wash, the pellet was 
resuspended in 2 ml of RP1 O medium and the cell number and viability was determined. 
4.8.1.1 Clonogenic assay 
After treatment, the cell number was adjusted to 2.5 x 103 cells per ml of RP1 O medium. 
The cell/agar layer was prepared as follows: 1 O ml of molten 1 . 32% agar (Bacto Difeo 
agar from Difeo) was mixed with 8 ml 2X RPMl-1640 medium and 2 ml FCS. This 
mixture was kept at 42°C until required . 1 ml of cells was mixed with 1 ml of the agar 
mixture. 0.5 ml of the cell/agar mixture was seeded on top of a feeder layer of 0.5 ml 
0.5% agar in the wells of a 24-well plate (Corning) (i.e. 625 cells were seeded). The 
feeder layer of agar was prepared as follows: 1 O ml of molten 1 % agar was mixed with 
8 ml 2X RPMl-1640 medium and 2 ml FCS. 0.5 ml of the agar (0.5%) was added to each 
well of a 24-well plate and allowed to set before the cell/agar layer was added. Each 
dosage sample was set up in triplicate. The plates were incubated for 14 days in a 
humidified 37°C incubator containing 5% CO2. The colonies were fixed with 250 µI 3% 
glutaraldehyde in 0.54 M PBS and scored. 
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4.8.1.2 Cell survival growth curves 
Cell survival growth curves were generated in order to study the recovery of cells after 
drug treatment. The cell number was adjusted to 1.25 x 104 cells per ml of RP1 O 
medium. 2 ml of cells (2.5x104 cells) in RP1 O medium was plated onto 35 mm Petri 
dishes (Corning). 10 Petri dishes per drug dosage was set up. Cell number was 
assessed on a daily basis over a time interval of 168 hours. 2 Petri dishes per drug 
dosage per time point were counted. The viability of the cells was also determined using 
trypan blue (Sigma). At each time point the remaining Petri dishes of cells that were still 
to be counted, were fed by removing the old culture medium and adding 2 ml of fresh 
RP10 medium. 
4.8.2 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) cytotoxicity assay 
The in vitro cytotoxicity of CDDP and 5-fU, either alone or in combination, as well as in 
either the free drug or encapsulated form, was evaluated by using the MTT assay. This 
assay was used to assess the viabilty of cells after continuous exposure of the cells to 
drugs or to study the proliferation of cells after exposure to drugs (i.e. the long term 
effect). 
The survival of cells after continuous exposure to drug was evaluated as follows: A 
single cell suspension of DMBA-OC-1 R cells was obtained and the cell number adjusted 
to 5 x 104 cells per ml of RP10 medium. 100 µI of cells (5x103) were aliquoted into the 
wells of flat-bottom 96-well plates (one set of plates per time point) . After allowing the 
cells to adhere overnight, the culture medium was removed and 200 µI of RP 1 O medium 
containing the appropriate amount of drug was added to each well. Cells were exposed 
to concentrations of 'free' CDDP ranging from 0.01 µg/ml to 1 µg/ml and 'free' 5-Fu 
ranging from 0. 1 µg/ml to 1 µg/ml. The cells were also exposed to CDDP and 5-FU 
encapsulated in albumin microspheres in concentrations ranging from 5 µg/ml to 25 
µglml. The control population was provided by cells that had not been exposed to drugs. 
Each dosage sample was set up in triplicate. The plates were incubated for varying 
lengths of time ranging from 24 to 120 hours and the surviving cells assayed for 
reduction of MTT. 
The long term effect of the drugs after exposure was evaluated as follows: 
1 x 105 DMBA-OC-1 R cells were seeded per 35 mm Petri dish (Corning) containing 2 
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ml of RP1 O medium. After allowing the cells to adhere overnight, the cells were exposed 
to 'free' drugs for 24 hours. The final concentration of COOP in 2 ml of RP1 O medium 
ranged from 0.01 µglml to 1 µg/ml and that of 5-FU from 0.1 µglml to 1 µg/ml. Cells 
were also exposed to concentrations of encapsulated COOP or 5-FU ranging from 5 
µglml to 25 µg/ml for 96 hours. The control consisted of cells that had not been exposed 
to drug. After drug exposure, the cells were rinsed with RPMl-1640 medium and then 
detached from the surface of the dishes with versene. They were washed three times 
with RPMl-1640 medium to remove any traces of drug. After the final wash, the cell 
pellet was resuspended in RP10 medium and then the cell number and viability was 
determined. The cell number was adjusted to 5 x 104 cells per ml. 5 x 103 cells in a 100 
µI of RP1 O medium were seeded in the wells of flat-bottom 96-well plates (Corning). 
The proliferation of drug-treated cells was assayed on a daily basis over a 168 hour 
interval using the MTT assay. One plate was set up for each time point. Each sample 
was set up in triplicate per time point. 
A stock solution of 1 mg/ml MTT (Sigma) was prepared in phenol red-free RPMI medium 
(Sigma R-7509) and stored in the dark at 4°C for two weeks or frozen at -20 °C. Four 
hours before the end of the appropriate incubation time at 37°C in a humidified 5% CO2 
incubator, the culture medium was removed by aspiration, 100 µ I of MTT ( 1 mg/ml) was 
added to each well and the plate returned to the incubator to complete the incubation 
time. Untransformed MTT was removed by careful aspiration so as not to disturb the 
blue formazan crystals. 100 µI OMSO (Merck) was added to each well to dissolve the 
formazan crystals and the absorbance was measured at 540 nm on the ELISA reader. 
The amount of formazan present is proportional to the number of viable cells as only 
living cells will reduce MTT to blue formazan. Results were expressed as a % of the 
absorbance of the MTT reduced by the control cells. Wells containing no cells were 
used as blanks. 
4.8.3 Assessment of nuclear damage caused by 5-fluorouracil and 
cisplatin (free drug and encapsulated) by induction of micronuclei 
The presence of micronuclei in a cell is an indicator of chromosomal damage. In order 
to assess the cytotoxicity of COOP and 5-FU at the molecular level in DMBA-OC-1 R 
cells, micronuclei were induced. DMBA-OC-1 R cells were detached from the surface of 
two 25 cm2 culture flasks (Corning) with versene and centrifuged at 1500 rpm for 5 
minutes. After discarding the supernatant, the cells were resuspended and washed in 
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RPMl-1640 medium and centrifuged at 1500 rpm for 5 minutes. The cell pellet was 
resuspended in 5 ml RP1 O medium and the cell number was determined. The cell 
number was adjusted to 5 x 104 cells per ml. 2 ml of the cell suspension was seeded 
on top of sterile coverslips placed in 35 mm Petri dishes (Corning). The cells were 
allowed to adhere to the coverslips overnight in a 37°C humidified incubator containing 
5% CO2 before the drug treatment commenced. The culture medium was removed and 
to each Petri dish, 2 ml of RP1 O medium containing either COOP, 5-FU or a combination 
of both drugs (encapsulated or in the free form) at the appropriate concentration, was 
added. The amount of 'free' COOP that was added ranged from a final concentration 
of 0.005 µg/ml to 0.1 µg/ml, while that of 'free' 5-FU ranged from 0.5 µg/ml to 10 µg/ml. 
The concentrations of drug that was encapsulated in albumin microspheres ranged from 
10 µg/ml to 25 µg/ml for both COOP and 5-FU. Each dose was set up in triplicate. The 
control consisted of cells which had not been exposed to drug. After exposing the cells 
to the drugs for either 1, 24 or 96 hours, the drug-containing medium was removed and 
the cells were rinsed three times with RPMI -1640 medium to remove any trace of drug 
that had not been taken up by the cell. 2 ml of RP1 O medium was added to each Petri 
dish and then, in order to induce mitotic arrest in the cells, cytochalasin-8 (Sigma) was 
added to each Petri dish to give a final concentration of 2 µg/ml for 24 hours. The cells 
were fixed with cold fixative consisting of 3 parts methanol to 1 part acetic acid. After 
air drying the cells, they were stained with 0,001 % acridine orange in phosphate buffer 
(pH 6.8), a nuclear specific stain, for 1 minute and rinsed five times with distilled water. 
The coverslips containing the cells were mounted in buffer and the cells were examined 
using fluorescence microsocopy at 495 nm. The nucleation index in each sample was 
determined and the micronuclei in binucleated cells enumerated. 
4.9 The tumour host system 
Note: Prior to the experimental procedures performed on the animals.approval by the 
Ethics Committee of the Faculty of Medicine, UCT was obtained. 
All the experiments used female rats of the Wistar albino strain at age 8-1 O weeks and 
weighing ± 200g . Very young rats were chosen as to minimise possible antigenic 
interaction between the implanted tumours and their hosts, often found in older animals. 
The original breeding pairs were obtained from the animal unit of the Medical Research 
Council (RSA) where the strain has been inbred for more than 20 years. In our 
laboratory, the strain was further inbred by brother-sister mating for over 4 years without 
selective sublining. No exogenous oncogenic virus or carcinogenic substances have 
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ever been introduced into the laboratories or animal house in which the rats were 
housed. 
The environmental temperature of the animal house was kept constant at approximately 
25°C. The cages in which they were kept, were cleaned in the same way each time by 
the same personnel and the bedding consisted of a mixture of sterile straw and corn 
cobs. Fresh water was readily at each animal's disposal, as well as rat and mouse 
breeder feed (Animat Specialities, RSA). The composition of the feed was as follows: 
Composition g/kg 
Protein (min) 210 
Fat (min) 40 
Fibre (max) 60 
Moisture (max) 120 
Phosphorous (min) 8 
Calcium (max) 18 
The animals were always handled by the same personnel who checked them for 
pregnancy, transferring to other cages, anaesthetising, collection of blood, tumour 
inoculation, etc. as to keep stress levels as low as possible. 
For blood collection, use was made of Halothane (Rhone-Poulec Rorer, RSA) inhalation 
to induce mild anaesthesia to restrain the animals for approximately 15-30 minutes. For 
surgical procedures, a mixture of Ketalar (Warner-Lambert, RSA) and Rumpon (Bayer, 
RSA) was used at a dose of 0, 14 ml/kg. This dose was found to anaesthetise the 
animals for approximately 20 minutes to 4 hours. This anaesthetic mixture was 
preferred to pentobarbital anaesthesia, which frequently shows some serious side 
effects on vital regulatory processes in small laboratory animals. 
Blood was collected for haematological and biochemical assays from the tail vein, after 
cleaning and disinfecting the skin with a 70% ethyl alcohol swab and restraint of the 
animal under mild Halothane anaesthesia. For haematological studies, 200 µ I of blood 
was collected into Microtainer (Becton Dickinson, RSA) tubes containing EDT A 
anticoagulant. A further 500µ1 of blood was collected for blood chemistry and allowed 
to clot before separating the serum from the cells by centrifugation at 2500 rpm for 15 
minutes. The serum was used for the assays. 
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As background contrast medium for taking X-ray images, approximately 1 ml 70% 
barium sulphate (X-ray grade, Kyranhebo, RSA) in egg albumin was slowly injected 
directly into the stomach via a 1,5 mm latex tube inserted into the stomach through the 
oral cavity and oesophagus. For this procedure mild Halothane anaesthesia was 
employed. 
X-rays were performed under Ketalar/Rumpon anaesthesia in a Shimadzu condensor 
discharge mobile unit at 50 KV and 120 mAs. 
4.9.1 Drug distribution studies 
To determine the drug distribution to the major organs, 2 groups of 1 O female Wistar 
rats were respectively injected with 20 mg/kg of 5-FU and 25 mg/kg of COOP via the tail 
vein . The rats were sacrificed at 2 hours for 5-FU determination and at 4 hours for 
COOP determination, respectively. After exsanguination, the major organs were 
removed and the drug levels (5-FU and COOP) and/or its metabolites determined by the 
methods described in Section 4.3.1. 
4.9.2 Blood chemistry and haematological profiles for the assessment of 
the effects of 5-fluorouracil and cisplatin (free drug and 
encapsulated) in female Wistar rats 
To obtain blood chemistry and haematological profiles of the effects of 5-FU and COOP 
in combination (free drug and encapsulated), 3 groups of 20 female Wistar rats, 
weighing ± 300 g, were used. 
Group I rats (free drug group) were injected intraperitoneally with a combined bolus dose 
of chemotherapeutic agents containing 5 mg/kg COOP and 20 mg/kg 5-FU. 
Group II rats (high dose immunomicrosphere group) were injected intraperitoneally with 
a combined bolus dose of immunomicrospheres containing 1 O mg/kg COOP and 40 
mg/kg 5-FU. The reason why the dose was double that of Group I was because of the 
slow fashion in which the drugs are released from the immunomicrospheres and to 
achieve optimum drug delivery at the target site. 
Group Ill rats (no drug group) were the control animals. No drug treatment was given 
to this group. 
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From each rat of each group, 200 µI of blood was collected into Microtainer (Becton 
Dickinson, RSA) tubes containing EDT A anticoagulant for haematological studies. This 
included white blood cell count, platelet count, haemoglobin, hematocrit, red blood cell 
count, red blood cell indices and differential leucocyte count. Haematology counts and 
indices were performed on a Coulter T890 cell counter. The differential leucocyte count 
was performed on a methanol-fixed blood smear stained with Wright's stain (Merck) and 
counted on a Leitz Laborlux K light microscope utilizing a 50x oil immersion objective. 
A further 500 µI of blood was collected from each rat for blood chemistry. The blood 
was allowed to clot before separating the serum from the cells by centrifugation at 2500 
rpm for 15 min. The serum was used to quantitatively measure urea, creatinine, lactate 
dehydrogenase, gamma glutamyl transferase, alkaline phosphatases, alanine 
aminotransferase and aspartate aminotransferase. Blood chemistry was performed on 
a Ciba Corning Express Plus random access analyzer. 
4.9.3 The tumour model 
Primary, transplantable rat ovarian adenocarcinomas were induced in 1 O female Wistar 
rats, 3-6 weeks old and weighing 40-100 g by intraperitoneal inoculation of 4x106 DMBA-
OC-1 R cells, suspended in RPMl-1640 medium, using a 27 gauge needle. The tumours 
were allowed to establish themselves for 14 days in the animals. Abdominal distension 
due to the accumulation of ascitic fluid was considered to be evidence of reasonably 
sized tumour-formation. X-rays were also taken to observe for tumour mass formation. 
The rats were sacrificed by decapitation and the primary tumours immediately removed 
aseptically and placed in a sterile Petri dish containing RPMl-1640 medium at 37 °C. 
After dicing the tumour into 3 mm3 cubes, the tumour tissue was transplanted 
intraperitoneally into 4 groups of 20 female Wistar rats, 4-8 weeks old and weighing 80-
120 gm. Secondary tumours were allowed to develop for 10 days in the peritoneal 
cavities of each animal before treatment commenced. Also, a few 3mm3 cubes of 
tumour tissue were placed in RP10 medium for cell counting. Any fat was trimmed off 
the tissue. The tissue was minced with a pair of scissors and then placed in a 
McCartney bottle containing 1 O ml of a 0.25% trypsin solution (Difeo 1 :250) and a 
magnetic stirring bar. Digestion took place at 37°C for 20 minutes with slow stirring. 
Erythrocytes were then lysed with 0,83% ammonium chloride for 5 minutes. The cells 
were washed twice for 5 minutes per wash with RPMl-1640 medium, and pelleted by 
centrifugation at 1500 rpm for 5 minutes. A cell count of the tumour cells was performed 
using an Improved Neubauer haemocytometer and RP10 medium as the diluent. 
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Samples of the primary and secondary tumours were taken for electron microscopical 
examination and placed in cold 2,5% phosphate buffered glutaraldehyde for further 
processing. Samples were also taken for histological examination and placed in 10% 
formal-saline for further processing. 
4.9.3.1 Tissue preparation for light (LM) and transmission microsocopy 
(TEM) 
Tissue specimens for LM were collected in 10% formal-saline at room temperature. 
Representative samples were trimmed to a thickness of 3 mm and further fixed in 10% 
formal-saline for 24 hours at room temperature. The tissues were further processed in 
an automatic tissue processor (Shandon Duplex) for routine paraffin wax embedding i.e. 
fixation, dehydration, clearing and impregnation before final blocking of the tissue in 
Histosec embedding medium (Merck). 
Tissue sections (3 µ m thick) were cut on a Reichert OmE sliding microtome with a sharp 
steel knife, floated on the surface of a warm water bath and picked up on clean glass 
slides. 
Deparaffinisation was done in xylene and the sections hydrated through graded ethanol 
solutions (100%, 96%, 70%) to distilled water before staining. The following staining 
methods were performed: (1) Haematoxylin and Eosin; (b) Alcian Blue PAS; (c) Reticulin 
stain ; (d) Van Gieson and (e) Southgate's Mucicarmine, (see Appendix for methods). 
After coverslipping the sections, they were viewed at various magnifications with a light 
microscope. 
Tissue specimens for TEM were collected in cold 2,5% phosphate buffered 
glutaraldehyde (Merck) at pH 7,4. After dicing into 1 mm3 cubes, the tissue blocks were 
further fixed in fresh 2,5% phosphate buffered glutaraldehyde for 8 hours at 4 °C. After 
2 rinses of 15 minutes each in cold phosphate buffer (pH 7,4), secondary fixation of the 
tissue blocks occurred in cold 1 % osmium tetroxide in veronal-acetate buffer (pH 7,4) 
for 1 hour. The tissue blocks were washed 3 times for 1 O minutes each in distilled water 
and then dehydrated in graded ethanol solutions (70%, 96%, 96%+1 % uranyl nitrate, 
100%). The blocks were then impregnated with equal amounts of Spurr's resin and 
100% ethanol for 90 minutes. Two changes of pure Spurr's resin were used for 60 
minutes each at room temperature, then at 60°C for the same length of time. 
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Embedding was performed with fresh Spurr's resin in predried gelatine capsules (Elanco 
size 0) . Polymerization took place at 60-70°C for 16-18 hours in an incubator. The 
capsules were trimmed in a Reichert TM 60 block trimmer with a steel cutter. 1 µ m 
survey sections were cut on an LKB Ultratome Ill with a glass knife, picked up and 
placed on a drop of water on a glass slide. The slide was placed on a hot plate until the 
water had evaporated and the sections adhered to the glass. The slides were stained 
with a heated solution (70°C) of 1 % toluidine blue for 1 minute, washed in tap water, air-
dried and mounted in DPX (BDH). The sections were then examined with a light 
microscope to select a suitable area for viewing with the electron microscope. The most 
suitable block was trimmed for thin sectioning with a diamond cutter in the block trimmer. 
Thin sections (60-90 nm thick) were cut on the LKB ultramicrotome with a glass knife, 
stretched by chloroform fumes and the ribbons of sections were picked up on 150 or 200 
mesh copper grids (Bio-Rad) and stored on filter paper in a small tissue culture dish 
(Greiner) until dry. 
When the sections had dried, they were stained upside down on drops of uranyl acetate 
(Merck) in 50% ethanol on strips of dental wax for three minutes, rinsed by the dipping 
method, first in 50% ethanol, then in two changes of distilled water (30 dips each). The 
sections were then placed on drops of Reynolds' lead citrate stain for 5 minutes, rinsed 
in two changes of distilled water and placed in their respective dishes. 
After drying, the sections were viewed in a Hitachi 600/2 transmission electron 
microscope at 75Kv, and relevant areas photographed. 
4.9.3.2 Drug therapy protocols 
The drug therapeutic trials were performed over a 90 day trial period before termination. 
Group IA rats (free drug group) were given an intraperitoneal combined bolus dose of 
chemotherapeutic agents containing 5 mg/kg COOP and 20 mg/kg 5-FU on Day 1 o after 
primary tumour transplantation. The same dose was repeated 7 days later. 
Group IIA rats (low dose immunomicrosphere group) were injected intraperitoneally with 
a combined bolus dose of immunomicrospheres containing 1 mg/kg COOP and 4 mg/kg 
5-FU on Day 1 O after primary tumour transplantation. 
Group 118 rats (high dose immunomicrosphere group) were injected intraperitoneally with 
a combined bolus dose of immunomicrospheres containing 1 O mg/kg COOP and 40 
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mg/kg 5-FU on Day 1 O. The reason for doubling the dosage as a bolus dose as 
compared to the dosage of Group IA (free drug group) , was that the drug is released 
slower and in sustained fashion and can be tolerated well by the animals. This dosage 
was given to compare the survival rate of this group of rats with those of Group IIA (low 
dose immunomicrosphere group). 
Also, mild anaesthesia was required to inject the immunomicrospheres into the 
peritoneal cavity via a catheter and it was therefore performed once only to reduce 
stress levels in the animals. 
Group IIIA rats (no drug group) were the control animals. No drug treatment was given 
to this group. 
From each rat of each group, 500 µI of blood was collected at fortnightly intervals into 
heparinized tubes and centrifuged at 2500 rpm at 4 °C for 5 minutes. The plasma was 
discarded and the erythrocyte pellet stored at -20°C before the superoxide dismutase 
levels were assayed. 
No blood was taken for blood chemistry or haematological tests from the above groups 
of animals, as it was considered a risk factor which could affect the animal survival rate 
data after treatment with free drugs and immunomicrospheres respectively. 
Note: Groups IA, IIA and IIIA animals could possibly be seen as control groups for Group 
118 , which is in fact the immunomicrospheres evaluated for efficacy as a treatment 
modality. Group IIIA is the untreated control group. 
4.9.3.3 Quantification of superoxide dismutase levels in tumour-bearing rats 
In order to monitor disease progression or regression in all groups of the tumour-bearing 
rats, the levels of superoxide dismutase (SOD) enzymes were quantified using the 
BIOXYTECH SOD-525 assay kit (Oxis International, Inc.). This method, as mentioned 
in Chapter 2, Section 2.3, was preferred to CA-125, as also described by Yamanaka and 
Deamer (1974), Dionisi et al. (1975) , Sahu et al. (1977), Oberley and Buettner (1979) 
and Ishikawa et al. (1990). 
The erythrocyte pellet was resuspended in 4 packed cell-volumes of ice-cold water and 
thoroughly vortexed. 400 µI of ice-cold extraction reagent (absolute ethanol/chloroform, 
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62.5/37.5 (v/v) was added to 250 µI of lysate in a glass test tube. The mixture was 
vortexed for 30 seconds and then centrifuged at 3000xg and 4°C for 10 minutes. The 
upper aqueous layer was collected and kept at 4 °C for the assay. The 50 mM 2·amino-
2-methyl-1 ,3·propanediol/HCI buffer containing 0.11 mM diethylenetriaminepentaacetic 
acid, which was provided in the kit, was brought to 37°C. 40 µI of sample or water 
(control) was added to a tube containing 900 µI of the buffer. 30 µI of the mercaptan 
scavenger reagent was added, vortexed for 3.4 seconds and then incubated at 37°C for 
1 minute. 30 µI of chromogen was added and the solution immediately vortexed for 3-4 
seconds. The solution was transferred to a cuvette and the absorbance change was 
measured within 10-15 seconds at 525 nm for 1 minute. The spectrophotometer 
(Beckman) was calibrated against air. The SOD activity of each sample was determined 
from the ratio of auto·oxidation rates measured in the presence (test sample) and 
absence (control sample) of SOD. 
4.10 Animal survival endpoints 
After all procedures were performed, all the animals were placed back in their cages in 
the air-conditioned animal room where they had free access to water and food. They 
were observed on a daily basis and their status recorded. 
Each death was recorded, an autopsy performed and tissue removed for macroscopical 
and/or microscopical evaluation. 
After a 90 day interval all remaining living animals were killed as this was considered to 
be the termination of the study as no further information could be gained and natural 
deaths or deaths not necessarily related to the experiments may occur at this stage. 
Autopsies were performed on all the animals and the findings recorded. 
4.11 Statistical methods 
To obtain meaningful comparisons of the various treatment protocols, the significant data 
was analysed employing Corel Quatro Pro 8® software. An analysis of variance was 
performed on the data from the different test groups including in vitro assays as well as 
the rodent test groups at a significance level of 0,05 (p<0.05). From the results of the 
ANOVA, the p-values were compared in an attempt to prove variances between the test 
groups. The NCSS software was used to establish the trends for blood chemistry and 
haematological profiles within each group treated by the different therapy protocols. 
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CHAPTERS 
RESULTS 
5.1 Human serum albumin microspheres 
The preparation of human serum albumin microspheres by employing a heat-
crosslinking method, proved to be suitable for this study and led to the production of 
well-defined microspheres. The incorporation of cisplatin (COOP) and 5-fluorouracil (5-
FU) in albumin microspheres by the method used, was found to be acceptable for the 
entrapment of these relatively heat-stable drugs. Microspheres containing 5-FU were 
prepared at 120°C, well below the decomposing temperature of 282°C for this drug. 
COOP-containing microsphereswere prepared at 100°C, also well below270°C, which 
is the decomposing temperature of cisplatin. 
The microspheres (Fig. 3) prepared by heat stabilization, were found to be almost 
perfect round beads, free-flowing and non-conglomerated, in the size range of 1-5 µm 
in diameter (Tables 2a & b). Although the microspheres were hydrophobic due to the 
preparation technique, they were found to be readily suspendable by vigorous shaking 
in physiological saline in high concentrations, rendering them ideal for intraperitoneal 
injection. Swelling of the microspheres in saline were negligible and considered to be 
insignificant. 
Fig. 3: Scanning electron micrograph of heat-stabilized human serum albumin 
microspheres containing 5-FU. 
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Batch 
Table2a 
Batch 
Table 2b: 
Size (µm) 
<1 1-2 2-3 3-4 4-5 5-6 >6 
1 3 6 21 36 18 12 4 
2 2 2 15 27 39 14 1 
3 5 9 19 31 22 11 3 
4 4 2 24 31 16 18 5 
5 4 8 17 29 26 13 3 
Mean 3.6 5.4 19.2 30.8 24.2 13.6 3.2 
Std Dev 1.020 2.939 3.124 2.993 8.158 2.417 1.327 
Size distribution of heat-stabilized albumin microspheres containing 5-FU 
(expressed as a percentage after counting 750 microspheres per batch). 
Size (µm) 
<1 1-2 2-3 3-4 4-5 5-6 >6 
1 1 3 18 35 22 13 8 
2 2 4 13 29 27 18 7 
3 4 3 11 32 25 16 9 
4 2 2 19 30 24 15 8 
5 1 4 18 28 31 12 6 
Mean 2 3.2 15.8 30.8 25.8 14.8 7.6 
Std Dev 1.095 0.748 3.187 2.482 3.059 2.135 1.020 
Size distribution of heat-stabilized albumin microspheres containing 
COOP (expressed as a percentage after counting 750 microspheres per 
batch). 
The reproducibility of microsphere preparation in large batches was easy to maintain 
and lyophilization and dry storage at 4 °C appeared to have no detrimental effect on the 
quality and characteristics, even if stored for 7-1 O days prior to use. 
5.1.1 Drug incorporation in human serum albumin microspheres 
To determine the entrapment concentration of 5-FU in the albumin microsphere matrix, 
the fluoride content was firstly determined by using a fluoride ion selective electrode 
(Metrohm Mod. 632) as described in Chapter 4, section 4.3.1. Using the constructed 
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calibration curve, the millivolt readings were plotted on a graph against the concentration 
[in ppm(Q)], in order to determine the fluoride concentration in the albumin microsphere 
sample (Table 3 and Fig 4) . 
5-FU cone. 
Batch mV ppm(I) ppm(s) 5-FU ppm(s) % 5-FU 
1 247 0.6 1500 12063 1.03 
2 248 0.57 1425 9750 0.98 
3 249 0.55 1375 9408 0.94 
4 251 0.52 1300 8895 0.89 
5 252 0.5 1250 8553 0.85 
Mean 249.4 0.548 1370 9374 0.94 
Std Dev 1.855 0.035 88.600 606.212 0.061 
Table 3: Data obtained from 5 batches of heat stabilized HSA microspheres with 
entrapped 5-FU. 
260 
250 
240 
> 230 
E 220 
210 
200 
190 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 
ppm(I) fluoride 
Fig. 4: Graph demonstrating the calibration curve (blue line) and millivolt readings (red 
line) to determine the average fluoride concentration in 5 samples of HSA 
microspheres prepared in separate batches. 
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To determine the average total 5-FU concentration of the HSA microspheres, the 
following calculation was employed to firstly determine fluoride concentration: 
ppm(s)F = 
ppm(s)F = 
= 
ppm(Q) x dilution 
sample mass 
0.548 ppm(Q) x 25 ml 
0.010g 
1370 ppm{s) fluoride 
The 5-FU content was then calculated: 
ppm(s) 5-FU = ppm(s)F x mol. mass of 5-FU 
mol mass of F 
= 1370 X 130 
19 
= 9373 ppm(s) 5-FU 
or 
0.94% entrapment of 5-FU in the HSA microspheres 
To determine the entrapment concentration of COOP in the albumin microsphere matrix, 
the platinum content was firstly determined by using an atomic absorption 
spectrophotometer (Varian Mod. AA 1275) fitted with a graphite tube atomizer (GTA95) 
as described in Chapter 4, section 4.3.2. Using the constructed calibration curve, the 
absorbance was plotted on a graph against the concentration [in ppm(Q)]. A linear 
regression was performed and the equation for the best straight line was obtained. 
Using the equation, the absorbance readings were converted to ppm(Q), in order to 
determine the platinum concentration in the albumin microsphere sample (Table 4 and 
Fig. 5). 
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Batch 
1 
2 
3 
4 
5 
Mean 
Std Dev 
Table 4: 
Cl) 
0.8 
0.7 
0.6 
0.5 
~0.4 
0.3 
0.2 
0.1 
0 
COOP cone. 
abs ppm(I) ppm(s) ppm(s) COOP %COOP 
0.554 0.7963 7963 12251 1.23 
0.549 0.789 7890 12139 1.21 
0.562 0.808 8080 12430 1.24 
0.542 0.7788 7788 11982 1.20 
0.565 0.8123 8123 12498 1.25 
0.554 0.7969 7969 12260 1.23 
0.008 0.012 112.5 188.44 0.019 
Data obtained from 5 batches of heat-stabilized HSA microspheres with 
entrapped COOP. 
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Fig. 5: Graph demonstrating the calibration curve (blue line), absorbance 
readings (red line) and linear regression line (green line) to determine 
the average platinum concentration in 5 samples of HSA microspheres 
prepared in separate batches. 
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To determine the average total CDDP concentration of the HSA microspheres, the 
following calculation was employed to firstly determine the platinum concentration: 
X=Y-C 
M 
(X= Pt cone. in ppm(Q); Y = absorbance; M = X coefficient; C = constant) 
X = 0.5544 - 0.01085 
0.6864 
= 0. 79689 ppm(Q) Pt 
The ppm(Q) was then converted to ppm(s) using the following equation: 
ppm(s) Pt = ppm{Q) x dilution 
sample mass 
ppm(s) Pt = 0. 797ppm(Q) x 100 ml 
0.010 g 
= 7970 ppm(s) Platinum 
The CDDP content was then calculated: 
ppm(s) CDDP = ppm(s) Pt x mol. mass of CDDP 
mol. mass of Pt 
= 7970 X 300 
195 
= 12261 ppm(s) CDDP 
or 
1.23% entrapment of CDDP in the HSA microspheres 
From the above calculations, it was thus found that the concentrations of 5-
fluorouracil and cisplatin entrapped in the crosslinked matrix of heat-stabilized human 
serum albumin microspheres was 0.94% and 1.23% respectively. These values 
were considered to be satisfactory for the purpose of this study, as extrusion for size 
distribution and centrifugation in ether and ethanol for removal of the cottonseed oil 
used during microsphere preparation, decreased the drug levels slightly. 
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5.2 The monoclonal antibodies 
5.2.1 Establishment of hybridomas 
The indirect ELISA on the test bleeds from all 3 BALB/c mice indicated that the mice 
had responded to the immunogen (DMBA-OC-1R cells) (Fig. 6) . Three fusions were 
performed. Two assays were used to select hybridomas producing antibody against 
the immunogen. 
The hybridoma culture supernatants were first screened in an indirect ELISA The 
low absorbance readings, which were obtained when the supernatants of the first 
fusion were screened, improved when the multi-well plate was air-dried overnight, 
instead of only for 90 minutes, before the cells were fixed with glutaraldehyde. The 
positive supernatants of the first fusion were, however, also found to be non-
selective as they also reacted with NRK and RESF cells in the indirect ELISA 
However, since glutaraldehyde permeabilizes cells, the antibodies could have been 
binding not only to cell membrane antigens, but also to intracellular antigens. 
With immunocytochemistry on live, unfixed cells in suspension, only membrane 
antigens will be bound by the antibodies and this assay confirmed that intracellular 
antigens were being bound in the ELISA Whereas a strong signal was obtained in 
the ELISA, weak or no fluorescence was observed when the antibodies were reacted 
with NRK and RESF cells in suspension (Table 5). 
72 
Intensity of 
Absorbance in ELISA Membrane Fluoresence 
Clone 
Number DMBA NRK RESF DMBA NRK RESF 
8 0.873 0.995 1.038 ++ +/-
15 1.124 1.216 1.272 ++ + 
27 1.083 1.199 1.22 ++ + 
28 0.907 0.968 1.037 + + 
29 0.873 1.075 1.024 ++ ++ 
31 1.065 1.291 1.223 + + 
66 0.956 1.095 1.069 ++ ++ 
67 1.057 1.183 1.117 +++ +/-
77 1.103 1.202 1.265 ++ ++ 
79 1.154 1.2 1.229 + + 
Intensity of staining: +++ = strong, ++ = moderate, + = weak, +/- = borderline, - = absence of staining 
Table 5: Comparison of results obtained for screening hybridomas using an 
ELISA with fixed cells and immunofluoresence on unfixed cells. 
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Fluorescence of varying intensities was observed when DMBA-OC-1 R cells were 
reacted with the various supernatants. From the first fusion, 3 of the 22 hybridomas 
screened for antibody production by immunocytochemistry, were selected for further 
cloning by limiting dilution to establish a monoclonal antibody, since at this stage 
more than one type of antibody-secreting cell was present in the culture. 
Only anti-DMBA56 gave rise to clones which did not react with NRK and RESF cells. 
One of these subclones was cloned further to ensure monoclonality. An average of 
50% of the viable DMBA-OC-1 R cells fluoresced when the supernatants were tested. 
It could be possible that this antibody is cell cycle-dependent. 
The subsequent two fusions yielded 51 hybridomas of which 1 O were selected by the 
ELISA for further screening with immunofluorescence membrane staining. These 
were highly specific for DMBA-OC-1 R cell membrane antigens and did not bind to 
NRK and RESF cells. The reactivities of the 1 O hybridomas were also tested on 
formalin-fixed paraffin-embedded wax sections of DMBA-OC-1 R tumour grown 
subcutaneously in athymic nude mice (Fig. 7) and normal rat tissues. Trypsin 
digestion was included to unmask any antigenic sites which may have been obscured 
by the protein cross-linkages caused by formalin fixation . 2 of the 1 O hybridomas 
(anti-DMBA11 and anti-DMBA61) did not react with the nude mice DMBA-OC-1 R 
tumour sections (Table 6). The epitopes recognised by these antibodies are either 
sensitive to trypsin digestion or they have been altered by formalin fixation so that 
they can no longer bind to the antibodies. The antigenicity of these two epitopes may 
have been preserved had the supernatants been tested on cryostat sections of 
frozen tissue samples instead of paraffin-embedded sections. The non-specific 
staining which was found when the antibodies were tested on sections of normal 
ovary, spleen and liver (Table 6), was not reduced by preliminary blocking of Fe 
receptors with normal goat serum or by diluting the second antibody (FITC-goat anti-
mouse) in RPMI medium with 10% FCS and 5% normal rat serum. 
The monoclonality of the final two selected antibodies, designated anti-DMBA43 and 
anti-DMBA93, was ensured by further cloning of the hybridomas using the limiting 
dilution technique. 
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Fig. 7: lmmunohistochemical localisation of anti-DMBA20 in a formalin fixed 
section of DMBA-OC-1 R tumour grown in a nude mouse. The binding 
of anti-DMBA20 to the tumour was detected by staining the section with 
FITC-goat anti-mouse lg and counterstained with ethidium 
bromide.(Mag x400) 
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Nude 
Clone mouse 
tumour Ovary Kidney Intestine Liver Spleen 
anti-DMBA9 +++ +/- - - + +++ 
anti-OM BA 11 - N.D. N.D. N.D. N.D. N.D. 
anti-DMBA20 +++ +/- - +/- + ++ 
anti-DMBA43 +++ +/- - +/- ++ +++ 
anti-DMBA61 - N.D. N.D. N.D. N.D. N.D. 
anti-DMBA62 N.D. +/- - +/- + ++ 
anti-DMBA65 N.D. +/- - +/- ++ ++ 
anti-DMBA87 ++ +/- - - ++ ++ 
anti-DMBA93 +++ - - +/- +++ +++ 
anti-DMBA94 +++ +/- - +/- ++ ++ 
anti-~-galacto- - +/- - +/- + ++ 
sidase neg. 
control 
Table 6: lmmunohistochemical localisation of clones of anti-DMBA hybridomas in 
formalin-fixed, paraffin-embedded normal rat and nude mouse DMBA-
OC-1 R tumour tissues. (N.D. = not determined) 
5.2.2 Purified monoclonal antibodies 
Ascitic fluid titers of both anti-DMBA43 and anti-DMBA93 hybridomas showed 
maximal plateau binding at titers of 1: 104 (Fig. 8). 
Anti-DMBA43 and anti-DMBA93 were purified from both serum-free and protein-free-
conditioned media and from ascites by column chromatography on hydroxyapatite. 
The localisation and purity of the antibodies in the peaks were determined by SOS-
PAGE (Fig 9 & 10). The presence of reduced antibodies is demonstrated by the 
presence of 2 bands on the gel - the one at 78 000 daltons (D) represents the heavy 
chain of lgM while the other at 25 000 Dis the light chain (Fig 9C). 
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determined by ELISA. 
The antibodies were mainly eluted by 300 mM sodium phosphate buffer and a little 
was eluted with 200 mM (Fig 9 & 10). Antibodies purified from ascites were heavily 
contaminated with serum albumin (molecular weight of 66 000 D) and other proteins 
(Fig. 1 OC) and further purification by ammonium sulphate precipitation did not reduce 
the contamination significantly (Fig 1 OD). The dense band (66 000 - 76 0000) in 
lanes 6 and 9 in Fig. 1 OC and lanes 5 and 8 in Fig. 1 OD corresponds to the heavy 
chain of lgM contaminated with albumin. 
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11 % SDS-polyacrylamide gel electrophoresis of reduced samples of 
fractions of antibodies eluted from ascites by hydroxyapatite column 
chromatography and subjected to further purification with ammonium 
sulphate precipitation. Molecular weight markers (lanes 1 and 2); anti-
DMBA43: fractions 8-12 (lane 3) corresponding to peak 1 in Fig.10A, 
fractions 13 & 14 (lane 4) , fractions 15-17 (lane 5) corresponding to 
peak 2 in Fig. 1 OA; anti-DMBA93: fraction 6-11 (lane 6) corresponding 
to peak 1 in Fig. 1 OB, fraction 12 (lane 7) and fractions 13-17 (lane 8) 
corresponding to peak 2 in Fig 1 OB. 
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5.2.3 Further characterisation of purified anti-DMBA43 and anti-DMBA93 
monoclonal antibodies 
Both stable hybridoma lines produced antibodies of the lgM isotype. 
lmmunocytochemistry on acetone-fixed DMBA-OC-1 R cells demonstrated that the 
epitopes were resistant to acetone fixation (Fig. 11A & 11 B). The resistance of the 
antigens to trypsin digestion was again confirmed. The monoclonal antibodies 
reacted equally strong with DMBA-OC-1 R cells that had been trypsinised off the 
dishes (Fig. 12) as those that had been removed with versene (Fig. 11A and 118). 
The reactivities of anti-DMBA43 and anti-DMBA93 with cultured cell lines from various 
species were examined by immunofluorescent studies on acetone-fixed cells (Fig. 
11A-H). It can be seen from Table 7 that both antibodies reacted strongly with only 
one out of sixteen cell lines (besides the one that they are naturally reactive against), 
namely a human melanoma cell line, Seafield (Fig. 11 F). The 2 antibodies reacted 
weakly with the Goliath and MCF7 cell lines (Fig. 11 G and 11 H, respectively). 
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Table 7: lmmunofluorescent reactivity of the test antibodies, anti-DMBA43 and anti-
DMBA93, and the negative control antibody, anti-J138, with different cell lines. 
Cell Line Species and Type Anti-DMBA43 Anti-OMBA93 Anti-J138 
DMBA-OC-1R Rat ovarian carcinoma +++ +++ -
MTW9/PL Rat mammary gland - . . 
carcinoma 
NRK Normal rat kidney - . . 
RESF Rat embryo skin . - -
fibroblasts 
GH3 Rat pituitary gland - - -
tumour 
B-OV2* Human melanoma - . -
GOLIATH Human ovarian + (only on a few + (only on a few . 
carcinoma cells) cells) 
KERCHOFF Human ovarian - - -
carcinoma 
SK-OV-3 Human ovarian - . -
carcinoma 
UW-OV-1 Human ovarian - - -
carcinoma 
Seafield Human ovarian +++ +++ +/-
carcinoma 
MCF7 Human breast + (only on a few + (only on a few -
carcinoma cells) cells) 
. 
MDA231 Human breast - - -
carcinoma 
Rogina Human breast - . -
carcinoma 
T47D Human breast - . -
carcinoma 
K562 Human chronic - . -
myelogenous 
leukemia 
Small Human melanoma - . -
Intensity of staining: +++ = strong, ++ = moderate, + = weak, +/- = borderline, - = absence of staining. 
* = This cell line was derived from the Bowes human melanoma cell line which was injected subcutaneously into 
athymic nude mice. The cells metastasised to the ovary in one of the mice. A cell line was established from this 
metastasis in culture. 
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Fig 11a-i: Specificity of anti-DMBA93 and anti-DMBA43 to various cell lines 
(arrows indicate fluoresence) 
Fig. 11A: Versened DMBA-OC-1 R 
cells with anti-DMBA43 
(mag x400) 
Fig. 11 C: NRK cells with anti-DMBA93 
(Mag x400) 
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Fig.11 B: Versened DMBA-OC-1 R 
cells with anti-DMBA93 (Mag x400) 
Fig. 11 D: RESF cells with anti-
DMBA43 (Mag x400) 
Fig. 11 E: SK-OV-3 cells with anti-
DMBA43 (Mag x400) 
Fig. 11 G: Goliath cells with anti-
DMBA93 (Mag x400) 
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Fig. 11 F: Seafield cells with anti-
DMBA93 (Mag x400) 
Fig. 11 H: MCF7 cells with anti-
DMBA43 (Mag x400) 
Fig. 111: DMBA-OC-1 R cells with 
anti-J138 (Mag x400) 
The reactivities of anti-DMBA43 and 
anti-DMBA93 with cultured cell lines 
from various species were examined by 
immunofluorescent studies on acetone-
fixed cells (Fig. 11A-H). 
Fig. 12. lmmunofluorescence reactivity 
as detected by FITC goat anti-
mouse lg of anti-DMBA93 
binding to live unfixed cells 
trypsinized off the dish, shows 
that the epitope is not destroyed 
by trypsin treatment (Mag x400) 
5.3 Drug release from the immunomicrospheres 
Drug release from human serum albumin microspheres can be sustained and 
controlled by various stabilization procedures, including heat, to facilitate cross-linking 
of the protein matrix. Previous experience showed that for the purpose of this project, 
heat cross-linked albumin microspheres were superior to chemically cross-linked 
albumin microspheres as regards stability and the leakage of COOP and 5-FU, when 
incubated in plasma at 37°C. 
Figure 13 shows the release behavior of 5-FU and/or its metabolites, as well as 
COOP, from heat-stabilized albumin immunomicrospheres in plasma at 37°C. 
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Fig. 13: 
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Graph showing the trends of in vitro release of 5-FU and CDDP 
from albumin immunomicrospheres in plasma at 37°C. See 
Section 5.1.1 for quantitative analysis. 
As shown in the above figure and as described in Section 5.1.1, the maximum levels 
of 5-FU in a fixed plasma volume of 3 ml, containing 150 mg 5-FU-loaded HSA 
immmunomicrospheres of 9373 µgig (ppm) 5-FU concentration, 14 days after 
initiation of the experiment were 0. 799 µglml plasma. The maximum levels of CDDP 
in the same volume of plasma, but containing 100 mg CDDP loaded HSA 
immunomicrospheres of 12261 µgig (ppm) CDDP concentration, 14 days after 
initiation of the experiment, were 0.283 µglml plasma. These experiments 
demonstrated a slow degradation pattern of the protein microspheres. 
As from Day 1 up to Day 5 of storage, the degradation rate showed only a slight 
increase when both 5-FU and CDDP leakage occured (0.273 µg 5-FUlml plasma and 
0.091 µg CDDPlml plasma respectively). From Day 5 up to Day 9 of storage, the 
degradation rate increased substantially reaching levels of 0.635 µg 5-FUlml plasma 
and 0.214 µg CDDPlml plasma, respectively. At Day 14, when these studies were 
terminated, the drug levels were 0.799 µg 5-FUlml plasma and 0.283 µg CDDPlml 
plasma respectively. The degradation pattern appeared to continue until the 
microspheres had released their total payloads which took approximately 30 days for 
microspheres prepared by heat-stabilization procedures. 
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5.4 Drug Treatment of DMBA-OC-1 R cells for use in clonogenic assays and 
cell survival growth curves. 
The long term cytotoxic effects of a combination of COOP at a fixed dose and 5-FU 
at varying concentrations, on OMBA-OC-1 R cells were evaluated. The clonogenicity 
in soft agar of these cells was determined and cell survival growth curves were 
established to study the cytotoxic effects of the drugs after 24 hour exposure to free 
drugs and 96 hour exposure to the drugs encapsulated in albumin microspheres. 
5.4.1 Clonogenic assays 
OMBA-OC-1 R cells, incubated for 14 days following drug treatment as described in 
Chapter 4, Section 4.8.1.1 , were studied for colony formation from single cells and 
enumerated. The results were expressed as a percentage of the number of colonies 
arising from the control cells. The results , as demonstrated in Fig.14, suggests that 
5-FU modulates the effect of the COOP and there appears to be a dose-dependent 
decrease in the number of colonies when the 5-FU concentration is increased. This 
finding confirms the results as shown in the cell survival growth curves (Section 
5.4.2). 
As demonstrated in Fig. 14 and Table 8, the effects of low-dose COOP on 
OMBA-OC-1 R cells exposed for 24 hours, demonstrates 24. 73% survival of the 
control cell growth (p<0.05). The addition of 5-FU in varying concentrations 
demonstrates a dose-dependent decrease in the ability of the cells to form clones in 
soft agar. The synergistic effect of COOP and 5-FU is thus clearly demonstrated 
when cells were treated with 0.025 µg/ml COOP and 1 µg/ml 5-FU (p<0.05). 
It is thus clinically possible using a COOP/5-FU free-drug infusion protocol to produce 
and maintain cisplatin serum concentrations of 0.025 µg/ml COOP and 
1 µg/ml 5-FU for 24 hours with acceptable host toxicity. Therefore the effects of 
prolonged high-dose COOP/5-FU exposure on the same cell line, but from a targeted 
drug delivery system were examined. This was performed in order to 
examine if the cell sensitivity employing this modality, increased and fell within a 
clinically achievable range (also see the survival growth curves - Section 5.4.2) . 
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Fig. 14: 
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Clonogenicity of DMBA-OC-1 R cells cultured in soft agar for 14 days 
following 24 hr exposure to either no drugs (control) or 0.025 µg/ml 
CDDP together with varying concentrations of 5-FU. Results are 
expressed as a percentage of the number of colonies arising from 
untreated cells (mean +/-SEM). 
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First Second p-Value Significant 
Parameter Parameter difference 
Control 0.025 µglml COOP p= 1.098x 10·2 yes 
Control 0.025 µglml COOP+ 0.1 µg/ml 5- p = 7.040x10·3 yes 
FU 
Control 0.025 µg/ml COOP+ 0.25 µg/m p = 4.975x10-3 yes 
5-FU 
Control 0.025 µglml COOP+ 0.5 µg/ml p = 3.554x10·3 yes 
5-FU 
Control 0.025 µg/ml COOP+ 1µg/ml 5-FU p = 3.155x10·5 yes 
0.025 µg/ml 0.025 µg/ml COOP+ 0.1 µglml p = 4.53 X 10·1 no 
COOP 5-FU 
0.025 µg/ml 0.025 µglml COOP+ 0.25 µg/ml p =1.854 x10·1 no 
COOP 5-FU 
0.025 µglml 0.025 µg/ml COOP+ 0.5 µg/ml p =5.845 x10·2 no 
COOP 5-FU 
0.025 µ glml 0.025 µglml COOP+ 1 µg/ml p =3.803 x10·2 yes 
COOP 5-FU 
Table 8: Statistical analysis was performed on the results obtained in the 
clonogenic assay in which OMBA-OC-1 R cells were treated with free 
drugs, to compare the effects of (a) 0.025 µg/ml COOP+ x µg/ml 5-FU 
against the control and (b) 0.025 µg/ml COOP +x µg/ml 5-FU against 
0.025 µglml COOP. 
Fig. 15 demonstrates the effect on the colony-forming ability of cells exposed for 96 
hours to immunomicrospheres containing encapsulated drugs. As was observed in 
Fig. 14, the results as demonstrated in Fig. 15, also suggest that the addition of 5-FU 
modulates the effect of COOP. The addition of 5-FU immunomicrospheres together 
with COOP immunomicrospheres not only enhances, but emphasises the synergism 
between the two drugs. When comparing cells treated with 5-FU and COOP with 
those treated only with COOP, a significant difference is observed. However, a 
greater significance can be observed when cells treated with 5-FU and COOP is 
compared to untreated cells (Table 9) . 
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The comparative results between free drug and sustained drug release indicates the 
possibility of greater clinical outcome when employing immunomicrospheres 
containing drugs as compared to free drug alone. This is supported in the results 
observed by the cell survival growth studies in the following section. 
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Clonogenicity of OMBA-OC-1 R cells cultured for 14 days in soft 
agar following 96 hour exposure to either no drugs (control), 
10 µg/ml COOP alone or 1 O µg/ml COOP in combination with either 1 o 
µglml 5-FU or 25 µg/ml 5-FU. These drugs were encapsulated in 
albumin immunomicrospheres. 
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First 
parameter 
Control 
Control 
Control 
10 µg/ml 
COOP 
10 µg/ml 
COOP 
Table 9: 
Second p-Value Significant 
parameter difference 
10 µg/ml COOP p = 1.146x10-5 yes 
10 µglml COOP+ 10 µglml 5-FU p = 1.688X10·5 yes 
10 µg/ml COOP + 25 µg/ml 5-FU p = 2.565x10-5 yes 
10 µg/ml COOP + 10 µg/ml 5-FU p = 2.572x10-2 yes 
10 µg/ml COOP + 25 µglml 5-FU p = 1.417x10-2 yes 
Statistical analysis was performed on the results obtained in the 
clonogenic assay in which OMBA-OC-1 R cells were treated with 
encapsulated drugs, to compare the effects of (a) 1 O µg/ml COOP + 
x µglml 5-FU against the control and (b) 1 O µg/ml COOP +x µg/ml 
5-FU against 10 µg/ml COOP. 
5.4.2. Cell survival growth curves 
Cell survival growth curves were generated for free drug and microspheres (non-
antibody-linked and antibody-linked). Fig. 16(a) depicts the survival of cells over a 7 
day period following 24hours exposure of exponentially growing OMBA-OC-1 R cells 
to varying concentrations of 5-FU together with or without 0.025 µg/ml COOP. A 
dose-dependent response is observed when the cells are treated with either 5-FU 
(Fig. 16 a & b) or COOP (data not shown). The addition of increasing concentrations 
of 5-FU to 0.025 µg/ml COOP significantly inhibits the survival of cells in a dose-
dependent manner (Fig. 16(b) and Table 10). As observed in the clonogenic assays, 
the synergistic action between the two drugs, is once again evident. Cell survival is 
reduced to 21 .95% (4.56-fold reduction) when cells are treated with 0.025 µg/ml 
COOP only. Total cell kill is achieved when 1 µg/ml 5-FU is added together with 
0.025 µglml COOP. This represents a further 24,66-fold reduction in survival. 
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Fig. 16a: 
107 r-;::::::::::::::::::::::::::::::;::::::::::::::::::::::::::::::::;~~~~~~--, 
5Fu only + 0.025µg/ml CDDP 
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0.5!lg/ml 5Fu ..... . 
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150 180 
Cell survival growth curves for OMBA-OC-1 R cells treated 
for 24hours with 0.1 µg/ml 5-FU (dark blue), 0.25 µg/ml 5-FU (green), 
0.5 µglml 5-FU (pink), 1 µg/ml 5-FU (light blue) together with (unbroken 
line) or without (dotted line) 0.025 µglml COOP. After the 24 hour 
treatment, cells were plated in 35 mm dishes and their growth was 
monitored. At each time point, cells from duplicate dishes were 
enumerated after they had been versened off the dishes. 
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Fig. 16b: 
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Dose-response curves for varying concentrations of 5-FU on its 
own (green bars) and 5-FU together with 0.025 µg/ml COOP (blue 
bars) were generated using the data from the 168 hour time point in 
Fig. 16a. Cell survival was calculated as a percentage of the control cell 
growth. 
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First Second p-Value Significant 
parameter parameter difference 
Control 0.025 µg/ml COOP p = 3.693x10-6 yes 
0.1 µglml 5- 0.025 µglml COOP+ 0.1 µglml p = 3.876x10-3 yes 
FU 5-FU 
0.25 µglml 5- 0.025 µg/ml COOP+ 0.25 µg/ml 5- p = 2.265x10-3 yes 
FU FU 
0.5 µglml 5- 0.025 µg/ml COOP + 0.5 µg/ml p = 6.877x10-3 yes 
FU 5-FU 
1 µg/ml 5-FU 0.025 µg/ml COOP+ 1 µg/ml 5-FU p = 9.339x104 yes 
Control 
Control 
Control 
Control 
Control 
Control 
Control 
Control 
Table 10: 
0.1 µg/ml 5-FU p = 2.56x10-1 no 
0.25 µg/ml 5-FU p = 1.408x10-3 yes 
0.5 µg/ml 5-FU p = 1.552x10-3 yes 
1 µg/ml 5-FU p = 3.566x10-6 yes 
0.025 µg/ml COOP+ 0.1 µg/ml p = 1.156x104 yes 
5-FU 
0.025 µglml COOP+ 0.25 µg/ml 5- p = 4.008x10-5 yes 
FU 
0.025 µglml COOP+ 0.5 µg/ml p = 3.988x10-6 yes 
5-FU 
0.025 µglml COOP+ 1 µg/ml 5-FU p = 8.246x10-7 yes 
Statistical analysis was performed on the results obtained in the cell 
survival growth curve assays after 168 hours (Fig. 16b) in which 
OMBA-OC-1 R cells were treated with free drugs, to compare the 
effects of (a) 0.025 µg/ml COOP + x µg/ml 5-FU against varying 
concentrations of 5-FU; (b) varying concentrations of 5-FU against the 
control and (c) 0.025 µg/ml COOP +x µg/ml 5-FU against the control. 
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Exposure of cells to 400x COOP (10 µg/ml) encapsulated in albumin microspheres 
for 96 hours (in comparison to 0.025 µg/ml in the free form for 1 hour), did not 
succeed in total cell kill (Fig. 17a & b) as COOP leaks very slowly from the 
microspheres, as can be seen from the leak profile for COOP (Fig. 13). Cell death, 
however, was enhanced by the addition of 5-FU (Fig. 17a & b). Despite the addition 
of 10 µg/ml 5-FU and 10 µg/ml COOP, cells were able to recover (Fig. 17a), though 
at a slower rate than without 5-FU. Cell survival was reduced significantly by 42-fold 
to 1.2% when 25 µg/ml 5-FU was added together with COOP (Table 11 & Fig. 17b). 
Fig. 17a: 
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immunomicrospheres on the survival of DMBA-OC-1 R cells. Cells were 
exposed for 96 hours to either 1 O µg/ml COOP (green), 1 O µg/ml COOP 
+ 10 µg/ml 5-FU (light blue) or 10 µg/ml COOP+ 25 µg/ml 5-FU (dark blue). 
Recovery of the cells was monitored over a period of 7 days and compared to 
that of cells that were not exposed to drugs (red). 
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Fig. 17b: Effect of increasing the dosage of 5-FU on cells that were treated 
simultaneously with COOP. This graph was generated by using the data from 
the 168 hour timepoint in Fig. 17a. Cell survival was calculated as a 
percentage of the survival of control cells. 
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First Second p-Value Significant 
parameter parameter difference 
10 µg/ml 10 µg/ml COOP + 10 µg/ml 5-FU p = 5.378x10-5 yes 
COOP 
10 µg/ml 10 µg/ml COOP + 25 µg/ml 5-FU p = 1.367x10-5 yes 
COOP 
10 µglml 10 µg/ml COOP + 25 µg/ml 5-FU p = 1.358x10-3 yes 
COOP+ 
10 µglml 
5-FU 
Table 11 : Statistical analysis was performed on the results obtained in the cell 
survival growth curve assays after 168 hours (Fig. 17b) in which OMBA-OC-
1 R cells were treated with encapsulated drugs, to compare the effects of (a) 
10 µg/ml COOP+ x µg/ml 5-FU against 10 µg/ml COOP and (b) 10 µg/ml 
COOP + 25 µg/ml 5-FU against 10 µg/ml COOP +10 µg/ml 5-FU. 
The efficiency of targeted immunomicrospheres in comparison to untargeted 
microspheres in causing cell death was investigated. There was a significant 
decrease in cell survival to 4.03% when cells were exposed to antibody-targeted 
immunomicrospheres (Fig. 18b & Table 12). Untargeted microspheres had no growth 
inhibitory effect on the cells (Fig. 18a). These results demonstrate that 
immunomicrospheres are more effective in delivering drug directly to the cells than 
those which are not linked to cell-specific monoclonal antibodies. 
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Fig. 18a: 
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10µg/ml CDDP: Ab-conjugated 
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Survival profiles of cells exposed to untargeted and antibody-targeted 
microspheres. OMBA-OC-1 R cells were exposed for 96 hours to either no drug 
(dark blue), 1 O µg/ml COOP + 25 µg/ml 5-FU encapsulated in either antibody-
targeted microspheres (pink) or untargeted microspheres (light blue). Cell 
survival was observed over a period of 7 days. (Ab=antibody) 
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Fig. 18b: Inhibition of cell survival by immunomicrospheres. The recovery of cells 
treated with 1 O µg/ml COOP and 25 µg/ml 5-FU encapsulated in untargeted 
and antibody-targeted microspheres was determined by calculating the survival 
at 168 hours as a percentage of the control cell growth. (Ab= antibody) 
First Second p-Value Significant 
parameter parameter difference 
Control 
Control 
Table 12: 
10 µg/ml COOP + 25 µg/ml 5-FU p = 2.553x10-1 no 
(untargeted) 
10 µg/ml COOP + 25 µglml 5-FU p = 2.402x10-3 yes 
( antibody-targeted) 
Statistical analysis was performed on the results obtained in the cell 
survival growth curve assays after 168 hours (Fig. 18b) in which 
OMBA-OC-1 R cells were treated with encapsulated drugs, to compare 
the effects of untargeted and targeted microspheres against untreated 
cells ( control) 
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5.4.3 MTT Assays 
The in vitro cytotoxicity of COOP and 5-FU, either alone or in combination, as well as 
either in the free drug or encapsulated form, was evaluated by using the MTT assay. 
The viability of OMBA-OC-1 R cells was assessed after continuous exposure to free 
drug for 24, 48 and 120 hours, as described in Section 4.8.2 in Chapter 4. The results 
were expressed as% cell survival of the control cells (untreated cells). The results, as 
demonstrated in Fig. 19 (free drug), showed that after 24 hours (Fig. 19a) no 
significant effect was observed. However, after 48 hours (Fig. 19b), a significant trend 
towards cell cytotoxicity was observed which was well established after 120 hours 
(Fig. 19c). Once again the observation is made that when the amount of 5-FU added 
to the cells is increased together with a constant amount of COOP, cell survival 
decreases, reiterating the modulation of COOP cytotoxic activity by 5-FU, as seen in 
the results of the clonogenic assays and cell survival growth curves. In Fig. 19c, we 
observed that total cell kill was achieved when 0.5 µg/ml 5-FU was added to the cell 
cultures, irrespective of the amount of COOP that was added. 
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Fig. 19: Dose response curves for DMBA-OC-1 R cells. The viabilty of 
DMBA-OC-1 R cells was assesed by the MTT assay after continuous 
exposure to free drug for (a) 24 hours, (b) 48 hours and (c) 120 hours. Cells 
were exposed to no CDDP (red), 0.01 µglml (green), 0.025 µglml (light blue). 
0.05 µglml (dark blue) and 0.1 µg/ml CDDP together with varying 
concentrations of 5-FU (error bars: SEM) 
Fig. 20 illustrates the survival of DMBA-OC-1 R cells for 168 hours after exposure for 
96 hours to 1 O µg/ml CDDP and varying concentrations of 5-FU contained in albumin 
microspheres which were either linked to antibody or not . Once again the 
modulation of CDDP by 5-FU is dose-dependent. This echoes the trend seen in the 
cell survival growth curves (Fig. 17a). Significant cell death was observed after 96 
hours of treatment when antibody-linked immunomicrospheres were employed as 
compared to non-antibody-linked microspheres at all concentrations. The results 
further indicate that the use of immunomicrospheres show an enhanced effect of cell 
kill as compared to microspheres without antibody. 
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The comparative results between free drug and sustained drug release from 
immunomicrospheres indicates the possibility of greater clinical outcome as 
immunomicrospheres can be loaded with drugs at very high concentrations without 
exhibiting serious cytotoxicity as compared to free drug where dosage may be 
limited. 
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Fig. 20: Survival curves for DMBA-OC-1 R cells as assessed by the MTT assay 
after exposure for 96 hours to encapsulated drugs. Cells were exposed to 1 O 
µg/ml COOP only (red), or 10 µg/ml COOP+ 5 µg/ml 5-FU (green), 10 µg/ml 
COOP+ 10 µg/ml 5-FU (light blue) or 10 µg/ml COOP+ 25 µg/ml 5-FU (dark 
blue) encapsulated in albumin microspheres which were either linked to 
antibody (unbroken lines) or not linked to antibody (dotted lines). 
5.4.4 Micronuclei 
The mode of action of COOP is to form intrastrand cross-links in the DNA of cells 
(Lippard, 1982). Cells are, however, capable of repairing this DNA damage. The 
inclusion of 5-FU in the treatment regimen is known to inhibit this repair and thereby 
enhances and ensures cell death. Micronuclei (Fig. 21), the presence of which is an 
indicator of chromosomal damage, have been induced in DMBA-OC-1 R cells to 
assess the cytotoxicity of COOP and 5-FU at a molecular level. 
DMBA-OC-1 R cells were exposed to either free drug for 1 hour or 24 hours or to 
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drugs encapsulated in albumin microspheres for 96 hours. After treatement they 
were arrested in their mitotic state by the addition of 2 µg/ml Cytochalasin B for 24 
hours. Micronuclei were enumerated in binucleated cells after the cells had been 
fixed and stained with acridine orange (see Chapter 4, Section 4.8.3). Results were 
expressed as the number of micronuclei per 500 binucleated cells. The background 
level of micronuclei in untreated DMBA-OC-1 R cells is 87.99 +/- 6.331 (SEM) as 
determined from results obtained from 15 experiments. 
Fig. 21. The mutagenicity of COOP and 5-FU is demonstrated by the induction 
of micronuclei (arrow) in binucleated DMBA-OC-1 R cells. 
Fig. 22 depicts the frequency of micronuclei in cells after exposure to either COOP 
or 5-FU. Cells were exposed to the same concentrations of 5-FU for either 1 or 24 
hours. A significant difference was observed with concentrations of 2.5-, 5- and 10 
µg/ml 5-FU when the exposure time was increased (Table 13). Although significant 
differences were observed when cells were exposed for 24 hours to increasing 
dosages of 5-FU (Table 14), they were not as pronounced as those observed in the 
cell growth survival studies where cells were treated for 24 hours with lower 
concentrations of 5-FU ranging from Oto 1 µg/ml in the free form (Fig. 16a & 16b), 
even when the dosage was increased to 10 µg/ml 5-FU in the micronucleus assay. 
The effect of 5-FU at the molecular level seems to reach a plateau at 5 µg/ml. This 
can be ascribed to the fact that 5-FU, unlike COOP, does not cause DNA-strand 
breakage. A dose-dependent effect is observed with a 24 hour exposure to COOP 
with significant increases in micronuclei at concentrations above 0.01 µg/ml (Table 
15). CDDP doses above 0.1 µg/ml resulted in the production of degenerated cells 
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and increase in the number of micronuclei per cell, which made enumeration difficult. 
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Fig. 22. Effect on the micronuclei frequency in OMBA-OC-1 R cells when 
exposed to varying concentrations of 5-FU for (a) 1 hour and (b) 24 hours and 
(c) varying concentrations COOP for 24 hours. Bars indicate SEM. 
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First Second p-Value Significant 
parameter parameter Difference 
Control Control p = 1 . 584 X 1 0-1 no 
1 µg/ml 5-FU 1 µg/ml 5-FU p = 7.283 X 10-2 no 
2.5 µglml 5- 2.5 µglml 5-FU p = 7.794 X 10-3 yes 
FU 
5 µglml 5-FU 5 µglml 5-FU p = 2.269 X 10-4 yes 
10 µg/ml 5-FU 10 µg/ml 5-FU p = 8.928 X 10-4 yes 
Table 13: 
First 
Statistical analysis was performed on the results obtained in the 
micronuclei assay to compare the effects of treatment on the induction 
of micronuclei in DMBA-OC-1 R cells with free drugs for 1 hour (first 
parameter) and for 24 hour exposure (second parameter). 
Second p-Value Significant 
parameter parameter Difference 
Control 
Control 
Control 
Control 
Control 
Table 14: 
0.5 µglml 5-FU p = 1 .486 X 1 0-2 yes 
1 µg/ml 5-FU p = 4.843 X 10-2 yes 
2.5 µglml 5-FU p = 2. 144 X 1 0-3 yes 
5 µglml 5-FU p = 1. 780 X 10-3 yes 
10 µg/ml 5-FU p = 1 .480 X 1 0-3 yes 
Statistical analysis was performed on the results obtained in the 
micronuclei assay to compare the effects of 24 hour exposure to 
varying concentrations of 5-FU against no drug on the induction of 
micronuclei in DMBA-OC-1 R cells. 
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First Second p-Value Significant 
parameter parameter Difference 
Control 
Control 
Control 
Control 
Control 
Table 15: 
0.005 µg/ml COOP p = 2.404 X 10-1 no 
0.01 µglml COOP p = 9.099 X 10-3 yes 
0.025 µg/ml COOP p = 7.074 X 10-3 yes 
0.05 µg/ml COOP p = 4.619 X 10-6 yes 
0.1 µglml COOP p = 6.520 X 10-5 yes 
Statistical analysis was performed on the results obtained in the 
micronuclei assay to compare the effects of 24 hour exposure to 
varying concentrations of COOP against no drug on the induction of 
micronuclei in OMBA-OC-1 R cells. 
Cells were treated with varying concentrations of COOP together with 1 µg/ml of 
5-FU for 24 hours (Fig. 23). The modulatory effect of 5-FU, as observed in the 
previous assays (i.e clonogenic assay, cell growth survival assay and the MTT 
assay), was once again evident here as the frequency of micronuclei increased with 
the addition of 1 µg/ml 5-FU. This was especially evident at the lower concentrations 
of COOP of 0.005 µg/ml and 0.01 µglml (Table 16). 
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Fig. 23: Effect of 24 hours of exposure of OMBA-OC-1 R cells to varying 
concentrations of COOP (green bars) and varying concentrations of COOP 
together with 1 µg/ml 5-FU (blue bars) on the frequency of micronuclei. Bars 
indicate SEM. 
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First Second p-Value Significant 
parameter parameter Difference 
Control No COOP + 1 µg/ml 5-FU p = 1.247x10-2 yes 
0.005 µg/ml 0.005 µg/ml COOP+ 1 µg/ml 5-FU p = 9.758x10-2 yes 
COOP 
0.01 µg/ml 0.01 µg/ml COOP+ 1 µg/ml 5-FU p = 2.185x10-2 yes 
COOP 
0.025 µg/ml 0.025 µg/ml COOP+ 1 µg/ml 5-FU p = 1.075x10-1 no 
COOP 
0.05 µg/ml 0.05 µg/ml COOP+ 1 µg/ml 5-FU p = 4.611x10-1 no 
COOP 
Table 16: Statistical analysis was performed on the results obtained in the 
micronuclei assay in which DMBA-OC-1 R cells were treated with free 
drugs for 24 hours, to compare the effects of x µg/ml COOP + 
1 µg/ml 5-FU against varying concentrations of COOP. 
Fig. 24 illustrates a significant dose-dependent increase in the frequency of 
micronuclei when cells are exposed to10 µg/ml COOP together with increasing 
amounts of 5-FU encapsulated in albumin microspheres for 96 hours. This trend was 
observed in the clonogenic assays (Fig.15), cell survival growth curves (Fig. 17a & 
b) and the MTT (Fig. 20) assays and further emphasises the modulatory effect of 5-
FU. 
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Fig. 24. Effect of 96 hour exposure of OMBA-OC-1 R cells to 1 O µg/ml COOP 
together with varying concentrations of 5-FU, encapsulated in microspheres, 
on the frequency of micronuclei. Bars indicate SEM. 
A significant 3.2-fold more micronuclei were found in cells that were treated for 96 
hours with 1 O µg/ml COOP and 25 µglml 5-FU encapsulated in albumin 
microspheres that have been linked to antibodies and are therefore targeted to the 
cells. This is in comparison to the same amount of drugs in microspheres that have 
not been linked to antibodies (Fig. 24 and Table 17). This result once again 
emphasises the efficiency of targeted microspheres in achieving greater cell kill. 
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First Second p-Value Significant 
parameter parameter Difference 
Control 1 o µg/ml COOP (ab-linked) p = 6.440x10-1 no 
Control 10 µg/ml COOP + 25 µg/ml 5-FU p = 8.438x104 yes 
(ab-linked) 
Control 10 µg/ml COOP (non-linked) p = 3.267x10-1 no 
Control 10 µg/ml COOP + 25 µg/ml 5-FU p = 9.053x10·1 no 
(non-linked) 
10 µg/ml 1 O µg/ml COOP (non-linked) p = 2.077x10·1 no 
COOP (ab-
linked) 
10 µg/ml 10 µg/ml COOP + 25 µg/ml 5-FU p = 9.867x10-4 yes 
COOP+ 25 (non-linked) 
µg/ml 5-FU 
(ab-linked) 
Table 17: Statistical analysis was performed on the results obtained in the 
micronuclei assay in which DMBA-OC-1 R cells were treated with 
encapsulated drugs, to compare the effects of (a) antibody-linked and 
non-linked microspheres against the control and (b) non-linked 
microspheres against linked microspheres. 
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5.5 The tumour host 
5.5.1 Drug distribution studies 
The time-concentration profiles of COOP and 5-FU at concentrations of 20 mg/kg 5-FU 
and 25 mg/kg COOP, administered intravenously as free drugs via the tail vein of a 
group of female Wistar rats, are presented in Fig. 25 (See Chapter 4, Section 4. 9.1 ). As 
can be seen many organs of the reticuloendothelial system, as well as excreta (not 
shown due to difficulty in obtaining reliable samples), show high concentrations of both 
drugs. It was, however, observed that the disposition of the drugs in the ovary were of 
sufficient concentration to enable a therapeutic effect (9.3% for COOP and 6.0% for 5-
FU respectively) 
Fig. 25: 
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Tissue distribution of 5-Fu and COOP following intravenous drug 
administration (s int = small intestine; I int = large intestine; pancr = 
pancreas). 
5.5.2 Blood chemistry profiles to assess the effects of 5-fluororuracil and 
cisplatin (free drugs and encapsulated) in female Wistar rats 
As reported in Chapter 4, Section 4.9.2, three groups of female Wistar rats were used 
to obtain blood chemistry profiles in order to observe the toxic effects of the drugs on the 
organs. Group I rats were injected intraperitoneally with free drugs, Group II rats with 
immunomicrospheres containing the drugs and Group Ill rats were the control animals 
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who received no drug treatment. 
Fig. 26a and Fig. 26b depict the serum urea and creatine levels in the three groups of 
animals. As demonstrated, these parameters indicated only mild renal toxicity which 
corrected itself within three weeks after drug administration. Fig. 26c, Fig. 26d and Fig. 
26e shows the serum gamma glutamyl transferase, alanine aminotransferase and 
aspartate levels respectively in the three groups of animals. These parameters indicated 
mild hepatocellular toxicity which corrected itself three to four weeks after drug 
administration. Fig. 26f and Fig. 26g demonstrate serum alkaline phosphatases and 
lactate dehydrogenase levels in the three groups of rats. These parameters showed 
hepatocellular reactive changes which were sustained for a longer time period in the 
immunomicrosphere-inoculated group. Correction to normal levels after free drug 
administration took three to four weeks whereas in the case of drug-loaded 
immunomicrosphere administration, it took 8 to 9 weeks. 
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Figs. 26a & b, Serum urea and creatinine status after administration of 5-Fu and 
COOP (as free drug and drug-loaded immunomicrospheres). 
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Figs. 26 c, d, e, f & g. Serum gamma 
glutamyltransferase, alanine aminotransferase, 
aspartate aminotransferase, alkaline 
phosphatase and lactate dehydrogenase status 
after administration of 5-Fu and COOP (as free 
drug and drug-loaded immunomicrospheres). 
5.5.3. Haematological profiles to assess the effects of 5-fluorouracil and cisplatin (free 
drugs and encapsulated) in female Wistar rats 
As in the previous section, the same group of female Wistar rats were used to obtain 
haematological profiles in order to assess the toxic effects of the drugs on the bone ma row. Fig. 
27a, Fig. 27b and Fig. 27c depicts the erythrocyte count, haemoglobin and haematocrit levels 
which indicated mild erythropenia in the free drug and encapsulated drug groups. Haemoglobin 
levels returned to normal, 4 weeks after drug administration. Fig. 27d shows the total leucocyte 
count. Mild leukopenia was observed in the free drug group. Fig. 27e shows the platelet count 
which remained normal throughout the drug administration period. No thrombocytopenia was 
observed in any of the three groups of rats. 
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Figs 27 a& b. Erythrocyte count and haemoglobin levels after administration of 5-Fu 
and CDDP(as free drug and drug-loaded immunomicrospheres). 
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Figs. 27c, d & e: Haematocrit levels , leucocyte and platelet counts after 
administration of 5-Fu and COOP (as free drug and drug-loaded 
immunomicrospheres). 
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5.6 The tumour model 
Primary transplantable adenocarcinomas were induced in female Wistar rats as 
described in Chapter 4, Section 4.9.3. Abdominal distention due to retention of bloody 
ascitic fluid was noted within 1 O days following the intraperitoneal inoculation of 4 x 106 
DMBA-OC-1 R cells. The ascites contained tumour cells, as well as neutrophils, 
lymphocytes, histiocytes and mesothelial cells (Fig. 28). 
Fig. 28: General overview of neoplastic cells, lymphocytes and histiocytes in the 
ascitic fluid (Papanicolaou stain, original mag x40) 
The primary tumours (Fig. 29) were allowed to establish themselves for 14 days before 
removal for transplantation. The omentum was the first location in which the tumour 
appeared following inoculation, after which the tumour disseminated throughout the 
peritoneal cavity. 
117 
Fig. 29: Bulky tumour ( demarcated) in the peritoneal cavity of a female Wistar rat 
ten days after primary inoculation with 4x106 DMBA-OC-1 R cells 
lntraperitoneally transplanted 3 mm tumour cubes were allowed to develop into 
secondary tumours for 10 days before treatment commenced. Tumour development was 
monitored by X-rays to detect secondary tumour mass formation (Fig. 30) before 
treatment commenced. 
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Fig. 30: X-rays of control rat( left) without tumour and test rat( right) with 
secondary tumour mass( arrows) following intraperitoneal transplantation 
of 3mm3 primary tumour fragment after 10 days (barium contrasted). 
5.6.1 Histology of the tumour 
Tissue specimens taken for light- and transmission electron microscopy of both primary 
and secondary tumours revealed identical histological features. Generally, they were 
undifferentiated neoplasms characterised by high mitotic activity. Definitive evidence of 
a solid pattern was noted and glandular structures were scarcely seen. However, the 
transmission electron microscopy showed microvilli on the cell surface which suggests 
an adenocarcinoma. 
Neoplastic cells were arranged mostly in sheets or cords supported by a scant delicate 
connective tissue stroma with a fine reticular appearance with obvious vascular 
development (Fig. 31 & 32). The neoplastic cells were round or oval, becoming 
elongated in certain areas with large pleomorphic, vesicular nuclei, prominent 
eosinophilic nucleoli and abundant eosinophilic cytoplasm (Fig. 33). Occasional 
histiocytes were also observed in the neoplasms with occasional areas of tissue 
necroses and haemorrhages. Mucin was negative in the tumour cells as demonstrated 
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by the Alcian blue PAS and Mucicarmine stains (Data not shown). Neovascularization 
of the tumour was also found to be well-developed( Fig. 32). 
Fig. 31 : Histological section 
showing reticular fibres( arrow) in 
tumour tissue stroma 
(Gordon & Sweet's stain, original 
mag x40) 
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Fig. 32: Capillary sprouts( arrows) 
in tumour tissue stroma 
(Haematoxylin & Eosin, original 
mag x40) 
Fig. 33: Histology of transplanted, OM BA-induced ovarian tumour. Tumour cells 
proliferate in solid growth pattern. Tumour cells show large, pleomorphic 
nuclei , prominent eosinophilic nuclei and eosinophilic cytoplasm. 
Occasional histiocytes(arrow) were observed (Haematoxylin & Eosin, 
original mag x40) 
Electron microscopically, tumour cells had a nucleus in the middle of the cells. The 
nuclei with prominent nucleoli were mostly round in shape, however, some of them were 
markedly deformed (Fig. 34). Microvilli were noted on the cell surface. In the cytoplasm, 
rough endoplasmic reticulum, mitochondria and other cell organelles were well-
developed (Fig. 35). lntercellularly, desmosome-like junctions were frequently seen, 
however in some areas contact with obscure intercellular junctions were observed (Fig. 
36). 
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Fig. 34: Tumour cells showing 
large, centrally positioned nuclei, 
however, some were markedly 
deformed (arrow) (original mag 
x7500) 
Fig. 35: Microvilli (arrow) on some 
tumour cell surfaces. Well developed 
cytoplasmic organelles are evident in 
this micrograph (original mag x12000) 
Fig. 36: Tumour cells showing intercellular desmosome-like structures(arrow) 
(original mag x36000) 
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5.6.2 Therapy studies 
As described in Chapter 4, Section 4.9.3, primary tumour fragments, 3 mm3 in size, were 
intraperitoneally transplanted into 4 groups of female Wistar rats. Secondary tumours 
were allowed to develop over a 1 O day period before chemotherapeutic treatment 
commenced. No surgical debulkings were performed prior to treatment. 
In an attempt to monitor disease progression or regression in the therapeutic groups of 
the tumour-bearing rats, superoxide dismutase (SOD) enzymes were quantified for each 
group as described in Chapter 4, Section 4.9.3.3. Fig. 37 shows the profiles obtained 
for each group monitored over a 90 day period. 
Fig. 37: 
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As demonstrated in Fig. 38, the animal survival studies indicate the various outcomes 
of the three different treatment protocols employed and studied over the 90 day trial 
period, as well as the group of animals (control group) which received no treatment after 
primary tumour transplantation. 
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The maximum survival time for Group IIIA rats (no treatment group) who received no 
treatment, was 19 days. Gross examination of the peritoneal cavities of the animals who 
died showed extensive intraperitoneal disease, demonstrating massive hemoascites 
and peritoneal carcinomatosis with metastases to the liver and spleen. Diffuse studding 
of tumour deposits on the peritoneal surfaces, viscera and diaphragm was also noted. 
Group IA rats (free drug group) were given an intraperitoneal combined bolus dose as 
free drugs at a dose of 5 mg/kg CDDP and 20 mg/kg 5-FU, followed by a repeat dose 
at the same concentrations 7 days later. The two separate doses spaced 7 days apart, 
was performed to reduce the effects of free drug toxicity. Survival studies of this group 
showed that only 14% of the animals survived the 90 day trial period. All animals who 
died showed the same peritoneal carcinomatosis as the untreated animals (Group IIIA). 
Group I IA rats (low dose immunomicrosphere group) were given an intra peritoneal bolus 
dose of immunomicrospheres at a dose of 1 mg/kg CDDP and 4 mg/kg 5-FU. This group 
also indicated that only 14% of the animals survived the 90 day trial period. At post 
mortem, animals who died showed peritoneal carcinomatosis. 
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Group 118 rats (high dose immunomicrosphere group) were given an intraperitoneal 
bolus dose of immunomicrospheres at a dose of 10 mg/kg COOP and 40 mg/kg 5-FU. 
Fig. 39 shows drug-containing immunomicrospheres attached to the tumour tissue in 
the peritoneal cavity. This group of animals showed a markedly improved survival period 
when compared with the previous treatment protocols with 60% of all animals surviving 
the 90 day trial period. Again the animals who died showed extensive peritoneal 
carcinomatosis. 
Fig. 39: lmmunomicrospheres(blocked and arrows) attached to OMBA-OC-1 R 
tumour tissue in the peritoneal cavity of a female Wistar rat 
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Chapter 6 
Discussion 
6.1 Feasibility of Human Serum Albumin microspheres as a drug delivery 
system for cisplatin and 5-fluorouracil 
While drugs are available to combat a wide range of malignant diseases, the therapeutic 
efficacy of these agents is often diminished by their inability to gain access to the 
diseased site at the appropriate dosage. 
In order to achieve a therapeutically relevant dose in tumour cells, the amount of drug 
required usually proves to be highly toxic to normal tissues and cells. Therefore, what 
is needed are vehicles capable of carrying the cytotoxic agent in a highly concentrated 
form directly to the tumour target, thus allowing for more efficient tumour cell kill while 
largely sparing surrounding normal tissues and cells. 
Since the feasibility of artificial cells was first demonstrated by Chang in 1957, an 
increasing number of approaches in their preparation and application have become 
available. By employing an immunospecific drug delivery system such as monoclonal 
antibody conjugated albumin microspheres containing the cytotoxic agent, cisplatin, and 
separately, a system containing the antimetabolite, 5-fluorouracil , we demonstrated that 
the carriers can be targeted directly to tumour cells where the drugs were delivered and 
caused tumour cell death by interference with DNA synthesis (Butour & Macquet, 1977). 
We also demonstrated that albumin microspheres containing therapeutic relevant 
concentrations of cisplatin and 5-fluorouracil, can readily be prepared by a heat-
stabilization technique. Not only did we achieve to prepare microspheres in the size 
range of 1-5µm, but also found that they released the drugs in a sustained fashion. By 
employing the heat-stabilization technique, the reproducibility of the technique was 
confirmed, in that stable 1-5µm albumin microspheres were readily prepared in large 
batches by the method described by Truter (1995). We demonstrated that 
therapeutically relevant doses of cisplatin and 5-fluorouracil were released in sustained 
fashion and reached maximum levels in 14 days after incorporation in a plasma milieu 
and maintaining therapeutic levels for at least another 14 days. However, as Stella and 
Himmelstein (1980, 1985) showed, the retention of drugs at the site where they are 
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needed, is important if successful site specific delivery is to be followed by an 
improvement in therapeutic index and clinical effect of the drug. 
Various approaches, such as chemical modulation of the drug carrier system, have been 
considered to achieve the above. In our studies, we opted to apply the concept of 
employing heat-stabilised albumin immunomicrospheres containing cisplatin and 5-
fluorouracil as an alternative approach in the treatment of an ovarian adenocarcinoma 
model, DMBA-OC-1R, on which we performed a series of in vitro and in vivo studies. 
We found heat-stabilised albumin immunomicrospheres containing cisplatin and 5-
fluorouracil to: 
* 
* 
* 
* 
* 
* 
* 
* 
be relatively innocuous in terms of toxicity; 
be relatively non-antigenic within the body; 
be metabolizable within the body; 
possess high drug-entrapment properties; 
be capable of accommodating cisplatin and 5-fluorouracil in relatively high 
concentrations; 
be chemically stable in solution; 
be amenable to preparation in large batches , and 
allow the attachment of monoclonal antibodies to its surface. 
It was thus possible for us to demonstrate the potential use of heat-stabilised human 
serum albumin immunomicrospheres for carrying the chemotherapeutic agents as they 
complied satisfactorily with the above-mentioned criteria as was also demonstrated by 
Cheng et al. (1993) and Hagiwara et al.(1997). 
6.2 Monoclonal antibodies against DMBA-OC-1 R ovarian adenocarcinoma 
A rat ovarian adenocarcinoma cell line, DMBA-OC-1 R, was obtained from the 
Department of Obstetrics and Gynaecology, Kurume University, Japan. This cell line 
was originally established in Wistar rats by employing the carcinogen, 7, 12-
dimethylbenz(a)anthracene by Kato et al.(1974), and characterised by others (lmaishi, 
1992; Kataoka et al., 1987; Sugiyama et al., 1986). The cell line was found by these 
authors to resemble its human counterpart and also to be transplantable from one 
animal to another within the species with little or no change in the heterogeneity of the 
tumour. Our studies confirmed these findings and made it possible for us to raise two 
lgM monoclonal antibodies against the DMBA-OC-1 R cell line in order to successfully 
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link to drug-containing albumin microspheres rendering immunomicrospheres. 
6.2.1 Target specificity of anti-DMBA43 and anti-DMBA93 
The answer to the success of employing immunomicrospheres in ovarian cancer therapy 
lies in the identification of ovarian tumour-specific antigens. A number of tumour-
associated antigens have been identified by mouse monoclonal antibodies against 
ov arian cancer in humans and are used in clinical studies. Examples are CA-125, 
epithelial surface antigen (ESA), folate-binding protein, carcinoembryonicantigen (CEA), 
human milk fat globule (HMFG) and placental-type alkaline phosphatase (PLAP) (Bast 
et al., 1990; Finkler et al., 1988; Kuby, 1992; Tucker & Ward, 1988). These antigens 
are, however, also found in normal tissues and are therefore generally not suitable for 
use as targets for immunoconjugates. Attempts have been made to produce monoclonal 
antibodies with tumour-restricted specificity. MOV16, MOV18 and MOV20 were raised 
against an ovarian carcinoma which had not reacted with existing monoclonal antibodies 
(Isaacson & Wright, 1986). 
We developed and partially characterised two stable hybridomas obtained from the 
fusion of spleen cells of BALB/c mice injected with the rat ovarian cell line, DMBA-OC-
1 R, and the mouse myeloma cell line, SP2. Two lgM antibodies, designated anti-
DMBA43 and anti-DMBA93, were selected for their ability to bind membrane antigens 
on DMBA-OC-1 R but not on NRK and RESF cells by means of screening using 
immunofluorescence techniques on live, unfixed cells. The indirect ELISA was found to 
be unsuitable for screening as intracellular antigens were also detected due to the 
permeabilisation by glutaraldehyde. 
We were unsuccessful in our attempts to establish whether the two antibodies 
recognised different antigenic determinants by means of a reciprocal blocking inhibition 
test. This involved the detection of a FITC-conjugated antibody binding to the cells which 
had been previously blocked with the other antibody in a direct immunofluorescence 
assay on cells in suspension . This assay was previously used to establish that three 
monoclonal antibodies raised against a human osteosarcoma recognised different 
epitopes (Hosoi et al., 1982). 
The factors determining the clinical success of an immunoconjugate include the lg class 
of the monoclonal antibody and the degree of its cross-reaction with normal tissue. 
Ideally the antibody should be tumour-specific and bind to its epitope with a high affinity 
(Gregoriadis, 1977; Hellstrom et al. , 1987). By immunofluorescence staining of acetone-
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fixed cell lines and formalin-fixed, paraffin-embedded tissues of rats, we demonstrated 
that the two anti-OM BA monoclonal antibodies reacted with only DMBA-OC-1 R rat 
ovarian carcinoma cells and not with normal rat tissues or cell lines. The antibodies 
reacted strongly with only one out of the five human ovarian cell lines and not at all with 
any of the other cell lines established from different origins and species. These results 
bode well for their use in coupling to albumin microspheres. 
The anti-DMBA antibodies localised specifically in the paraffin wax sections of DMBA-
OC-1 R tumour were obtained from nude mice. Both antibodies were found to be lgM 
and may be thought to be less effective for antigenic coupling as lgM antibodies have 
lower affinities than the preferred lgG antibodies which also localise better in a tumour 
than lgM, due to their smaller molecular size. The pentameric lgM antibodies could have 
been fragmented into bivalent monomer lgMs in order to overcome this disadvantage. 
However, a loss of avidity and possibly also affinity may have ensued. 
lgM antibodies are generally generated by carbohydrate antigens (Ritter, 1986). We 
were unable to determine whether the specificity was associated with carbohydrate 
residues by labelling for carbohydrate on a Western blot using the ECL method. Most 
of the antigens associated with ovarian carcinomas have been identified as high 
molecular weight glycoproteins with a carbohydrate content of more than 50% and are 
known as mucins (Burchell & Taylor-Papadimitriou; 1990; Graham et al.; 1996; Lloyd, 
1993; Shimizu & Yamauchi, 1982). The immunogenicity of these molecules, due to their 
large size, in rodents has resulted in the generation of a number of monoclonal 
antibodies which have the potential in being developed into immunoconjugates. 
lmmunoblot analysis has revealed that the molecular weight of molecules such as 
polymorphic epithelial mucins containing the epitopes, differs amongst different 
mucinous tumours. The variation in molecular weight can be explained by the fact that 
the mucins contain large domains of tandem repeats of amino acids rich in threonine, 
serine and proline (Burchell & Taylor-Papadimitriou, 1990; Graham et al.; 1996) 
containing five potential 0-glycosylation sites and antibodies generally recognise 
epitopes of 4-5 amino acids. The polymorphic epithelial mucin which is encoded by the 
MUC 1 gene, is expressed abundantly in carcinomas but is not a true mucin as it has a 
transmembrane domain. As a result of aberrant glycosylation, it has shorter sugar side 
chains, probably owing to the lack of B 1-6GlcNAc transferase and a concurrent increase 
in a-2-3-sialyl transferase (Graham et al., 1996). This results in the exposure of epitopes 
which are masked on normal mucin as well as the creation of novel carbohydrate 
epitopes, 
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However, Alcian Blue PAS and Mucicarmine stains performed on paraffin wax 
embedded sections of the DMBA-OC-1 R tumour, were negative. These results suggest 
that the antibodies raised were not against carbohydrate antigens. 
6.3 Effects of drug-containing immunomicrospheres on the DMBA-OC-1R cell 
line 
The lgM monoclonal antibodies, anti-DMBA43 and anti-DMBA93, raised against the 
DMBA-OC-1 R cell line were shown to readily attach itself to the cisplatin- and 5-
fluorouracil-containing albumin microspheres when the carbodiimide method of Ilium 
and Jones (1985) was employed. 
Clonogenic assays performed by us demonstrated the synergistic effect of cisplatin and 
5-fluorouracil and also that the 5-fluorouracil modulated the effect of cisplatin (Harstrick 
et al. , 1997 and Rooney et al., 1985). Our results demonstrated that sustained drug 
release from targeted immunomicrospheres inhibited colony formation of DMBA-OC-1 R 
cells in culture, to a much greater extent than when the drugs (in free form) were added 
to the cells. This finding was considered to be of major importance, as the possibility of 
a greater clinical outcome could possibly be expected. Also, these results were 
supported by the cell survival growth studies and micronuclei assays. Comparative free-
drug and drug-containing immunomicrosphere and no antibody-linked microsphere 
profiles indicated that antibody-free microspheres had no growth inhibitory effect on the 
DMBA-OC-1 R cells in culture. However, only about 1.2% of cells survived when they 
were exposed to the antibody-targeted immunomicrospheres. Cell survival was reduced 
significantly by 42 fold to 1,2% when the drug concentration was at 25µg/ml 5-
fluorouracil and 1 O µg/ml cisplatin . 
These results thus demonstrated that the immunomicrospheres containing 5-fluorouracil 
and cisplatin are more effective in delivering drug directly to the tumour cells than those 
which are not linked to cell-specific monoclonal antibodies. When using free drugs, we 
demonstrated that total cell kill could be achieved when drug concentrations were 1 
µg/ml 5-fluorouracil and 0.025 µg/ml cisplatin. However, these results may be misleading 
in the clinical setting as the toxicity to normal cells in the body should seriously be 
considered when applying this type of protocol. 
In order to demonstrate the toxicity of cisplatin and 5-fluorouracil as free drug or 
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contained in immunomicrospheres, we performed the MTT assay which demonstrated 
an enhanced effect of cell kill by the drug-containing immunomicrospheres as compared 
to drug-containing microspheres without antibody. We further showed comparative 
results between free drugs and sustained drug release from immunomicrospheres which 
indicated the possibility of greater clinical outcome as microspheres can be loaded with 
drugs at very high concentrations, without causing serious cytotoxicity to normal cells 
and tissues as compared to free drugs where dosage may be limited. The cytotoxic 
effects to all major organs may be extrapolated from the drug distribution studies which 
we performed in Wistar rats, as well as the blood chemistry and haematology profiles 
obtained. 
As regards the drug distribution studies when using free drugs, only 9.3% cisplatin and 
6% 5-fluorouracil respectively were found in the ovaries, 2 hours after intravenous 
administration of a bolus dose of 20 mg/kg 5-fluorouracil and 2,5 mg/kg cisplatin. The 
highest levels most of drugs were found to have been deposited in vital organs of the 
haematopoeitic system and kidneys. Although only mild renal toxicity was observed 
when observing urea and creatinine status in the free drug and immunomicrosphere 
groups, correction to normal levels after free drug administration occured at a faster rate 
compared to the immunomicrosphere groups. However, it should be remembered that 
drugs were released in sustained fashion by the immunomicrospheres. Liver function 
tests showed the same phenomenon with these parameters indicating mild 
hepatocellular toxicity which corrected itself three to four weeks after administration of 
free drugs and eight to nine weeks in the case of immunomicrosphere administration. 
As regards the haematology, mild erythropenia and leukopenia were observed in both 
groups. Other parameters were normal. 
It should, however, be kept in mind, that, in the clinical setting, repeated administration 
of free drugs as used in routine treatment protocols, will result in severe side-effects on 
the blood chemistry and haematology. This will also perpetuate the problem, as a 
reduction in dose due the toxicity of the drugs used, will neutralize any advantage of the 
therapy due to the disadvantage of dose reduction (Frei, 1995). In the case of an 
immunomicrosphere protocol, the procedure may be only a "once-off" bolus dose or at 
the most, fewer doses at longer time-intervals due to a sustained supply of drugs at the 
target site. In this situation, less long-term side-effects can be expected. 
Therefore, pertaining to the above discussion, toxic side-effects should be weighed 
against survival and thus therapy protocols were investigated in the rodent tumour 
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model. 
6.4 The Tumour Model 
We studied the potential role of tumour-targeted albumin immunomicrospheres 
containing cisplatin and 5-fluorouracil in female Wistar rats with peritoneal ovarian 
adenocarcinoma. Tumour mass was observed by X-rays before treatment commenced. 
Histology of the tumour confirmed an ovarian adenocarcinoma. 
Animal survival curves, as demonstrated in Chapter 5, Section 5.6.2, clearly showed that 
immunomicrosphere protocols had superior survival times as compared to those treated 
by a free drug protocol. Comparative results of animals treated intraperitoneally by a free 
drug protocol at a dose of 5 mg/kg cisplatin and 20 mg/kg 5-fluorouracil , followed by a 
repeat dose at the same concentrations showed a survival rate of 14% over a 90 day 
trail period. Animals treated with an intraperitoneal bolus dose of immunomicrospheres 
at a dose of 1 O mg/kg cisplatin and 40 mg/kg 5-fluorouracil showed a survival rate of 
60 % over the 90 day trial period. 
Superoxide dismutase assays performed over the 90 day trial period indicated a 
substantial decrease in levels in the high dose immunomicrosphere group (Group 118) 
when compared with the free drug group (Group IA). These results further accentuate 
the superiority of drug-loaded immunomicrosphere protocols over those employing free 
drugs at the same concentrations. 
From the above results it was thus possible to extrapolate mortality probability profiles 
(Fig. 40) for all 4 groups of animals used in the survival studies. The results revealed a 
marked difference in the possible prediction of death of the grouped animals. The 
untreated control group (Group IIIA) indicate the probability of death of the surviving 
animals to be 1 in 3,8 at Day 14 after primary tumour transplantation. For animals of the 
free drug treated group (Group IA), death probability is 1 in 2, 1 at Day 72, for animals 
of the low drug dose immunomicrosphere group (Group IIA), it is 1 in 2, 1 at Day 60 and 
for animals of the high drug dose immunomicrosphere group (Group 118) it is 1 in 0.45 
at Day 60. 
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Fig. 40: 
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The mortality probability profiles for Group of Wistar rats of which 3 
groups recieved different regimes: 
a)Group IA = free drug group, 
b) Group IIA = low dose immunomicrosphere group, 
c)Group 118 = high dose immunomicrosphere group 
d)Group IIIA = no treatment group( control ) 
The above data indicates that the survival probability of animals from Group 118 (high 
dose immunomicrosphere group) is substantially superior to the other protocols 
employed in this study. 
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Chapter 7 
Conclusion 
We have clearly demonstrated that a targetable sustained drug delivery system can be 
developed and implemented as a treatment modality for ovarian adenocarcinoma. 
We were able to demonstrate that the concept of employing immunomicrospheres 
containing chemotherapeutic agents may be a feasible alternative approach in the 
treatment of intraperitoneal cancers such as ovarian adenocarcinoma as compared to 
conventional chemotherapeutic regimens. This modality is dependent on the physical 
and chemical characteristics of the drug carrier to be used. Our results demonstrated 
that heat-stabilised albumin microspheres are not only capable of entrapping cisplatin 
and 5-fluorouracil in high concentrations, but also capable of delivering the drugs in a 
sustained fashion in a plasma milieu. These albumin microspheres were further capable 
of being coupled quite readily to monoclonal antibodies by a carbodiimide technique, 
thus rendering targetable immunomicrospheres. By employing this method, carboxyl 
groups present on the surface of the microspheres can be coupled to the amino group 
on the antibody molecule through an amido linkage. 
Our results reiterated the synergistic effect of cisplatin and 5-fluorouracil whether they 
were employed as free drug or released from the immunomicrospheres. In vitro assays 
such as clonogenic assays, cell growth survival studies, MTT assays and micronuclei 
assays demonstrated that greater cell kill was achieved when cisplatin and 5-fluorouracil 
were released in sustained fashion by immunomicrospheres as compared to cell 
exposure to free drug. We could thus conclude that a drug delivery system is more 
effective in delivering its payload to the target site than free drugs. 
As regards cytotoxicity studies, we demonstrated that drugs delivered to the target site 
by immunomicrospheres had no greater side-effects than drugs delivered in free form. 
The blood chemistry and haematology profiles supported these findings. However, the 
cytotoxic effects to the targeted tumour cells, were greatly enhanced by employing 
target-directed immunomicrospheres containing cisplatin and 5-fluorouracil. Animal 
survival studies demonstrated this hypothesis as 60% of animals treated with drug 
containing immunomicrospheres survived a 90 day trial period as compared to 14% of 
animals treated by a free drug protocol at the same dosage. These results were further 
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supported by decreasing superoxide dismutase levels in immunomicrosphere treated 
animals. Hence, we could postulate mortality probability profiles which greatly favoured 
survival of animals treated by drug-containing immunomicrospheres as shown in 
Chapter 6, Section 6.4. 
Further work will include studies to quantify the amounts of cisplatin and 5-fluorouracil 
entering the tumour cells to cause DNA damage. This is considered essential as 
successful treatment depends on drugs entering the tumour cell. 
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APPENDIX 1 
50% Human serum albumin 
50 g human serum albumin was obtained in the lyophilised form from the Western 
Province Blood Transfusion Services. It was reconstituted by the addition of 100 ml of 
distilled water. 
Total Ionic Strength Adjustment Buffer (TISAB) 
Dissolve 58 g NaCl and 3.6 g trans-1,2-diaminocyclohexane-N,N-N',N'-tetraaeceticacid 
in 900 ml distilled water. Adjust to pH 5 and the volume to 1000 ml with distilled water. 
Sodium Fluoride Solutions 
Prepare a 1000 ppm stock solution of Na Fl by dissolving 2.21 g NaFI in 1000 ml of 
distilled water. Dilute to the required concentrations with distilled water. 
1% Hydrochloric Acid 
Add 3 ml of concentrated (10.18 M, 34%) hydrochloric acid (Saarchem) to 99 ml distilled 
water. 
5x Versene (EDTA in buffered saline) 
0.65 g di-sodium EDTA 
0.5 g KCI 
20 g NaCl 
2.85 g Na2HP04.2H20 
0.5 g KH2P04 
Dissolve the reagents in 450 ml of distilled water and adjust the pH to 7.2 - 7.4. Make 
up to 500 ml in a volumetric flask. Dilute 1 part versene with 4 parts distilled water for 
use. Filter-sterilise through a 0.22 µ m filter. 
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RPMl-1640 Medium 
Add to 900 ml of triple-distilled water : 
10.41 g RPMl-1640 (Sigma, cat no. R 6504) 
2 g NaHC03 (Merck) 
20 mg Streptomycin sulphate (Merck) (final concentration of 20 µg/ml) 
0.1 ml Penicillin at 500 000 units/ml (final concentration of 50 units/ml) 
Stir the reagents until they have dissolved. Adjust pH to 7.1 with concentrated HCI. 
Make up to 1000 ml in a volumetric flask and filter-sterilise through a 0.22 µ m filter. 
Store at 4°C. 
Trypan Blue Viability Test 
Add 0.1 ml trypan blue (Sigma) stain to 0.9 ml of cells. Only non-viable cells will take 
up the blue stain. 
White Cell Counting Fluid 
Dissolve 1 O mg crystal violet in 2% acetic acid. 
PEG 4000 (for fusion of lymphocytes with myeloma cells) 
2 g of polyethylene glycol (PEG), molecular weight 4000 daltons, is weighed out and 
autoclaved. 2 ml of warm (37°C) RPMl-1640 is added to the PEG while it is still molten. 
Store at 4°C. Discard if not used within 2 weeks of preparation. 
HAT-HUCS-RPMl-1640 Medium 
Add to 88 ml of RPMI: 
Store at 4°C. 
10 ml HUGS 
1 ml of 1 OOx aminopterin stock solution 
1 ml of 1 OOx hypoxanthine (HT) solution 
HUCS (Human Umbilical Cord Serum) 
Human umbilical cord serum was pooled from different patients and then 
decomplemented by heat inactivation at 56°C for 30 minutes. It was filter-sterilized and 
stored frozen at -20°C in 50 ml aliquots. 
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100x Aminopterin Stock Solution (4 x 10·7 M) 
Add 25 ml of distilled water and 0.5 ml of 5 M NaOH to 1. 76 mg of aminopterin. 
Neutralize with 5 M HCI and adjust the volume to 100 ml with distilled water. Filter-
sterilize and store at -20°C. Keep away from light. 
10 M NaOH 
Dissolve 40 g NaOH pellets in 100 ml of distilled water. 
Dilute as required with distilled water. 
5 M HCI 
Add 49 ml of concentrated HCI (10.18 M, 34%) to 51 ml of distilled water. 
Dilute to required concentrations with distilled water. 
100x HT (Hypoxanthine) Stock Solution 
0.34 g hypoxanthine (1 x 10·3 M) 
0.0968 g thymidine (1 .6 x 10-3 M) 
o. 0055 g glycine (2. 93 x 10-4 M) 
2.7515 g sodium pyruvate (0.1 M) 
Add 125 ml of distilled water to the hypoxanthine and add up to 2.5 ml of 1 O M NaOH 
dropwise until the hypoxanthine has dissolved. Add the remaining compounds and stir 
until they have dissolved. Adjust the final volume to 250 ml with distilled water, filter-
sterilize and store in aliquots at -20°C. 
HT-HUCS-RPMl-1640 Medium 
Add to 89 ml of RPMl-1640, 10 ml HUCS and 1 ml of 100x HT solution. Store at 4°C. 
FCS (Foetal Calf Serum) 
This was obtained from the State Vaccine Institute (Pinelands, South Africa}, thawed at 
37°C and decomplemented by heat inactivation for 30 minutes at 56°C. It was filter-
sterilized by passing the serum through a pre-filter, a 8 µ m filter and finally through a 
0.22 µ m filter. 50 ml aliquots were stored at -20°C. 
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Serum-free and Protein-free Hybridoma Medium 
Add to 900 ml of triple-distilled water: 
18.5 g Serum-free and protein-free hybridoma medium ( Sigma Cat no. S2772) 
2.25 g NaHC03 (Merck) 
20 mg Streptomycin sulphate (Merck) (final concentration of 20 µg/ml) 
0.1 ml Penicillin at 500 000 units/ml (final concentration of 50 units/ml) 
Stir the contents until they are dissolved. Adjust the pH to 7.1 with concentrated HCI. 
Make up to 1000 ml in a volumetric flask and filter-sterilise through a 0.22 µ m filter. 
Store at 4°C. 
1% Sodium azide in 0.54 M PBS 
Dissolve 100 mg in 10 ml of 0.54 M PBS, pH 7.2. 
For storage of antibodies, add 20 µ I of 1 % sodium azide per 1 ml of antibodies. 
0.54 M Phosphate-buffered Saline (PBS), pH 7.2 
8 g NaCl 
0.2 g KCI 
1.442 g Na2HP04.2H20 
0.2 g KH2P04 
Add 800 ml of distilled water to the above reagents and stir until dissolved. Adjust the 
pH to 7 .2 with concentrated HCI . Adjust the volume to 1000 ml in a volumetric flask and 
autoclave. 
0.1% Glutaraldehyde in 0.54 M Phosphate-buffered Saline 
Add 0.4 ml of a 25% glutaraldehyde solution (Merck) to 99.6 ml of PBS, pH 7.2. 
ELISA Blocking Buffer (2% skim milk, 100 mM glycine in 0.54 M PBS) 
2 g of skim milk powder and 0.75 g of glycine were dissolved in 90 ml of 0.54 M PBS, 
pH 7.2 and the volume was adjusted to 100 ml. 
ELISA Diluent 
29.22 g NaCl (0.5 M) 
1.799 g Na2HP04 (0.01 M) 
5 ml Triton X-100 (0.5%) 
Dissolve the reagents in distilled water and adjust the volume to 1000 ml. 
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Tris-Saline-Tween (TST), pH 8 
5.844 g NaCl (0.1 M) 
6.055 g Tris (0.05 M) 
0.5 ml Tween 20 (0.5%) 
Dissolve the NaCl and Tris in 800 ml of distilled water. Adjust the pH to 8.0 with 
concentrated HCI. Add Tween and adjust the volume to 1000 ml. 
ABTS Substrate 
Add 100 µI ABTS and 10 µ I of 30% H20 2 (Merck) to 10 ml 0.1 M citrate buffer. Store in 
the dark until required . 
0.1 M Citrate Buffer 
Dissolve 525 mg citric acid monohydrate in 40 ml distilled water. Adjust the pH to 4 with 
3M NaOH. Adjust the volume to 50 ml. 
40 mM ABTS (2,2' azino-di(3-ethyl-benzthiazolne) sulfonic acid) 
219 mg of ABTS is dissolved in 10 ml of distilled water and frozen at -20°C in 120 µ I 
aliquots. 
0.25% Trypsin for Tissue Culture 
A 0.5% stock solution is prepared by dissolving 2.5 g of 1 :250 Difeo-certified trypsin in 
500 ml of 0. 001 M HCI. Stir at room temperature for 90 minutes to 2 hours. Filter through 
Whatman filter paper No. 541 . Add 1 ml of 0.5% phenol red (for tissue culture) and 
filter-sterilize through a pre-filter and a 0.45 µ m filter. Store frozen until required . In order 
to prepare EDTA-trypsin for trypsinising cells, add an equal volume of 2x TD to the 
thawed trypsin and add 1 ml of 2% EDTA in TD per 100 ml of the diluted trypsin. Store 
at -20°C. 
0.001 M HCI 
Add 0.5 ml of 1 M HCI to 500 ml distilled water. 
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2xTD 
Dissolve each of the following reagents in order in 900 ml distilled water, ensuring that 
each one has dissolved before the following one is added: 
16 g NaCl 
0.76 g KCI 
0.25 g Na2HP04.2H20 
6 g Tris base 
Allow the solution to be exposed to the air for 30 minutes at room temperature. Adjust 
the pH to 7.4 - 7.5 with 3M HCI and leave for another 30 minutes. Check the pH and 
make up to 1000 ml, aliquot and autoclave. For 1X TD, add 1 part 2X TD to 1 part distilled 
water and filter-sterilise. 
2% EDTA in 1X TD 
Dissolve 2 g of EDTA in 100 ml of 1X TD and filter-sterilise. 
30% glycerol in 0.54 M PBS 
Add 30 ml of glycerol to 70 ml PBS. 
0.1% Trypsin in 0.05 M Tris 
Add 0.1 g of 1 :250 Difeo certified trypsin to 100 ml of 0.05 M acidified Tris buffer, adjust 
the pH to 7.6 and stir at 37°C. 
0.05 M acidified Tris-buffer, pH 7 .6 
Dissolve 6.1 g of Tris (Boehringer Mannheim) in 50 ml distilled water and add 31 ml of 
1 M HCI. Adjust to pH 7.6 and make up the volume to 1000 ml in a volumetric flask. 
Store at 4 °C. 
Tris-buffered Saline (TBS), pH 7 .6 
Dissolve 8. 77 g NaCl (0.15 M) and 6. 05 g Tris base (25 mM) in 900 ml of distilled water. 
Adjust the pH to 7.6 with concentrated HCI and make the volume up to 1000 ml in a 
volumetric flask. 
100 µg/ml Ethidium Bromide 
Dissolve 1 mg ethidium bromide in 10 ml distilled water. Dilute to required concentration. 
Store at 4°C. 
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0.1% Bovine Serum Albumin (BSA) in 0.54 M PBS 
Dissolve 0.1 g BSA in 100 ml of PBS, pH7.2. 
0.3 M Sodium Phosphate Buffer, pH 6.8 
Prepare stock solutions of 0.3 M Na2HP04.2H20 (dissolve 13.349 gin 250 ml distilled 
water) and 0.3 M NaH2P04.2H20 (dissolve 10.349 gin 250 ml distilled water) . Mix the 
two solutions to obtain a pH of 6.8. 1 O mM, 50 mM, 100 mM and 200 mM sodium 
phosphate solutions can be obtained by diluting the 0.3 M sodium phosphate solution 
with distilled water to the required molarities. 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (11% Running Gel) 
Assemble the clean glass plates with the spacers aligned between the two plates and 
clamp them. Seal the sides of the plates with 1.5% sealing agar. Seal the bottom end 
by pouring sealing agar onto a spare glass plate and place the assembled plates upright 
on the agar. 
Prepare the running gel solution by mixing 3.3 ml acrylamide, 2.25 ml running gel buffer 
and 3.45 ml distilled water. Finally add the catalysts, 25 µ I ammonium persulphate and 
25 µITEMED (N, N, N', N'-Tetramethylethylenediamine). Immediately pipette this mixture 
between the two glass plates so that the level is about two comb lengths away from the 
top of the glass plates. Gently overlay with isopropanol so as to prevent oxygen from 
inhibiting polymerisation and to get rid of air bubbles. Allow to set. Once the running gel 
has set, remove the isopropanol and make up the 4% stacking gel by combining 1.1 ml 
acrylamide, 2 ml stacking gel buffer, 4.9 ml water, 25 µ I ammonium persulphate and 25 
µI TEMED. Pipette this mixture on top of the running gel. Slide in the comb and allow to 
set. Once the stacking gel has set, clamp the plates into the electrophoresis apparatus 
and seal with 1. 5% sealing agar. Add the reservoir buffer to the tanks and check for any 
leakages. 
1.5% Sealing Agar 
Dissolve 1.5 g agar in 100 ml distilled water by heating in a microwave oven. 
30% Acrylamide 
Dissolve 30 g Acrylamide and 0.8 g bis-acrylamide (N,N'-Methylene-bis-acrylamide) in 
50 ml distilled water. Adjust the volume to 100 ml and filter the solution through 
Whatman's No. 1 filter paper. Store the solution in a dark bottle at 4°C. 
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Running Gel Buffer, pH 8.8 
(1 .5 M Tris-HCI; 0.4% SOS) 
Dissolve 18.17 g Tris and 0.4 g SDS in 80 ml distilled water. Adjust the pH to 8.8 with 
concentrated HCI and adjust the volume to 100 ml. 
Ammonium Persulphate 
Dissolve 0.1 g ammonium persulphate in o. 9 ml distilled water. This solution is stable for 
1 week when stored at 4°C. 
Stacking Gel Buffer, pH 6.8 
(0.5 M Tris-HCI; 0.4% SOS) 
Dissolve 6.06 g Tris and 0.4 g SOS in 80 ml distilled water and adjust the pH to 6.8 with 
concentrated HCI. Adjust the volume to 100ml. 
Reservoir buffer, pH 8.5 
(0.025 M Tris; 0.192 M Glycine; 0.1% SOS) 
Dissolve 3.03 g Tris, 14.41 g glycine and 1 g SOS in 950 ml distilled water. Adjust the 
volume to 1000 ml and check that the pH is 8.5. Do not adjust the pH if it is incorrect but 
discard the solution and start again. 
2X SOS/Sample Buffer 
Combine 2.5 ml stacking gel buffer, 2 g sucrose, 0.4 ml of a 0.04% solution of 
bromophenol blue, 4.6 ml of a 10% solution of SOS and 0.5 ml distilled water. Store 
frozen at -20°C in 200 µI aliquots. In order to reduce the samples, add 1 o µI of a 400 
mg/ml OTT to 200 µ I of the thawed 2X SOS/sample buffer. 
0.04% Bromophenol Blue 
Dissolve 40 mg bromophenol blue in 100 ml distilled water and filter through Whatman's 
filter paper No. 541 . 
10% sos 
Dissolve 1 O g SDS in 100 ml distilled water. 
400 mg/ml OTT (Dithiothreitol) 
Dissolve 400 mg OTT in 1 ml distilled water. Store frozen at -20°C in 20 µ I aliquots. 
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Destain for SOS-PAGE gels 
Mix 3 parts of methanol, 1 part of acetic acid and 6 parts distilled water. 
1% PAGE Blue (for the staining of SOS-PAGE gels) 
Dissolve 1 g PAGE Blue 83 (BDH) in 100 ml of destain for SOS-PAGE gels. 
Dilute 1: 1 O in destain for use. 
0.1 M Sodium Chloride, pH 7 
Dissolve 5.844g NaCl in 11 distilled water and autoclave. 
Hoechst Stain 
Dissolve 50 mg Hoechst compound 33258 (or bis-benzamide) and 10 mg thiomersal in 
100 ml 0.54 M PBS, adjust the pH to7.2 and store in a dark bottle away from light. 
0.56% Potassium Chloride 
Dissolve 0.56 g of potassium chloride in 100 ml of distilled water and filter-sterilise. 
1.32% Agar 
Dissolve 1. 32 g agar (Bacto Difeo) in 100 ml distilled water by heating in a microwave 
oven. 
1% Agar 
Dissolve 1g agar (Bacto Difeo) in 100 ml distilled water by heating in a microwave oven. 
2X RPMl-1640 
Add to 450 ml of triple-distilled water : 
10.41 g RPMl-1640 (Sigma, cat no. R 6504) 
2 g NaHC03 (Merck) 
20 mg Streptomycin sulphate (Merck) (final concentration of 20 µg/ml) 
0.1 ml Penicillin at 500 000 units/ml (final concentration of 50 units/ml) 
Stir the reagents until they have dissolved. Adjust the pH to 7.1 with concentrated HCI. 
Make up to 500 ml in a volumetric flask and filter-sterilise through a 0.22 µ m filter. Store 
at 4°C. 
3% Glutaraldehyde in 0.54 M PBS 
Add 12 ml of 25% glutaraldehyde (Merck) to 88 ml of 0.54 M PBS, pH 7.2. 
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1 mg/ml MTT 
Dissolve 100 mg of MTT in 100 ml of phenol-red free RPMI and filter-sterilise through 
a 0.22 µ m millipore-filter. Store at 4°C in the dark for up to 2 weeks or store frozen at -
20°c. 
100 ug/ml Cytochalasin B 
Dissolve 1 mg Cytochalasin B in 1 o ml distilled water. Store in 1 O ul aliquots at -20°C. 
0.001% Acridine Orange 
0.1 g acridine orange is dissolved in 100 ml distilled water (i.e. 0.1 % solution) . This is 
diluted further to 0.001% for staining by adding 0.4 ml of the 0.1% acridine orange 
solution to 40 ml phosphate buffer (pH 6.8) (Merck). 
Ketalar/Rumpon 
Mix 5 parts Rumpon (Bayer) to 9 parts Ketalar (Warner-Lambert) 
70% Barium Sulphate in Egg Albumin 
Make a paste by adding 70 g barium sulphate to 100ml of egg albumin 
0.83% Ammonium Chloride 
Dissolve 0.83 g ammonium chloride in 100ml of distilled water. Filter sterilise through a 
0.22 µ m filter. 
2.5% Phosphate-buffered glutaraldehyde 
Add 1 O ml of a 25% stock solution of glutaraldehyde to 90 ml of phosphate buffer, pH 
7.4 
10% Formal Saline 
Add 1 O ml formalin and 1 g sodium chloride to 85 ml distilled water. Adjust the volume 
to 100 ml with distilled water. 
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Haematoxylin and Eosin Stain 
Dewax the sections in xylene. 
Hydrate the sections through graded alcohols to water: 
- absolute alcohol 
- 90% alcohol 
- 70% alcohol 
- tap water 
Stain in Mayer's Haematoxylin for 1 O minutes. 
Wash well in running tap water. 
Briefly, differentiate the sections in 1 % acid alcohol 
"Blue" in Scott's tap water 
Wash in tap water 
Stain in 0.1% aqueous eosin for 3 minutes 
rinse the sections briefly in water 
Dehydrate the sections in alcohols: 
- 70% alcohol 
- 90% alcohol 
- absolute alcohol 
- absolute alcohol 
Clear the sections in Xylene 
Mount the sections in DPX 
Mayer's haematoxylin 
Dissolve 1 g haematoxylin, 50 g potassium or iron alum and 0.2 g sodium iodate in 1000 
ml distilled warm water. Add 50 g chloral hydrate and 1 g citric acid and boil the mixture 
for 5 minutes. Allow the mixture to cool before it is filtered. 
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Alcian Blue PAS 
Reagents: 1) 0.3% alcian blue in 3% acetic acid 
Method: 
Dissolve 0.3 g alcian blue in 100 ml of 3% acetic acid. 
2) 3% acetic acid 
Add 3 ml glacial acetic acid to 97 ml distilled water. 
3) 0.1% nuclear fast red in 5% aluminium sulphate 
Dissolve 0.1 g nuclear fast red in 5% aluminium sulphate. 
4) 5% aluminium sulphate 
Dissolve 5 g aluminium sulphate in 100 ml distilled water. 
5) Periodic acid solution 
Dissolve 1 g periodic acid in 200 ml distilled water. 
6) Schiff's reagent (Merck) 
Dewax sections in xylene and hydrate through a series of alcohols to 
water. Stain sections in alcian blue solution for 20 minutes. Rinse well 
in distilled water. Stain for 1 O minutes in nuclear fast red. Rinse the 
sections in distilled water, dehydrate rapidly in a series of alcohols, 
clear in xylene and mount in DPX. 
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Reticulin Stain (Gordon & Sweet's Method): 
Reagents: 1) 10.2% aqueous silver nitrate solution 
Dissolve 10.2 g silver nitrate in 100 ml distilled water. 
2) Silver solution 
Add strong ammonia solution drop by drop to 5 ml of 10.2% aqueous 
silver nitrate solution until the precipitate which it forms, just dissolves. 
Add 5 ml of a 3.1 % solution of NaOH. Add strong ammonia drop by drop 
until the resulting precipitate just dissolves (not completely clear). 
Make up the solution to 50 ml with distilled water. 
3) 3.1% NaOH 
Dissolve 3.1 g NaOH pellets in 100ml distilled water. 
4) Acid-KMn04 
Mix 95 ml of 0.5% KMn04 and 5 ml of 3% H2S04. 
5) 0.5% Kmn04 
Dissolve 0.5 g Kmn04 in 100 ml distilled water. 
6) 1% Oxalic acid 
Dissolve 1 g oxalic acid in 100 ml distilled water. 
7) 2.5% iron alum 
Dissolve 2.5 g iron alum (ammonium iron (Ill) sulphate dodecahydrate) 
in 100 ml distilled water. 
8) 10% aqueous formalin 
9) 0.2% gold chloride 
Dissolve 0.2 g gold chloride in 100 ml distilled water. 
10) 5% sodium thiosulphate 
Dissolve 5 g sodium thiosulphate in 100 ml distilled water. 
Method: Dewax sections in xylene and hydrate through a series of 
alcohols to water. Oxidise the sections in acidified Kmn04 for 1-5 
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Von Gieson Stain 
minutes. Wash the sections in water and bleach in 1 % oxalic acid 
for 3-5 minutes. Rinse in distilled water, wash again in tap water 
and 2-3 changes of distilled water. The sections are mordanted in 
2.5% iron alum for 1 O minutes to 2 hours and washed in 2-3 
changes of distilled water. They are then treated with silver solution 
until transparent ( about 30 seconds) and washed well in distilled 
water. The sections are reduced in 10% aqueous formalin, washed 
in tap water and rinsed in distilled water. Sections are toned in 
0.2% gold chloride for 10-15 minutes, rinsed in distilled water and 
treated with 5% sodium thiosulphate for 5 minutes. After washing 
the sections in water, they are dehydrated in a series of alcohols, 
cleared in xylene and mounted in DPX. 
Reagents: 1) Von Gieson's reagent 
Add 1 O ml 1 % acid fuchsin to 100 ml saturated picric acid solution. 
Oxidise this solution by boiling it for 3 minutes 
2) Weigert's haematoxylin 
Solution A: Dissolve 1 g haematoxylin in 100 ml of absolute ethanol. 
Solution B: Add 4 ml 30% ferric chloride and 1 ml cone. HCI to 100 ml 
distilled water. Allow the solution to ripen for 1 week. 
Mix equal parts of solutions A & B just before use. 
Method: Dewax sections in xylene and hydrate through a series of 
alcohols to water. Stain the sections in Weigert's haematoxylin for 
15 minutes and wash well in running tap water. Differentiate in 1 % 
acid alcohol, rinse in water, blue in Scott's tap water, rinse well in 
water and counterstain in Von Gieson's reagent for 3 minutes. 
Rapidly rinse the sections in water so as not to wash the fuschin 
out of the tissues. Rapidly dehydrate the sections through a series 
of alcohols as picric acid is removed by alcohol. Clear the sections 
in xylene and mount in DPX. 
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Southgate's Mucicarmine Method 
Reagents: 1) Carmine solution 
Add 1 g carmine and 1 g aluminium hydroxide to 100 ml 50% ethanol. Mix 
well and then add 0.5 g anhydrous aluminium chloride and boil for 3 
minutes. Allow the solution to cool and make up the volume to 100 ml with 
50% ethanol. 
2) Mayer's haematoxylin 
Method: Dewax sections in xylene and hydrate through a series of alcohols to 
water. Stain the nuclei with Mayer's haematoxylin and differentiate with 1 % acid 
alcohol. Wash the sections with water, blue them in Scott's tap water and wash 
again. Stain the sections in carmine solution for 30 minutes, rinse in distilled 
water, dehydrate through an alcohol series, clear in xylene and mount in DPX. 
1% Osmium Tetroxide in Veronal-Acetate Buffer pH 7.4 
Mix 12.5 ml of 2% Os04, 5 ml veronal -acetate buffer and 2.5 ml distilled water in a 
glass-stoppered bottle. pH to 7.4 with 0.1M HCI (+/- 5 ml). 
Veronal-acetate buffer 
Dissolve 2.89 g barbitone sodium (sodium veronal) and 1.15 g sodium acetate 
(anhydrous) in 100 ml distilled water. Store at 4°C. 
2% Osmium Tetroxide 
Dissolve 1 g Os04 in 50 ml distilled water in a clean glass beaker. Store at 4°C. 
1% uranyl acetate in 96% ethanol 
Dissolve 1 g uranyl acetate in 100 ml 96% ethanol. 
Spurr's Embedding Resin 
Weigh the following reagents into a polythene beaker sequentially: 1 O g ERL 4206 ( a 
cycloaliphatic diepoxide), 6 g DER 736 (a flexibiliser) and 26 g nonenyl succinic 
anhydride (NSA). Mix thoroughly with a magnetic stirrer and then, whlie stirring, add 400 
ul S-1 accelerator dropwise. 
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1% Toluidine Blue in 1% Borax 
Dissolve 1 g T oluidine Blue in 100 ml of 1 % Borax. 
1% Borax 
Dissolve 1 g borax in 100 ml distilled water. 
Reynold's Lead Citrate Stain 
Add 1.33 g lead nitrate (Pb(N03h), 1. 76 g sodium citrate (NaiC6H 50 7).2H20and 30 ml 
distilled water to a 50 ml volumetric flask and shake the suspension vigorously for 1 
minute. Allow the suspension to stand for 30 minutes with intermittent shaking to ensure 
complete conversion of the lead nitrate to lead citrate. Add 8 ml 1 M NaOH and make 
the volume up to 50 ml with distilled water. Mix by inversion. If any faint turbidity is 
present, centrifuge the solution. The pH should be 12+/- 0.1. 
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